



HAL
open science

Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases

Nicole Campese, Giovanni Palermo, Claudia Del Gamba, Maria Francesca Beatino, Alessandro Galgani, Elisabetta Belli, Eleonora Del Prete, Alessandra Della Vecchia, Andrea Vergallo, Gabriele Siciliano, et al.

► To cite this version:

Nicole Campese, Giovanni Palermo, Claudia Del Gamba, Maria Francesca Beatino, Alessandro Galgani, et al.. Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2021, 10.1080/14789450.2021.1886929 . hal-03138524

HAL Id: hal-03138524

<https://hal.sorbonne-universite.fr/hal-03138524>

Submitted on 11 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases

Journal:	<i>Expert Review of Proteomics</i>
Manuscript ID	ERU-2020--0079.R1
Manuscript Type:	Review (Invited)
Keywords:	Alzheimer's Disease, Fluid biomarkers, Neurodegenerative diseases, Tau, Tau-PET, Ultrasensitive techniques

SCHOLARONE™
Manuscripts

Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases

Abstract

Introduction Tau protein misfolding and accumulation in toxic species is a critical pathophysiological process of Alzheimer's Disease (AD) and other neurodegenerative disorders (NDDs). Tau biomarkers, namely cerebrospinal fluid (CSF) total-tau (t-tau), 181-phosphorylated tau (p-tau) and tau-PET tracers, have been recently embedded in the diagnostic criteria for AD. Nevertheless, the role of tau as a diagnostic and prognostic biomarker for other NDDs still remains controversial.

Areas covered We performed a systematical PubMed-basedly review of the most recent advances in tau-related biomarkers for NDDs. We focused on papers published in the last five years from 2015 to 2020, assessing the diagnostic or prognostic value of each biomarker.

Expert opinion The assessment of tau biomarkers in alternative easily accessible matrices, through the development of ultrasensitive techniques, represents the most significant perspective for AD-biomarker research. In NDDs, novel tau isoforms (e.g., 217p-taup-tau217) or proteolytic fragments (e.g., N-terminal fragments) may represent candidate diagnostic and prognostic biomarkers and may help monitoring disease progression. Protein misfolding amplification assays, allowing the identification of different tau strains (e.g. 3R- vs. 4R-tau) in CSF, may constitute a breakthrough for the in vivo stratification of NDDs. Tau-PET may help tracking the spatial-temporal evolution of tau pathophysiology in AD but its application outside the AD-spectrum deserves further studies.

Keywords: Alzheimer's Disease, Fluid biomarkers, Neurodegenerative diseases, Tau, Tau-PET, Ultrasensitive techniques

Article highlights

- Tau protein misfolding and accumulation in toxic species and tangles is a critical pathophysiological process of Alzheimer's Disease (AD) and other neurodegenerative disorders (NDDs);
- Cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) are included in the current diagnostic criteria for AD; in primary tauopathies and in other NDDs (ALS-FTD spectrum and [synucleinopathies](#)-[synucleinopathies](#)) the role of tau as a diagnostic and prognostic biomarker is still controversial;
- The quantification of t-tau and p-tau and of emerging tau biomarkers in plasma by using ultrasensitive techniques are gaining momentum in the AD diagnostic workup;
- Novel tau fragments and tau isoforms detectable by means of ultrasensitive methods including Protein Misfolding Cyclic Amplification (PMCA) and Real-time quaking-induced conversion (RT-QuIC) may improve the *in vivo* stratification of NDDs;
- Tau-PET tracers are useful tools for the *in vivo* tracking of the spatial-temporal evolution of tau pathophysiology in AD but further studies are needed to define their proper context-of-use in other tauopathies.

1. Introduction

Tau is a natively unfolded microtubule-associated protein largely expressed in the central nervous system[1]. This protein plays an important role in microtubule polymerization, stabilization and remodeling, and is mainly expressed in the axons, where it also participates in regulating cellular transport processes[2,3]. Tau exists in 6 isoforms generated through the alternative splicing of the exons 2, 3 and 10 of the microtubule-associated protein tau (MAPT) gene[4]. The microtubule-binding domain (MBD) is encoded by the exon 10, whose alternative splicing produces 3 isoforms, each with 3 or 4 repeats, respectively called 3-repeat (3R) and 4-repeat (4R) tau[2]. Under pathological conditions, mutations in the MAPT gene along with a hyper-phosphorylation of tau may reduce the affinity of the MBD to the microtubules[5]. Accordingly, tau free-protein concentrations increase to a tipping point after which misfolded protein intermediates self-assembly into unwanted oligomers, fibrils, and neurofibrillary tangles (NFT)[5].

The neuronal and/or glial accumulation of aberrant tau aggregates represents the pathological hallmark of a broad spectrum of neurodegenerative disorders (NDDs) called tauopathies [6]. These include the so-called primary tauopathies, a group of NDDs, in which tau aggregates, including NFT, represents the main pathological hallmark ~~that drives the neurodegenerative process~~. Primary tauopathies can be classified into 3R-~~tauopathies~~, 4R-~~tauopathies~~ ~~and~~, mixed 3R/4R tauopathies. The major clinical phenotypes belong to the spectrum of Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) and ~~Frontotemporal Lobar Degeneration with tau deposits (FTLD-Tau)~~ ~~Frontotemporal-lobar Degeneration associated with MAPT mutations (FTLD-MAPT)~~ [2,6]. Secondary tauopathies are conditions resulting ~~by~~ ~~from~~ a complex interplay between tau and other misfolded proteins (e.g., amyloid- β - ~~(A β)~~) or related to alternative causes (e.g., autoimmune processes). Alzheimer's Disease (AD) represents the best characterized and more intensively studied NDDs and is classified as secondary tauopathy[2,7]. More recently, other forms of secondary tauopathies have been described including chronic traumatic encephalopathy (CTE) and the autoimmune, anti-IgLON5 encephalitis [2]. Tau cytoplasmic inclusions have also been reported in ~~the Amyotrophic lateral sclerosis~~ Frontotemporal Dementia (FTD) ~~(ALS-FTD) spectrum~~; up to 30% of patients with the behavioral variant of frontotemporal dementia (bvFTD) and the majority (approximately 90%) of patients with the non-fluent variant of Primary progressive aphasia (nfvPPA) show tau pathologic depositions [8]. Also in α -synucleinopathies, where aberrant α -synuclein aggregates underpin the neurodegenerative mechanisms, NFT are likely to cause neurodegeneration and contribute to the disease burden [9,10].

1
2
3
4
5
6
7
8
9
10
11 [Tau biomarkers tracking tau pathology](#) are included in the diagnostic workup of AD
12 according to the 2011 National Institute on Aging – Alzheimer’s Association (NIA-AA), the 2014
13 International Working Group-2 (IWG-2) criteria and ~~to~~ the AT(N) classification system [11,12]. In
14 2018 the AT(N) scheme embed biomarkers of amyloid- β -related pathology (A), tau-pathology (T)
15 and other markers of neurodegeneration (N) [13]. This classification includes [validated biomarkers](#)
16 [to track tau pathology in AD such as cerebrospinal fluid \(CSF\) total-tau \(t-tau\), and 181-](#)
17 [phosphorylated-tau \(p-tau\), all increased in AD individuals, as biomarkers of neurodegeneration \(N\)](#)
18 [and 181-phosphorylated-tau \(p-tau181 or simply p-tau\), as biomarker of tau pathology](#) [13]. [These](#)
19 [biomarkers are all increased in AD individuals.](#) The AT(N) categorization for the first time added
20 cerebral tau- [positron emission tomography \(PET\)](#) as core biomarker of AD. Indeed, the
21 implementation of tau-PET tracers represents a recent step forward in the AD diagnostic workup
22 [13].
23
24
25

26 Currently, the *ante-mortem* diagnosis of non-AD NDDs mainly relies on pure clinically
27 based criteria. In this scenario, the diagnostic and prognostic value of tau protein in the spectrum of
28 primary tauopathies remains unsatisfactory when measured with traditional approaches (e.g.
29 ELISA) [14]. In fact, a biomarkers-based diagnosis is still an unmet need in NDDs and several
30 methodological challenges should be addressed to overcome this limitation. In the last years, the
31 use of ultrasensitive assays, the discovery of alternative tau byproducts in biofluids, and the
32 development of innovative techniques, enabling the differentiation of tau strains, [have represented](#)
33 [potential breakthroughs for the *in vivo* dissection of tau pathology spectrum.](#)

34 The validation of biomarkers tracking neurodegenerative processes and predicting
35 pathophysiological progression at the earliest molecular/cellular changes is an unmet need for the
36 early diagnosis, the prognostic evaluation and [for patients selection and follow-up in targeted-](#)
37 [therapies clinical trials the monitoring of targeted-therapies in clinical trials](#) [15].
38
39

40 We aim to review the current state of the art on the use of tau protein as a biomarker for NDDs.
41 First, we investigated recent advances of this fluid biomarker in the diagnostic and prognostic
42 workup of AD and other NDDs. Secondly, we evaluated the contribution of cerebral PET-imaging
43 in tracking tau pathology across the NDDs spectrum.
44
45
46
47

48 2. Literature search methods

49 The aim of the present work is to review the most recent advances on tau as a biomarker for
50 neurodegenerative diseases. A systematic PubMed-based literature search was performed to select
51 relevant papers assessing the diagnostic and/or prognostic value of plasma tau (both t-tau, p-tau,
52 and other tau fragments) in AD and other NDDs, as evaluated through novel ultrasensitive
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 techniques and of CSF tau in other neurodegenerative diseases. We screened the papers using the
11 following combination of keywords:

12
13 - for plasma tau in AD and other NDDs: (("plasma" OR "blood" OR "serum") AND ("tau") AND
14 ("Alzheimer" OR "Corticobasal degeneration" OR "Progressive Supranuclear Palsy" OR
15 "Amyotrophic Lateral Sclerosis" OR "Frontotemporal Dementia" OR "Parkinson" OR "Multiple
16 System Atrophy" OR "Lewy Body"));

17
18 - for CSF tau in NDDs (AD excluded): (("CSF") AND ("tau") AND ("Corticobasal Degeneration"
19 OR "Progressive Supranuclear Palsy" OR "Amyotrophic Lateral Sclerosis" OR "Frontotemporal
20 Dementia" OR "Parkinson's Disease" OR "Multiple System Atrophy" Or "Dementia With Lewy
21 Bodies"))).

22
23 Only papers written in English, assessing the prognostic and/or diagnostic value of tau and
24 published between 2015 and 2020, were included in the final analysis. A total number of 1480 and
25 297 articles for plasma tau and CSF tau respectively were initially screened. Fourteen papers on
26 plasma tau and 14 on CSF tau were retained in the final analysis (Fig.2).

27
28 For each study, we analyzed the study population, the technique used for biomarkers detection, the
29 diagnostic and/or prognostic performance of the investigated biomarker. [Given the high
30 heterogeneity of the papers included, we used the AuROC values as a concise measure of
31 diagnostic accuracy to compare different studies.](#) The diagnostic value of each marker to properly
32 allocate patients to different diagnostic groups was identified when available and classified as
33 follows: 'excellent' (area under ROC curve [AuROC] 0.90–1.00), 'good' (AuROC: 0.80–0.89),
34 'fair' (AuROC: 0.70–0.79), 'poor' (AuROC: 0.60–0.69), or 'fail' (i.e., no discriminatory capacity)
35 (AuROC: 0.50–0.59) [16]. [We used hazard ratios \(HR\) to compare the prognostic values. Possible
36 comparisons across studies are only qualitative, and not based on statistical analysis.](#)

3. Fluid biomarkers tracking tau-pathology: from conventional to ultrasensitive techniques

41
42 Fluid biomarkers represent promising tools for the in vivo tracking of early pathophysiological
43 changes in NDDs. Their detection and quantification in different matrices and related technical
44 issues are regarded as hot topics in biomarkers research[14].

45
46 Tau quantification in CSF represents the first and most widely validated approach for the in vivo
47 [assessment-detection](#) of tau [protein-pathology](#). Tau, quantified in the CSF both as ~~total-tau~~ and ~~181-~~
48 ~~phosphorylated-tau~~ (p-tau181) currently belongs to the core AD biomarkers, along with ~~amyloid-β₄₂~~
49 ~~(Aβ₄₂)~~, and its assessment is based on traditional Enzyme-linked immunoabsorbent assay (ELISA)
50 techniques [11–13]. Accordingly, several commercial kits are to date available for both clinical and
51 research purposes, ~~including the INNOTEST®hTAU Ag and the INNOTEST PHOSPHO-TAU~~

1
2
3
4
5
6
7
8
9
10 [17]. Even if broadly used and largely validated, standard tau quantification techniques present
11 three main limitations: 1) they are unable to effectively quantify tau in “peripheral” matrices (e.g.,
12 plasma), where its concentration is significantly low [18], 2) they fail in detecting alternative tau
13 species (e.g., [p-p217-tau-217](#)) 3) are ineffective in differentiating tau isoforms (e.g., 3R and 4R tau),
14 seeds (e.g., tau fibrils), based on their tridimensional conformation [19].
15

16 Traditional methods show unsatisfactory and suboptimal power in differentiating patients with
17 NDDs from healthy controls (HC) individuals when applied to biological matrices other than CSF
18 (e.g., blood), where these molecules are expressed at femtomolar ranges instead of picomoles [20].
19 The quantification of tau in [unconventional non-CSF](#) substrates is challenging because the
20 concentration of the analyte may not reflect primary neurodegenerative changes. [Unpredictable](#)
21 [Variations](#) in tau concentrations could be due to peripheral proteolytic processes, metabolic
22 clearance, the interaction with other proteins and modifications of the of brain blood barrier
23 permeability[21].
24

25 Novel techniques, developed and validated in the last five years, show better sensitivity in
26 measuring tau levels than traditional methods by detecting up to subpicomolar and even
27 subfemtomolar concentrations. [These techniques mostly address the N-terminal rather than mid-](#)
28 [region of tau](#). Single Molecule Array (Simoa), a fully-automated ELISA relying on antibody-coated
29 magnetic beads, has been used to assess t-tau, p-tau [22–24] and N-terminal tau fragments [25] in
30 blood samples of AD patients (Table 1). On the other hand, Electrochemiluminescence
31 immunoassays (ECLIA) provide a quantification of t-tau [26], p-tau181 [27–29] and [p217-taup-](#)
32 [tau217](#) [30,31] in patients with AD, with high accuracy even in low sample volumes (Table 1). An
33 upgrade of standard mass spectrometry (MS), combining immunoprecipitation reactions with MS
34 [32,33], tracks different phosphorylated tau isoforms like [p217-taup-tau217](#) and p-tau181 in plasma
35 [33](Table 1). Also immunomagnetic reaction (IMR) – an antibody-mediated reaction generating
36 changes in the magnetic fields that enable the quantification of the analyte [34,35] – detects t-tau
37 [36–39] and p-tau181 [37,39]– concentrations with a greater sensitivity compared to traditional
38 techniques, but with suboptimal specificity (Table 1).
39

40 However, these ultrasensitive techniques fail in discriminating different tridimensional
41 conformations of tau (e.g., 3R vs 4R tau–seeds). Nevertheless, the selective identification of
42 different tau seeds represents a critical issue to understand the pathophysiology of the [primary](#)
43 [tauopathies spectrum](#). Based also on the hypothesis of [a](#) prion-like transcellular propagation of tau,
44 real-time quaking-induced conversion (RT-QuIC) and protein misfolded cycle amplification
45 (PMCA) have been successfully applied in NDDs [40]. These techniques were initially developed
46 for the detection of prion proteins in [CreutzfeldtCreutzfeldt](#)-Jakob disease. RT-QuIC uses
47
48
49
50
51
52
53

1
2
3
4
5
6
7
8
9
10 recombinant protein substrates undergoing shaking and incubation cycles to quantify seeding
11 activity of prions (e.g. PrP) and prion-like proteins, such as α -synuclein ([\(α-syn\)](#)) and tau strains [41].
12 Similarly, in PMCA, seeding activity of substrates derived from brain homogenates or recombinant
13 proteins is amplified by cycles of sonification, enabling a sensitive detection and a selective
14 amplification of specific protein seeds [40].

15
16
17 More extensive research is necessary for the analytical and clinical validation of these approaches
18 by clarifying advantages and drawbacks. Finally, an accurate qualification process, mostly based on
19 clinical performance, will be required to define context(s)-of-use for pharmacological trials and
20 clinical practice.
21

22 23 24 **4. Advances in tau as a biomarker for Alzheimer's Disease: assessing novel matrices, 25 techniques and targets**

26 T-tau and p-tau proteins measured in CSF are core biomarkers of [neurodegeneration in AD](#) [11,12].
27 ~~However, their contribution in the identification of non-AD tauopathies is limited.~~ The finding of
28 alternative tau isoforms specific for the different [tauopathies clinical and pathological AD subtypes](#)
29 may represent a significant advancement, in parallel with the recent development of ultrasensitive
30 techniques that allow the measurement of tau proteins in ~~the~~ blood.
31

32
33 To overcome several technical issues including the higher dilution of tau biomarkers in
34 blood vs. CSF [42], several antibody-driven assays have been combined with different detection
35 systems reaching subpicomolar and even subfemtomolar limits of detection (LOD) [43]. A
36 metanalysis indicated that plasma t-tau is increased in AD [44]. A study performed with IMR
37 techniques showed that plasma t-tau levels discriminated AD from controls with optimal accuracy
38 (Table 2) [36]. By contrast, other studies conducted with Simoa and IMR reported higher plasma t-
39 tau concentrations in AD or [Mild Cognitive Impairment \(MCI\)](#) patients compared to HC, but with
40 consistent overlapping results [27,36,39,45,46]. Furthermore, plasma t-tau is not or only weakly
41 correlated with CSF t-tau, p-tau in different studies [45,47–49]. An inverse association between t-
42 tau and cortical thickness in AD-related areas has been reported [38,46]. Plasma t-tau was
43 associated in AD, MCI and HC with a longitudinal decline of cognitive scores and cerebral 18FDG-
44 uptake at PET imaging, increased ventricular volume, and a decrease of hippocampal volume
45 [47,50]. Combining plasma t-tau into ratios (e.g., with plasma amyloid- β_{1-42}) increases the
46 predictive value of cerebral tau accumulation, as assessed by PET, compared to t-tau alone [22]. On
47 the other hand, plasma t-tau did not predict the amyloid- β -status as assessed by cerebral amyloid-
48 PET [27] or CSF [26] in AD, MCI, and HC. Intriguingly baseline plasma t-tau levels seem to be
49 associated with atrophy of the basal forebrain cholinergic system (BFCS) in subjective memory
50
51
52
53
54

complainers, regardless of their amyloid- β -status [51], although no differences in plasma t-tau levels emerged between SCD and HC in a further study [48]. Finally, plasma t-tau levels were found to be associated with MAPT H1c haplotype in AD, MCI and HC, according to a genome-wide association study (GWAS) [52].

Full-length (FL) tau may account only for a small part of plasma tau proteins. Different proteolytic fragments of tau have been explored in plasma with ultrasensitive techniques so far. The levels of tau N1 fragments, measured with Simoa, are higher in AD and AD-MCI subjects than HC, showing good to optimal accuracy in discriminating HC from AD and MCI subjects, respectively [25] (Table 2). The actual eligibility of these fragments is still a matter of debate [53].

Conversely, pPlasma p-tau181 seems to be a robust-more specific AD biomarker. Plasma p-tau181 concentrations assessed by Simoa, IMR and ECLIA-based techniques are higher in AD and MCI-AD compared to HCs [23,27–29,39]. Plasma p-tau181 distinguishes AD patients from non-AD dementias taken together [28] and from vascular dementia (VaD) with optimal accuracy [23], from FTLD with good to optimal accuracy [23,29] and from PSP, CBD and Parkinson's disease (PD) or Multiple System Atrophy (MSA) with good accuracy [23] (Table 2). Furthermore, plasma p-tau concentration is consistent with CSF p-tau levels in A β -PET positive individuals [28,29]. Plasma p-tau181 predicts the A β -PET status with good accuracy and is associated with both A β and tau PET positivity in MCI, AD, and HC [27] (Table 2). Moreover, in a cohort of AD, MCI and HC, plasma p-tau181 correlated with the spreading of tauopathy-tau deposition within the brain [22].

Tau isoforms other than p-tau181 have been recently studied and showed a potential role in the differential diagnosis of AD from MCI and HC. Plasma p-tau217 was able to differentiate AD (clinically assessed) from non-AD patients and autopsy-confirmed AD from non-AD patients with slightly suboptimal accuracy [30] (Table 2). Plasma p-tau-217 levels predict the amyloid- β -status as assessed by amyloid-PET or CSF A β 42/A β 40 ratio with optimal accuracy across preclinical-AD, AD-MCI, moderate AD, non-AD-MCI and HC [33] (Table 2). Furthermore p-tau217 could discriminate amyloid- β positive and tau-PET negative participants from HC and unrevealed it has a potential role as an early, preclinical biomarker, being able to assess tau increase before detectable tau aggregation. Both plasma p-tau217 and p-tau181 correlated with their CSF counterparts and were shown to be released from CNS rather than from peripheral sources, thus probably representing more reliable AD biomarkers compared to than plasma t-tau and p-tau202 [33]. Moreover, the cerebral A β plaques and tau tangles accumulation are-is independently associated with ante-mortem concentrations of plasma p-tau217 in an autopsy-confirmed cohort [54].

Recently, dynamic trajectories of subsequent site-specific phosphorylation of tau have been reported from preclinical to full-blown AD stages in CSF. While p-tau217 and p-tau181 increase as

Commented [EB1]:

Commented [EB2]: idem

early as two decades before and tend to decline close to the symptomatic stage, the levels of t-tau and p-tau205 increase later (between 17-13 estimated years to symptom onset) and constantly increase along disease progression [55]. Also p-tau231 assessed in CSF by using a mid-region target antibody increases in preclinical AD, largely before p-tau181 and p-tau217, when only subtle A β pathology is detectable [56]. These preliminary data suggest the potential role of alternative site-specific phosphorylated isoforms of CSF p-tau for the identification of preclinical AD and for the subsequent risk of phenoconversion. Dynamic changes of tau phosphorylation profile may also represent a potential useful biomarker to assess the efficacy of disease modifying therapies in clinical trials but a better understanding of these changes and a more extensive validation of these biomarkers and their potential context-of-use is needed. Furthermore, whether these changes are reflected in plasma and their timing is ~~an~~ ~~issue that still needs to~~ ~~should be assessed~~.

Full-length (FL) tau may account only for a small part of plasma tau proteins. Different proteolytic fragments of tau have been explored in plasma with ultrasensitive techniques so far. The levels of tau N1 fragments, measured with Simoa, are higher in AD and AD-MCI subjects than HC, showing good to optimal accuracy in discriminating HC from AD and MCI subjects, respectively [24] (Table 2). The actual eligibility of these fragments is still a matter of debate [52].

5. The diagnostic and prognostic role of tau as a biomarker in 4R-tauopathies

Tauopathies are pathologically characterized by a predominant intracellular accumulation of hyperphosphorylated tau fibrils [1,2]. Primary tauopathies can be divided into 3R-tauopathies, including Pick's Disease (PiD), and 4R-tauopathies like ~~Progressive Supranuclear Palsy (PSP),~~ ~~Corticobasal Degeneration (CBD),~~ Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT). Mixed 3R- and 4R-tauopathies include Primary Age-Related Tauopathy (PART) and neurofibrillary tangles (~~NFT~~)-dementia[2]. The genetic FTLT due to MAPT mutations may be related either to 3R-, 4R- or 3/4 R-tau pathological patterns [3](Figure 1). The clinical phenotype of these forms is highly heterogeneous and may not reflect the underlying pathology [14,57].

Currently, the diagnosis of 4R-tauopathies relies on the post-mortem detection of disease-specific patterns of abnormal tau aggregates [3]. Nevertheless, the in vivo diagnosis of these disorders is based on purely clinical-based criteria without reliable biomarkers to track the different tau pathologies [3,14,58].

The potential role of CSF tau concentration as a diagnostic and prognostic biomarker in 4R-tauopathies (especially PSP and ~~corticobasal syndrome - CSBS~~) has been investigated by several studies since 1997, with conflicting results. The measurement of CSF t-tau and p-tau concentrations is helpful in the diagnostic workup of AD. Indeed the characteristic increase of tau species (t-tau or

Commented [EB3]: idem

Commented [EB4]: idem

Commented [EB5]: idem

1
2
3
4
5
6
7
8
9
10
11 p-tau) in the CSF is specific to AD pathology and lacks in non-AD dementias (including PSP and
12 CBS) [59,60]. Further, CSF t-tau and p-tau do not distinguish PD from atypical parkinsonism with
13 enough accuracy (in particular from PSP) [61]. Nevertheless these biomarkers when combined with
14 others in CSF – α -synuclein, A β 42, [neurofilament \(NFL\)](#) [62], ~~–~~ soluble amyloid precursor protein α
15 (sAPP α), soluble amyloid precursor protein β (sAPP β), monocyte chemoattractant protein-1 (MCP-
16 1), YKL-40 [63] – may discriminate PSP from PD individuals, as well as CBS from PD and
17 AD/FTD though with conflicting results (Table 3). Similarly, p-tau and t-tau CSF concentrations do
18 not differentiate idiopathic normal pressure hydrocephalus (iNPH), a well-known parkinsonian
19 syndrome-mimic, from PSP [64] (Table 3). Nonetheless, the combination of t-tau, A β 40 and MCP-
20 1 differentiate iNPH from other neurodegenerative movement disorders taken as a whole (e.g. PD,
21 MSA, PSP and CBD irrespective of their underlying pathology) with good accuracy (AuROC: 0.80)
22 [65].

23
24
25
26 Within the tau-spectrum, a trend towards higher CSF tau (both t-tau and p-tau) levels has
27 been reported in CBS compared to PSP and HCs [66–68]. Accordingly, Aerts and colleagues
28 showed that t-tau and p-tau differentiated CBD from PSP with fair diagnostic accuracy (AuROC:
29 0.77 and 0.76, respectively) and that increased tau levels were associated with lower [Mini Mental](#)
30 [State Examination \(MMSE\)](#) scores [69]. ~~These data could suggest a potential role of tau biomarkers~~
31 ~~in the differential diagnosis of tauopathies and a potential role in the stratification of different~~
32 ~~phenotypes (e.g. motor-dominant vs. cognitive-dominant).~~ However, these results should be taken
33 with caution since AD-pathology underpins CBS in about 20% of cases, thus representing a
34 potential bias for the correct interpretation of CSF tau levels. Additionally, these data ~~came come~~
35 from small samples, and ~~patients' selection relyare based on use old-obsolete~~ diagnostic criteria for
36 ~~patient selection~~ [58,70].

37
38
39
40 Tau isoforms may help in differentiating tauopathies from other neuropathologies and to
41 stratify the tau-spectrum. The quantification of alternative tau fragments compared to the classic
42 ones detected by standard ELISA methods is promising [71]. Borroni and colleagues, showed that
43 33kDa-tau/55kDa-tau ratio discriminate PSP from HCs (AuROC: 0.90) and other NDDs (e.g. AD,
44 CBD, FTD etc.) with ~~a good to excellent~~ diagnostic accuracy ~~ranging from good to excellent~~
45 (AuROC: 0.93 for AD, AuROC: 0.87 for CBD, AuROC: 0.86 for FTD) [68,72]. These authors
46 reported a lower 33kDa-tau/55kDa-tau ratio, as assessed by semiquantitative immunoprecipitation,
47 in patients with PSP compared to other tauopathies and α -synucleinopathies. They also showed a
48 correlation of this ratio with brainstem atrophy and motor impairment in PSP [68,72]. Other groups
49 did not replicate these results and further investigations are needed [73].
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 Available commercial kits currently quantify tau concentration targeting its central core region.
11 More recently, alternative tau fragments detected using antibodies recognizing the N-terminal
12 fragment τ_{12} -BT2 has been assessed, showing an excellent diagnostic accuracy in differentiating
13 PSP from AD [74](Table 3). Furthermore, a mass spectrometry-based study (~~(MS~~, see table 1),
14 identified 18 different CSF tau fragments with divergent patterns of expression in PSP compared to
15 AD and to HCs [71].
16

17
18 In last year the application of RT-QuIC and PCMA technologies may isolate and quantify
19 different tau strains (e.g. 4R and 3R tau) in CSF, thus representing an ideal tool to stratify *in vivo*
20 3R, 4R and mixed 3R/4R tauopathies [41].
21

22 Stepping aside from CSF, ~~only~~ a single study explored the potential discriminating value of
23 plasma p-tau181 in tauopathies, using ultrasensitive detection techniques (Simoa). Plasma p-tau was
24 able to differentiate PSP and CBS from AD with good diagnostic accuracy (Table 2), being
25 associated with A β 42 pathology assessed by cerebral amyloid-PET examinations [75]. The
26 validation of tau-biomarkers in plasma in large longitudinal cohorts using ultrasensitive techniques
27 is warranted.
28

29
30 Tau biomarkers may have a prognostic context-of-use in 4R-tauopathies. Constantinescu
31 and colleagues showed that t-tau CSF levels may predict mortality in a cohort of PSP patients (see
32 table 3 for the Hazard Ratio) [76]. Increased CSF t-tau levels at baseline are associated with a faster
33 decline as measured by clinical progression scores like the Schwab and England ADL (SEADL);
34 decreased baseline p-tau predicts low SEADL scores and rapid decrease in PSP Rating scale
35 (PSPRS). The prognostic value of tau is increased when combining biomarkers into ratios (e.g.,
36 baseline p-tau, t-tau and NFL concentrations) [77]. Currently, the role of tau as prognostic
37 biomarker in 4R-tauopathies is limited and should be clarified in longitudinal studies.
38
39

40 41 **6. The diagnostic and prognostic role of tau in ALS-FTD spectrum**

42

43 Frontotemporal dementia (FTD) and Amyotrophic lateral sclerosis (ALS) are NDDs with
44 significantly clinical and pathological overlaps.
45

46 FTD is a heterogeneous cognitive disorder, recognizing multiple clinical and pathological
47 phenotypes [78,79], related to the degeneration of frontal and temporal lobes [78]. Three main
48 clinical variants of FTD have been described: the behavioral variant of FTD (bvFTD) [80], primary
49 progressive aphasia (PPA) and the motor FTD syndromes (CBS and PSP) [81]. PPA can be further
50 divided into a semantic variant (svPPA) and in a non-fluent variant (nfvPPA) [82]; the logopenic
51 variant of PPA (lvPPA) is conversely considered an atypical AD variant rather than a proper
52 FTD-syndrome [78]. On the other hand, three main pathological FTD phenotypes have been
53
54

1
2
3
4
5
6
7
8
9
10 described, namely FTD with TDP-43 aggregates (FTD-TDP), FTD with tau depositions (FTD-Tau)
11 and FTD with FUS aggregates (FTD-FUS) [8]. It should be noticed that the correlation between the
12 clinical and the pathological phenotype is not always predictable. While nvPPA is associated in
13 most cases with FTD-tau (85% of all cases) and svPPA with FTD-TDP43 pathology (90% of
14 cases), bvFTD can be associated with both FTD-tau and FTD-TDP43 histological patterns [8].

15
16
17 ALS is progressive NDD characterized by motor symptoms related to the progressive
18 degeneration of the upper (UMN) and lower motoneuron (LMN) [83]. ALS is strictly associated to
19 TDP-43 pathology in about 95% of patients, alternative pathological inclusions (e.g. SOD-1
20 inclusions) may be reported in specific variants in a minority of cases [83].

21
22 The clinical and pathological boundaries between FTD and ALS are blurry and the current
23 diagnostic criteria consider ALS and FTD as a complex clinical *continuum* and pathologic *spectrum*
24 as well [84,85].

25
26 In fact, ALS patients show cognitive impairment in about 50% of cases, meeting current
27 criteria for diagnosing dementia in 10-15% of cases [86], and behavioral impairment in up to 45-
28 50% of patients baseline [87]. Conversely, FTD patients may present motor symptoms in
29 approximately 30% of cases showing motor neuron dysfunction (12.5% of bvFTD patients) [88].
30 The assessment of Tau as a biomarker in the ALS-FTD spectrum is controversial and recent studies
31 on CSF tau showed conflicting results.

32
33 Some authors observed a higher concentration of CSF t-tau in FTD patients compared to
34 HC, distinguishing them with a good diagnostic accuracy [89–91], (see Table 3 for AUROC
35 values). On the other hand, other investigations failed in detecting any significant difference [92–
36 95]. [These conflicting results may be due to the fact that FTD is a highly heterogeneous diagnostic
37 frame, including different clinical and pathological phenotypes.](#) Inconsistent results have been
38 reported in ALS studies [91,93,96–100].

39
40 Regarding the differential diagnosis between FTD and AD, p/t-Tau, t-tau and its ratios with A β 42
41 may be of clinical interest; FTD patients show lower levels of t-tau [91,94,95,101] and higher of
42 p/t-Tau [94] when compared to AD patients. Moreover, the ratios between t-tau and A β 42 are able
43 to distinguish between FTD and AD patients [91,95,101].

44
45 The CSF p-Tau and t-Tau ratio (p/t-Tau) is more interesting for the clinical workup. p/t-Tau was
46 observed to be significantly lower in ALS patients [89,96–99] and in FTD patients [89,90,92,102],
47 when compared to HC. Not surprisingly, ALS showed lower levels of CSF p/t-Tau than FTD
48 phenotypes with a likely related tauopathy. This ratio was significantly lower in FTD variants with
49 suspected TDP-related pathology (both patients with autopsy-proven TDP-related pathology and
50 TDP-related mutation carriers) compared to FTD phenotypes with a likely underlying tauopathy

[89,90,92,94,102,103] (Table 3). Low p/t-Tau may therefore represent a marker of an underpinning TDP-43 pathology. From a pathophysiological point of view this could be due to a lower tau burden in TDP-related compared to tau-related FTLD variants. On the other hand, the different proportion of patients with concomitant (MND) and amyloid- β co-pathology in the two groups may contribute to these observed differences [102]. [Furthermore p/t-Tau ratio seems to correlate with motor cortex thickness and seems to be associated with UMN involvement in ALS \[99\]. Accordingly the potential role of p-tau, t-tau and/or of their ratio may find a context-of-use in the differentiation of clinical endophenotypes within the ALS spectrum \(e.g. preponderant UMN vs. LMN involvement\) but may deserve further investigations are needed.](#)

Different concentrations of CSF tau fragments other than classic tau analytes have been reported by some authors in TDP-related vs. tau-related FTLD [90]. This suggests that differential proteolytic processes may occur in different FTLD variants but this hypothesis and its implications for novel biomarkers research deserves further studies and a more extensive assessment [90].

As regards the role of CSF tau as a prognostic biomarker, one study showed a potential prognostic value of baseline CSF t-tau in ALS, being a reduction of overall survival observed in individuals with higher CSF t-tau values (Table 3) [97]. Moreover p/t-tau ratio has been associated with survival in FTD [102] and disease progression in ALS [100].

Moving to surrogated progression biomarkers, a negative correlation between baseline CSF t-tau and the longitudinal increase of ALS Functional Rating Scale Revised (ALSFRS-R) score was described [100]; [furthermore p/t-Tau ratio seems to correlate with motor cortex thickness and seems to be associated with UMN involvement in ALS \[95\]. Accordingly the potential role of p-tau, t-tau and of their ratio in differentiating clinical phenotypes within the ALS spectrum \(e.g. preponderant UMN vs. LMN involvement\) may deserve further investigations.](#)

7. The diagnostic and prognostic role of tau in [alpha-synucleinopathies](#)

Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple system atrophy (MSA) belong to a group of NDDs collectively called [synucleinopathies](#). They are pathologically characterized by [abnormal deposition of \$\alpha\$ -synuclein](#) forming abnormal deposition such as the (α -syn)-rich neuron intracytoplasmic inclusions (Lewy bodies, Lewy neuritis and glial cytoplasmic inclusions) or the oligodendrocytes cytoplasmic inclusions [104]. Nevertheless, other misfolded proteins have been recognized in degenerated neurons, including tau proteins [105] highlighting the necessity of a more complex pathophysiological model.

In contrast to tau, which seems to require cofactors, in vitro and in vivo studies demonstrated how α -syn is able to self-polymerize [106] [107]. Several pathophysiological

mechanisms have been proposed to explain the interaction between α -syn and tau. According to a ~~two-step model (initiation followed by propagation), different models~~ α -syn ~~can~~ acts as the “amyloidogenic seed” ~~promoting tau aggregation with subsequent interaction between the two proteins enhancing promoting tau aggregation, whereas α -syn and tau interact subsequently to promote~~ each other’s fibrillization [108]. ~~or as the pathological chaperone~~ According to another model, ~~α -syn represents the pathological chaperone~~ for tau fibrillization [109]. Whatever the mechanism, oligomeric forms of α -syn and tau co-exist in ~~synucleinopathies~~ ~~synucleinopathies~~ and influence each other and perpetuate mutual aggregation, leading to hybrid oligomers’ formation [9,110,111]. ~~Pathogenetic mutations of α -syn provide evidence about the role of α -syn in promoting the formation of tau inclusions in the human brain. PD patients with A53T mutation in the α -syn gene (SNCA) revealed abundant α -syn and tau inclusions [108]. Nonetheless, tau and α -syn inclusions have been also demonstrated in individuals with sporadic neurodegenerative disorders [104].~~

Interestingly, levels of CSF α -syn and p-tau are directly correlated in ~~synucleinopathies~~ ~~synucleinopathies~~. This could be because the accumulation of α -syn in PD brain could inhibit the release of p-tau in CSF through unknown mechanisms, supporting the relationship between α -syn and tau in ~~synucleinopathies~~ ~~synucleinopathies~~ [112]. With regard to CSF, reduced levels of α -syn, t-tau, p-tau and β -amyloid- β at disease onset have been found in PD compared to HC [112][113]. Furthermore, p-tau levels and p-/t-tau ratio increased over time after PD onset despite stable levels of t-tau/ α -syn ratio. Patients exhibiting postural instability and gait impairment predominant phenotype had lower CSF p-tau and A β 42 concentrations than those with tremor-dominant phenotype [112]. Male sex and SNCA polymorphism rs316181 were linked to increased levels of p-tau, while an increased t-tau/A β 42 ratio was associated with REM behavior disorder [113].

The diagnostic value of CSF tau biomarkers is higher when they are combined into ratios [112][114][115][113][115]. The p-tau/ α -syn ratio (which is increased in PD compared to HC), showed the highest accuracy for PD diagnosis [115] (Table 3). Roughly 75% of PD patients with a disease course longer than 10 years evolve to PD with dementia (PDD) [116]. CSF t-tau has been reported to be increased in PDD compared to HC, while p-tau did not show differences in the two groups [117]. Longitudinal studies in PD patients found neither a predictive value for the subsequent development of dementia for CSF t-tau and p-tau levels measured at PD onset [118], nor an association with dementia severity in PDD [117]. In contrast, plasma t-tau and p-tau181 levels measured through immunomagnetic reduction (IMR) were increased in DLB compared to HC, and reduced compared to PDD [37] (Table 2).

1
2
3
4
5
6
7
8
9
10
11 DLB is the second most common cause of dementia after Alzheimer's disease (AD). DLB
12 belongs to the spectrum of [synucleinopathies](#), nevertheless, a mixed
13 neuropathology with amyloid- β plaques and tau pathology is present in nearly 40% of patients (α -
14 syn+AD) and are associated with an increased rate of dementia and a decreased survival time [119].
15 Although previous studies reported increased levels of t-tau in DLB compared to HC [120], these
16 findings were not replicated in more recent studies [121]. The use of different diagnostic criteria
17 and populations may in part explain these inconsistent results. In general, CSF t-tau and p-tau levels
18 are lower in DLB than AD [120], suggesting that levels of p-tau in CSF could represent a valuable
19 marker for the differential diagnosis between these two NDDs [123]. On the other hand, t-tau levels
20 are higher in DLB in comparison to PD and PDD, supporting the hypothesis that limbic and cortical
21 Lewy body pathology is the main and specific pathologic correlate of dementia in PD [124]. In a
22 neuropathological study, the regional distribution of tau and amyloid- β is different in α -syn+AD
23 patients and AD, with a greater proportion of tau in the temporal neocortex for DLB patients and in
24 frontal neocortex in AD. Moreover, the severity of tau burden was correlated with worse *ante-*
25 *mortem* cognitive performances in DLB individuals [125]. Tau pathology has also been correlated
26 to the pattern of brain atrophy in MRI. Indeed, increased CSF t-tau levels were associated with high
27 global atrophy scores [126] and elevated CSF p-tau with a more selective posterior atrophy [127].
28 CSF ratios t-tau/A β 42 and p-tau/A β 42 recently proved to predict the presence of AD co-pathology
29 in DLB, with higher levels of both ratios in α -syn+AD brains when compared to α -syn-AD brains,
30 while no correlation was found analyzing single biomarkers. Besides, higher CSF t-tau/A β 42 and
31 lower CSF A β 42 levels were associated with a higher burden of neocortical α -syn [121].

32
33
34
35
36
37 MSA is a NDD characterized by autonomic failure associated with a poorly levodopa-
38 responsive parkinsonian syndrome or cerebellar ataxia, thus defining two main phenotypes
39 respectively identified as MSA-P and MSA-C [128,129]. Differential diagnosis between PD and
40 MSA could be challenging because of the clinical overlap in the early stages and a reliable
41 biomarker for the differential diagnosis of MSA from PD yet represents an unmet need. ~~Reduced~~
42 ~~CSF levels α -syn in MSA patients compared to HC have been reported in most studies, while~~
43 ~~results on blood samples were inconclusive [111]. Also, data on CSF biomarkers in MSA are~~
44 ~~conflicting on tau are conflicting.~~ In some studies, CSF t-tau concentration was higher in MSA than
45 PD patients or HC [130][131], whereas others reported a reduction of its level [132]. By contrast, p-
46 tau concentration was similar in MSA and HC [130][132]. Conflicting data have been published on
47 the p-tau/t-tau ratio, reported either higher [130][132] or lower [133][134] in MSA compared to PD.
48 The combination of p-tau181, t-tau and DJ1 (a protein related to PD pathogenesis whose function is
49 still unknown in MSA) proved high sensitivity and specificity (respectively 82% and 81%) to
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10
11 discriminate MSA from PD [131], as well as the p-tau/A β 42 ratio (specificity 71%, sensibility
12 93%), which is significantly increased in MSA [134] (Table 3). Similarly, the AD index (CSF
13 A β 40/42 ratio \times t-tau) and the ratio t-tau/ α -syn were higher in MSA than HC, while no significant
14 differences were found comparing PD and HC [130]. Finally, no CSF biomarkers proved to be
15 reliable for the differential diagnosis between MSA-C and MSA-P [114].
16

17 Fluid biomarkers for ~~synucleinopathies~~ [\$\alpha\$ -synucleinopathies](#) were recently investigated also
18 in blood. Red blood cells (RBC) seem to be a preferential niche for misfolded proteins [135] and
19 oligomeric α -syn was described in RBC of patients with PD [136]. Analysis of RBC in PD patients
20 showed ~~reduced levels of α -syn and~~ increased levels of phospho-tau (p-tau) in PD compared to HC
21 [110]. Interestingly, RBC t-tau concentration was inversely correlated to MMSE scores both in the
22 general PD cohort and in PD drug naïve patients, suggesting a central role of tau pathology in
23 promoting cognitive decline in PD [110]. Plasma t-tau and p-tau were higher in MSA compared to
24 HC when measured through IMR [137][37], while levels of p-tau measured through Simoa did not
25 differ between MSA and HC [24].
26
27
28

29 **8. Tau PET in Tauopathies**

30
31 In the field of neurodegenerative dementias, in vivo imaging with radioligands designed to detect
32 each underlying proteinopathy aims to find a gold standard biological marker. Amyloid- β
33 imaging has been incorporated into AD diagnostic criteria since 2007 [138]. However, cerebral
34 amyloid-PET uptake did not correlate with cognitive performance nor neurodegeneration in AD.
35 Biomarkers of tau pathology may be closely related to neuronal injury and changes in cognition.
36 Tau-PET will support the investigation of the spatial-temporal evolution of tau pathophysiology in
37 AD and other NDD as well as the clinical validation of fluid biomarkers. Therefore, research effort
38 is focusing on the development of tau-~~selective positron emission tomography (PET)~~ radiotracers
39 in order to reveal underlying tau deposits in a broad range of tauopathies, such as AD, FTD, PSP.
40
41 A significant number of tau PET tracers have been synthesized so far, but many of those lack
42 sufficient specificity and selectivity [139,140]. The main difficulties to develop these tracers are
43 related to [141]: 1) lipophilicity, which is necessary to cross the blood-brain barrier and the cell
44 membrane (tau is located both intra and extracellularly); by contrast, excessive lipophilicity could
45 lead to unspecific binding; 2) affinity for tau, relevant to obtain high selectivity for tau molecule
46 and overcoming the high A β concentrations interfering with tau-ligand binding, but requiring
47 prolonged scanning time to reach the steady-state; 3) different conformations of tau aggregates
48 and different tau isoforms [142], making it challenging to develop a unique tau radiotracer for all
49 types of tauopathies. Based on both in vitro and in vivo results, three families of radiotracers were
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10 initially synthesized: 1) the THK family (THK117, its (S)-enantiomer THK5317, and THK5351;
11 2) 18F-AV1451, also known as T807 or Flortaucipir; 3) PBB3. The so-called first-generation tau
12 tracers finally showed a lack of specificity, with relevant off-target binding to monoamine
13 oxidase B (MAO-B) for the HK family and Flortaucipir [143], neuromelanin for Flortaucipir
14 [144], and A β -plaques and α -syn for PBB3 [145,146]. Hence, the second generation of tau PET
15 tracers has been developed: RO948, PI2620, JNJ311, MK6240, PM-PBB3 and AM-PBB3 [147].
16 However, the most widely studied agent is [18F]AV-1451 (Flortaucipir). It was the first approved
17 tau PET tracer for estimation of the density and distribution of aggregated tau neurofibrillary
18 tangles in adults with cognitive impairment and suspected AD [148].
19
20
21
22
23

24 **8.1 Aging**

25 First-generation tracers demonstrated retention of uptake confined to the medial temporal lobe in
26 normal cognitively elderly, in accordance with pathological data [149], likely reflecting an age-
27 related process of tau-deposition [150]. Accumulation of tau in the temporal cortex, without an
28 associated significant A β burden, may suggest a promoting effect of tau in mild amnesic deficits;
29 hippocampal atrophy or a PART related pathology in such subjects.
30
31
32

33 **8.2 Alzheimer's Disease**

34 There is now convincing evidence that cortical tau binding at PET imaging reflects tau
35 accumulation reported from histopathological studies in AD brains [149]. 18F-AV1451
36 demonstrated high affinity in vitro for paired helical filaments (PHF) of 3R/4R tau isoforms
37 reported in AD brains [151,152]. A recent study in 82 individuals with or without dementia
38 showed a high concordance between the visual reading of 18F-AV1451 PET scans and staging of
39 cortical neurofibrillary tangles, reinforcing the concept that Flortaucipir effectively reflects
40 pathological changes of AD [153]. Similar results were replicated in vivo, with 18F-AV1451
41 demonstrating to accurately differentiate clinically diagnosed AD from HC and other NDDs
42 [154]. Higher levels of tau tracer retention in the inferior lateral temporal region, but also in the
43 posterior cingulate and lateral parietal regions, provided the best discrimination areas between
44 AD patients and HC [155–158]. Other studies comparing [NCE-cognitively normal subjects](#) with
45 MCI patients showed differences in binding restricted to medial temporal regions
46 (parahippocampal and entorhinal cortex) [159,160], as well as lateral temporal and parietal areas
47 when examining only amyloid- β -positive MCI individuals [158]. Furthermore, some studies
48 reported greater retention of 18F-AV1451 in the cortex of younger compared to older AD
49 patients, with a cut off of 75 years-old [161], and in early-onset compared to late-onset AD
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10 patients with a cut off of 65 years-old [160], as similarly reported in previous post-mortem studies
11 [162]. Moreover, neocortical Flortaucipir retention was found in preclinical AD cases and rarely
12 in amyloid- β negative cases [161,163].

13
14 The extent of tau accumulation intimately correlates with the severity of MCI due to AD and AD
15 dementia, providing an objective index for disease severity. The few available longitudinal tau
16 PET studies in AD demonstrated a tracer retention related to disease duration [164–167].
17 However, results from the largest studies, which compared cognitively unimpaired A β -negative
18 and A β -positive individuals, MCI and AD dementia patients, are conflicting. Cho and colleagues
19 studied 107 participants (45 A β -negative cognitively unimpaired, 7 A β -positive cognitively
20 unimpaired, 31 MCI, and 24 AD dementia) who completed both 18F-flortaucipir and 18F-
21 florbetaben at baseline and who were followed up for 2 years. The authors found a predominant
22 tau accumulation in the medial and basal temporal cortices in MCI and in the lateral temporal
23 cortices in AD dementia [167], thus supporting a progressive tau accumulation pattern in line
24 with the Braak model [149]. Conversely, Jack and colleagues evaluated the longitudinal change in
25 tau PET signal during a one-year follow-up in a group of 126 individuals (59 cognitively
26 unimpaired A β -negative, 37 cognitively unimpaired A β -positive, and 30 cognitively impaired A β -
27 positive). They demonstrated a tau accumulation in the A β -positive clinically unimpaired group
28 in the medial temporal lobe and in the medial parietal areas, including posterior cingulate cortex.
29 This suggests that initial accumulation of tau aggregates in AD may not be restricted to the
30 medial temporal lobes as implied by Braak staging [165]. Overall these evidence proved that
31 longitudinal tau PET may be an useful biomarker in clinical trials to monitor the effect of disease-
32 modifying therapies tailored to reduce tau as well as cerebral amyloid- β plaque burden [168]. In
33 AD increased 18F-AV1451 uptake is strongly co-localized with hypometabolic regions and has
34 been associated with worse performance on various cognitive domains in regionally specific
35 patterns [169]. Accordingly, 18F-AV1451 distribution may predict the clinical variants of AD
36 suggesting on-site neurotoxicity provoked by tau aggregates in posterior cortical atrophy,
37 logopenic variant of primary progressive aphasia, or behavioral/dysexecutive variant of AD [169–
38 172]. The main ~~challenge~~ challenge for tau tracers remains the capability to detect preclinical /
39 prodromal / early AD stages. Importantly, the sensitivity for an early diagnosis is limited by the
40 fact that in the early AD stages (e.g. MCI) neurofibrillary tangles are only present in deep brain
41 regions. In more advanced AD stages 18F-AV1451 discriminate mild-to-moderate AD patients
42 from HC [154].

43
44
45
46
47
48
49
50
51 Currently, there are not conclusive studies on second-generation tau tracers in AD patients and we
52 do not have any head-to-head comparison between them. Available studies suggest that they may
53
54

1
2
3
4
5
6
7
8
9
10
11 be more useful in identifying earlier Braak stages. They also show substantially less non-specific
12 binding or higher affinities to primary tauopathies [173]. These agents include [18F]MK-6240
13 (Merck & Co), PM-PBB3 (APRINOIA Therapeutics), F18-PI-2620 (Life Sciences) (50) and
14 RO-948 (Roche). RO-948 tracer showed similar patterns of cerebral uptake then 18F-AV1451
15 [174]. Moreover, RO-948 showed a greater stability, a higher retention in the medial temporal
16 lobe and lower intracerebral “off-target” binding than Flortaucipir [175,176]. In AD subjects,
17 PET images of F18-PI-2620 showed a significantly higher uptake than control subjects in
18 temporal lobe, parietal and cingulate cortex. Importantly, in non-demented control subjects it
19 showed robust initial brain uptake and fast washout from the brain, as well as no age dependency.
20 This last finding suggests that F18-PI-2620 could improve the discrimination between non-
21 demented control and AD subjects in elderly. Moreover, excellent test-retest variability has been
22 demonstrated confirming the utility of F18-PI-2620 to evaluate longitudinal change of tau
23 deposition during disease course [177]. Finally, three recently published studies have evaluated
24 [18F]MK-6240 in vivo [178–180]. All these studies exhibited favorable kinetic and high binding
25 levels of [18F]MK-6240 to brain regions typically affected from NFT deposition in AD subjects.
26 [18F]MK-6240 PET images in another cohort of patients positive for cerebral amyloid- β deposition
27 (cognitive unimpaired/impaired elderly controls, MCI and AD patients) showed a
28 pattern corresponding to the anatomic distribution of tau as expected in the Braak model [178].
29
30
31
32
33
34
35

36 **8.3 Non-AD tauopathies**

37
38
39 Tau imaging may also be relevant for other tauopathies, such as CBD and PSP. These
40 atypical parkinsonian syndromes are characterized by abundant filamentous tau inclusions that
41 are made of isoforms with four microtubule-binding repeats in tubular or straight filaments. In
42 PSP and CBD abnormal aggregation of pathologically misfolded and hyperphosphorylated tau
43 proteins mainly occur in the basal ganglia in the early stages, spreading later to multiple brain
44 areas: brainstem, posterior frontal lobe, cerebellum and association cortices for PSP; primary
45 motor cortex, frontal lobe, brainstem or cerebellum for CBD [181–184]. Nevertheless, a variety
46 of overlapping syndromes are frequent in tauopathies.
47

48
49 To date few studies using low specific first-generation PET tracers have examined tau binding in
50 parkinsonian disorders. They revealed distinct patterns of tracer retention in PSP and CBD,
51 compared to controls, showing elevated PET signal in the basal ganglia and affected cortical
52 regions, in agreement with postmortem data [185].
53
54

1
2
3
4
5
6
7
8
9
10 Elevated tau deposition in PSP cases was observed in the basal ganglia, thalamus, dentate nucleus
11 of the cerebellum, and midbrain [186–192]. However, an extensive overlap and age-dependent
12 increase in both the PSP and control groups has been reported [187]. Significant differences in
13 18F-AV-1451 distribution between patients with PD and PSP, with increased uptake in the globus
14 pallidus, midbrain, and subthalamus in PSP cases, have been also described [193,194].
15 Interestingly, in some studies the radioligand accumulation correlated with the clinical disease
16 severity [189,195,196], but the lack of correlations between tau binding and symptom severity
17 was observed in the other cohorts [188,194]. A recent study by Whitwell and colleagues using
18 flortaucipir reported that the clinical heterogeneity present in PSP is mirrored by anatomical and
19 tau burden heterogeneity within the brain [197].

20
21
22
23 Studies analyzing the feasibility of tau PET in patients with CBS showed elevated asymmetrical
24 tracer deposition in dentate nucleus of the cerebellum, midbrain, subthalamic nucleus, globus
25 pallidus and putamen, precentral and postcentral cortex, superior frontal and parietal lobe, fitting
26 with the regional distribution of tau pathology [198,199]. Furthermore, longitudinal investigations
27 documented a correlation between tau accumulation over time and disease progression [166,200].
28 However, the degree of uptake in CBS using currently available tau ligands is variable, and some
29 patients resulted negative [201,202].

30
31
32 Overall, studies using in vivo tau PET in PSP and CBD individuals that received a postmortem
33 confirmation have shown conflicting results questioning the usefulness of tau imaging in early
34 diagnosis of such conditions. Indeed, the available tracers are not specific for 4R tau pathology
35 and show substantial off-target binding in the midbrain and basal ganglia to monoamine oxidase
36 B (MAO-B) and to neuromelanin-containing cells [192,203].

37
38
39 Second generation of tracers with improved off-target binding are under evaluation also in non-
40 AD ~~taopathistauopathies~~. Brendel and colleagues found a great potential to diagnose patients
41 with suspected PSP using 18F-PI-2620 which proved high affinity to recombinant 4R tau fibrils
42 and PSP brain homogenate [204,205].
43
44

45 **9. Discussion and perspectives**

46
47 [Epidemiological projections indicate that AD evolving epidemic represents a global threat for](#)
48 [healthcare systems \[54\]. Minimally invasive and globally accessible tests are needed to cope with](#)
49 [this expected burdensome demand and to manage individuals in suspected preclinical/prodromal](#)
50 [stages of NDDs \[206,207\]. Blood-based biomarkers represent cost-, resource- and time effective](#)
51 [tools \[208\]. They hold the potential to enable large-scale biological screening of individuals who](#)
52 [are very unlikely to have AD-related pathophysiology and would support the request of second-](#)
53
54

level investigations (e.g. PET imaging or CSF assessment). Blood-based biomarkers not only open up the opportunity of a multi-step diagnostic work-up but can also facilitate the re-engineering of drug Research & Development (R&D) pipelines, from subjects' enrollment, target engagement, to treatment efficacy monitoring. In Oncology, serial liquid biopsies offer clues about the evolution of cancer in individual patients across disease stages, enabling individualized genetically and biologically guided therapies [207].

The development of novel ultrasensitive measurement techniques has enabled the detection of tau-related biomarkers, facilitating a liquid biopsy-driven paradigm shift in the field of NDDs, including Alzheimer's disease AD [207]. Plasma t-tau seems to have a limited utility as diagnostic marker in NDDs when assessed alone [47]. On the other hand, plasma p-tau may find a context-of-use in the differential diagnosis between AD and non-AD dementias, including primary tauopathies and vascular dementia [25–29,75]. The combination of tau with other putative biomarkers (e.g. NFL) into panels or ratios seems to increase the diagnostic accuracy of tau biomarkers alone [22]. Sets of multiple biomarkers may accordingly find a context-of-use in both the clinical diagnostic workup of neurodegenerative dementias and, in patients' selection and their follow-up for targeted-therapies disease modifying clinical trials.

Studies investigating p-tau isoforms other than p-tau181 (e.g. p-tau217) [30,33,209], and alternative proteolytic fragments like the N1-tau [25] fragment have shown encouraging results in differentiating AD and MCI from HC and in predicting the amyloid β - in preclinical AD. Several studies, performed in AD and NDDs, indicate that plasma p-tau217 is a reliable predictor of tau pathology (as assessed through tau-PET)[210], amyloid- β -mediated tau pathophysiology, longitudinal cortical/subcortical atrophy and AD-like cognitive decline. These findings coupled with the evidence that p-tau217 discriminates AD from non-AD conditions [30,31] explain why plasma p-tau217 will be used as exploratory marker in different COU, including patients' selection and follow-up in clinical trials. The evidence about plasma p-tau217 also support its integration in the ATN matrix for disease diagnosis, prognosis and progression monitoring in clinical practice [31].

~~not yet available~~ A better understanding of time-trajectories of these alternative phosphorylation sites of p-tau ~~may~~ is mandatory to help understand the more adequate context-of-use of each isoform from preclinical to full-blown AD.

~~Tau protein misfolding and accumulation in toxic species and tangles is a critical pathophysiological process of AD and of primary tauopathies [1]; further, this protein contributes~~

1
2
3
4
5
6
7
8
9
10
11 to the pathophysiology of other brain proteinopathies (e.g. α -synuclein, TDP-43, FUS), leading to
12 mixed or overlapping neuropathologies [203].

13 Biomarkers tracking *in vivo* tau pathology are embedded in the most recent 2011 NIA-AA
14 and 2014 IWG-2 diagnostic criteria for AD, thus representing key elements for the diagnostic
15 workup of AD [11,135]. Currently CSF total-tau, 181phosphorylated-tau, and tau-molecular
16 imaging (PET), represent validated biomarkers for investigating tau-related pathology in AD
17 [11,135].

18
19 However, CSF assessment through lumbar puncture and PET assessment through
20 radiotracers and imaging device are invasive, time and resource demanding.

21
22 According to recent investigations plasma t-tau seems to have a limited utility as diagnostic
23 marker in NDDs when assessed alone [46]. On the other hand, plasma p-tau help differentiate AD
24 from non-AD dementias, including primary tauopathies and vascular dementia [24-28,71]. The
25 combination of plasma p-tau and t-tau into ratios with other candidate biomarkers (e.g. NFL) seems
26 anyway to increase the diagnostic power of these analytes [22]. Studies investigating p-tau isoforms
27 other than p-tau181 (e.g. 217p-tau) [29,32,204], and alternative proteolytic fragments like the N1-
28 tau [24] fragment have shown encouraging results in differentiating AD and MCI from HC but
29 these data should be regarded with caution and may deserve a more extensive validation.

30
31 In primary tauopathies CSF p-tau and t-tau, as assessed by traditional techniques, are not
32 reliable biomarkers for the diagnostic workup of 4R-tauopathies. In fact, both CSF t-tau and p-tau
33 and their combination do not discriminate primary tauopathies from HC and the tau-related
34 phenotypes within the pathologic tau-spectrum [64]. These biomarkers are useful in both clinical
35 and research settings for differentiating NDDs with an underlying AD pathology, which can mimic
36 primary tauopathies [59,60]. The detection of different tau isoforms and fragments (e.g. 33 KDa vs
37 55 KDa isoforms) [72] and of specific tau strains (e.g. 3R and 4R tau) by means of PMCA and RT-
38 QuIC [41] are promising strategies-tools to stratify the pathologic tau-spectrum and its clinical
39 continuum to identify different phenotypes. The prognostic value of tau biomarkers for in the 4R-
40 tauopathies remains to be clarified, especially when measured in plasma with the use of novel
41 ultrasensitive techniques, which allow minimally invasive and repeatable examinations.

42
43 As regards in the ALS-FTD spectrum, CSF t-tau and p-tau may contribute in discriminating
44 AD from FTD and in identifying patients with FTD phenotypes but with an underlying AD-
45 pathology [91]. The diagnostic value of p-tau and t-tau alone in differentiating the FTD-ALS
46 continuum from healthy controls HCs is controversial [89,91,98]. Nevertheless p-tau/t-tau ratio
47 seems to be lower in FTD and ALS compared to HC and may indirectly indicate useful in FTD for
48 the identification of patients with a TDP-43 underlying pathology related variants [89], and may be

1
2
3
4
5
6
7
8
9
10
11 ~~useful in ALS to discriminated clinical endophenotypes (UMN-predominant vs. LMN-predominant~~
12 ~~variants) [99]. A possible explanation could be the lower cerebral tau burden in TDP-43 related~~
13 ~~FTD-ALS phenotypes. Baseline CSF t-tau and p-tau/t-tau ratio could represent a prognostic marker~~
14 ~~for both FTD and ALS [97] but further studies are needed to identify the proper context-of-use of~~
15 ~~these biomarkers.~~

16
17 ~~In the reported studies, the high heterogeneity of the clinical diagnostic criteria used for~~
18 ~~patients' selection, the lack of post-mortem validation, and the unpredictable relationship between~~
19 ~~phenotypes and underlying pathology hamper the understanding of tau protein role as NDD~~
20 ~~biomarker.~~

21
22 ~~In α -synucleinopathies the co-occurrence of underlying tauopathy is commonly reported and~~
23 ~~tau may have a permissive role on α -synuclein aggregation. Reduced levels of t-tau have been~~
24 ~~reported in PD compared to HC [108,109], while p-tau levels and p/t-tau ratio seems to increase~~
25 ~~over time [109]. T-tau and p-tau concentration may vary according to PD phenotypes, thus~~
26 ~~suggesting a potential role of tau in differentiating clinical phenotypes (it is reported a reduction in~~
27 ~~CSF p-tau levels in patient with postural instability and gait disorder and an increase in patients~~
28 ~~with REM sleep behavior disorder) [112,113]. An potential association between tau burden and~~
29 ~~cognitive impairment in PDD and DLB has been postulated; nevertheless but data are conflicting~~
30 ~~and still inconclusive [117,118]. Similarly the diagnostic value of CSF p-tau and t-tau in atypical~~
31 ~~parkinsonism (e.g. MSA and DLB) is controversial [117,121,122,124,132,211][130,131].~~

32
33
34
35 ~~Recent investigations on plasma reported an increase of p-tau concentration in PD~~
36 ~~discriminating PD from HC, and inversely correlated with MMSE scores. Further studies are~~
37 ~~needed to establish the diagnostic and prognostic value of both p-tau and t-tau in α -~~
38 ~~synucleinopathies and their role in differentiating PD phenotypes.~~

39
40 ~~The development and validation of As regards tau-PET tracers, tau for the in vivo tracking of~~
41 ~~tau pathology has posed several challenging questions [138]. Tau-PET tracer uptake has been~~
42 ~~included in the current diagnostic criteria for AD as a surrogated marker of tau-accumulation [12].~~
43 ~~Tau-accumulation in the medial and basal temporal cortices was observed in MCI patients was~~
44 ~~demonstrated, thus suggesting a potential role of tau-PET tracers in the prodromal AD and a~~
45 ~~potential value of tau-PET uptake as a biomarker to in monitoring the efficacy of disease-~~
46 ~~modifying therapies in clinical trials [165,167]. Further longitudinal observations are required to~~
47 ~~corroborate this hypothesis. A possible role of tau-PET imaging in the differential diagnosis~~
48 ~~between 4R tauopathies is suggested by some studies highlighting a different deposition pattern~~
49 ~~of tau in PSP compared to CBS. Off-target binding in the midbrain and basal ganglia is currently~~
50 ~~limiting the use of first generation tracers but. This issue was partly resolved with the~~
51
52
53
54

development of second-generation tau tracers [145]. Further evidence on the physiological and pathologic variables influencing tau-PET tracers uptake, on the off-label binding and on the comparison of different tracers is warranted to understand the appropriate context-of-use of these biomarkers.

10. Conclusions and perspectives

In conclusions, biomarkers development and related research have significantly contributed to the reengineering of AD as a clinical-biological framework, as reflected by the ATN system, where preclinical stages of the disease are identified and potentially treated for preventive strategies, including tau-targeting approaches. It is conceivable that the same paradigm shift may take place also for NDD others than AD. Individuals with ~~no or subtle cognitive/motor/behavioral decline~~ different clinical presentations but similar biomarkers may be grouped into biological clusters facilitating a treatment ~~essentially~~ essentially based on pathophysiological mechanisms and not phenotypes ~~to treat with pathway-based, symptom (i.e., NDD clinical phenotype) agnostic therapies~~ [212,213], in line with the precision medicine paradigm [214].

Epidemiological projections indicate that AD evolving epidemic represents a global threat for healthcare systems, especially if a disease-modifying therapy becomes available [206]. Minimally invasive and globally accessible tests are needed to cope with this expected burdensome demand and to manage individuals in suspected preclinical/prodromal stages of NDDs, including Alzheimer's [207,208]. Blood-based biomarkers represent cost-, resource- and time-effective tools for critical clinical solutions [209]. They hold the potential to enable large-scale biological screening of individuals who are very unlikely to have AD-related pathophysiology and would support the request of second-level investigations (e.g. positron emission tomography [PET] imaging or cerebral spinal fluid [CSF] assessment) that have reduced accessibility and are more invasive. Blood-based biomarkers not only open up the opportunity of a multi-step diagnostic work-up but can also facilitate the re-engineering of drug Research & Development (R&D) pipelines, from subjects' enrollment, target engagement, to treatment efficacy monitoring. In Oncology, serial liquid biopsies offer clues about the evolution of cancer in individual patients across disease stages, enabling individualized genetically and biologically guided therapies [208].

The development of novel ultrasensitive measurement techniques has enabled the detection of tau-related (and others) biomarkers, facilitating a liquid biopsy-driven paradigm shift in the field of neurodegenerative diseases, including Alzheimer's disease [208].

In conclusions, biomarkers development and related research have significantly contributed to the reengineering of AD as a clinical biological framework, as reflected by the ATN system, where preclinical stages of the disease are identified and potentially treated for preventive strategies, including tau-targeting approaches.

It is conceivable that the same paradigm shift may take place also for NDD others than AD. Individuals with no or subtle cognitive/motor/behavioral decline may be grouped onto biological clusters to treat with pathway-based, symptom (i.e., NDD clinical phenotype)-agnostic therapies[210,211], in line with the precision medicine paradigm [212].

11. Expert opinion

Tau, as assessed in CSF in the form of t-tau and p-tau181, is an established diagnostic biomarker for AD. The detection of tau in alternative easily accessible matrices like plasma currently represents one of the most exciting future directions for AD biomarker research. The further development of ultrasensitive measurement techniques and their more extensive validation represent accordingly a hot topic in this field. The potential utility of alternative tau fragments and tau isoforms represents another challenge to improve AD diagnosis and stratification.

As regards primary tauopathies, alternative tau isoforms (e.g. 217p-taup-tau217) or proteolytic fragments (e.g. N-terminal fragments) quantified in CSF and in blood may represent candidate fluid diagnostic and prognostic markers overcoming the classic limitations of current CSF t-tau and p-tau measurement in these conditions NDDs.

In particular plasma p-tau217 could be used as exploratory marker in different drug development pipelines with distinct molecular target and for different COU, including patient selection, and theragnostic, and potently target engagement. The evidence about plasma p-tau217 also support its integration in the ATN matrix for disease diagnosis, prognosis and progression monitoring in clinical practice.

Nevertheless, the implementation of techniques enabling the identification of different tau strains (e.g. 3R- vs. 4R-tau), enabled by RT-QuIC and PMCA techniques, represents the most important frontier for fluid biomarker discovery in tauopathies.

The validation of biomarkers tracking tau pathology in the ALS-FTD spectrum is challenging. This could be also due to the high clinical and phenotypical heterogeneity intrinsic for this pathologic of this spectrum. However, tau biomarkers may identify AD-related pathology, and, to a lesser extent, differentiate tau-related from TDP-43 related pathology.

1
2
3
4
5
6
7
8
9
10 Intriguingly, tau biomarkers may reveal co-pathologies in NDDs. Biomarkers tracking tau
11 pathology in PD and atypical parkinsonism may in fact be potentially helpful for the segregation of
12 clinical subtypes and to combine tailor disease-modifying treatments.
13

14 The development of tau-PET tracers and the overcome of first-generation tracers' limitations
15 (especially the off-target binding and the necessity of a cyclotron) was a great step forward in the *in*
16 *vivo* understanding of early pathophysiological changes in AD. Further studies are needed to define
17 the context-of-use of tau-PET tracers in AD ([especially in preclinical and prodromal AD](#)) and their
18 potential applications outside the AD-spectrum.
19
20

21 **Funding**

22 [The study was not funded. Academic study without external financial support.](#)
23

24 **Financial disclosures**

25 [The authors have no relevant affiliations or financial involvement with any organization or entity](#)
26 [with a financial interest in or financial conflict with the subject matter or materials discussed in the](#)
27 [manuscript.](#)
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Bibliography

- [1] Spillantini MG, Goedert M. Tau pathology and neurodegeneration. *Lancet Neurol* [Internet]. 2013;12:609–622. Available from: [http://dx.doi.org/10.1016/S1474-4422\(13\)70090-5](http://dx.doi.org/10.1016/S1474-4422(13)70090-5).
- [2] Rösler TW, Tayanian Marvian A, Brendel M, et al. Four-repeat tauopathies [Internet]. *Prog. Neurobiol.* Elsevier Ltd; 2019 [cited 2020 Nov 22]. Available from: <https://pubmed.ncbi.nlm.nih.gov/31238088/>.
- [3] Höglinger GU, Respondek G, Kovacs GG. New classification of tauopathies. *Rev Neurol (Paris)*. 2018;174:664–668.
- [4] Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau Aggregates and Neurodegeneration. *Annu Rev Neurosci* [Internet]. 2017 [cited 2020 Nov 22];40:189–210. Available from: <https://pubmed.ncbi.nlm.nih.gov/28772101/>.
- [5] La-rocque S De, Moretto E, Schiavo G. Knockin ' on heaven ' s door : Molecular mechanisms of neuronal tau uptake. 2020;1–26.
- [6] Irwin DJ. Tauopathies as clinicopathological entities. *Park Relat Disord* [Internet]. 2016;22:S29–S33. Available from: <http://dx.doi.org/10.1016/j.parkreldis.2015.09.020>.
- [7] Braak H, Zetterberg H, Del Tredici K, et al. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of tau in cerebrospinal fluid. *Acta Neuropathol.* 2013;126:631–641.
- [8] Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol.* 2017;13:457–476.
- [9] Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, et al. Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. *Biol Psychiatry* [Internet]. 2015 [cited 2020 Oct 8];78:672–683. Available from: <https://pubmed.ncbi.nlm.nih.gov/25676491/>.
- [10] Henderson MX, Sengupta M, Trojanowski JQ, et al. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. *Acta Neuropathol Commun.* 2019;7:1–16.
- [11] Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement* [Internet]. 2011;7:257–262. Available from: <http://dx.doi.org/10.1016/j.jalz.2011.03.004>.
- [12] Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. *Lancet Neurol.* 2014.
- [13] Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* [Internet]. 2018;14:535–

- 1
2
3
4
5
6
7
8
9
10 562. Available from: <https://doi.org/10.1016/j.jalz.2018.02.018>.
- 11 **** Recommendations for a biomarker-based diagnosis of AD**
- 12
- 13 [14] Baldacci F, Mazzucchi S, Della Vecchia A, et al. The path to biomarker-based diagnostic
14 criteria for the spectrum of neurodegenerative diseases [Internet]. *Expert Rev. Mol. Diagn.*
15 Taylor and Francis Ltd; 2020 [cited 2020 Oct 8]. p. 421–441. Available from:
16 <https://pubmed.ncbi.nlm.nih.gov/32066283/>.
- 17
- 18 [15] Baldacci F, Lista S, Vergallo A, et al. A frontline defense against neurodegenerative
19 diseases: the development of early disease detection methods. *Expert Rev Mol Diagn*
20 [Internet]. 2019;19:559–563. Available from:
21 <https://doi.org/10.1080/14737159.2019.1627202>.
- 22
- 23 [16] Xia J, Broadhurst DI, Wilson M, et al. Translational biomarker discovery in clinical
24 metabolomics: An introductory tutorial. *Metabolomics*. 2013;9:280–299.
- 25
- 26 [17] Kawarabayashi T, Nakamura T, Miyashita K, et al. Novel ELISAs to measure total and
27 phosphorylated tau in cerebrospinal fluid. *Neurosci Lett* [Internet]. 2020;722:134826.
28 Available from: <https://doi.org/10.1016/j.neulet.2020.134826>.
- 29
- 30 [18] Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects
31 for the future. *J. Intern. Med.* 2018.
- 32
- 33 [19] Saijo E, Metrick MA, Koga S, et al. 4-Repeat tau seeds and templating subtypes as brain and
34 CSF biomarkers of frontotemporal lobar degeneration. *Acta Neuropathol* [Internet].
35 2020;139:63–77. Available from: <https://doi.org/10.1007/s00401-019-02080-2>.
- 36
- 37 [20] Hampel H, O’Byrne SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer
38 disease: mapping the road to the clinic. *Nat. Rev. Neurol.* 2018.
- 39
- 40 [21] Del Prete E, Beatino MF, Campese N, et al. Fluid Candidate Biomarkers for Alzheimer’s
41 Disease: A Precision Medicine Approach. *J Pers Med* [Internet]. 2020;10:221. Available
42 from: <https://www.mdpi.com/2075-4426/10/4/221>.
- 43
- 44 [22] Park JC, Han SH, Yi D, et al. Plasma tau/amyloid- β 1-42 ratio predicts brain tau deposition
45 and neurodegeneration in Alzheimer’s disease. *Brain* [Internet]. 2019 [cited 2020 Nov
46 22];142:771–786. Available from: <https://pubmed.ncbi.nlm.nih.gov/30668647/>.
- 47 [23] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for
48 Alzheimer’s disease: a diagnostic performance and prediction modelling study using data
49 from four prospective cohorts. 2020;19.
- 50 [24] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for
51 Alzheimer’s disease: a diagnostic performance and prediction modelling study using data
52 from four prospective cohorts. *Lancet Neurol.* 2020;19:422–433.
- 53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [25] Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau
12 aid development of a blood-based screen for Alzheimer's disease. *Alzheimer's Dement*
13 [Internet]. 2019 [cited 2020 Nov 22];15:487–496. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/30419228/>.
- 15 [26] Palmqvist S, Janelidze S, Stomrud E, et al. Performance of Fully Automated Plasma Assays
16 as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. *JAMA Neurol*
17 [Internet]. 2019 [cited 2020 Nov 22];76:1060–1069. Available from:
18 <https://pubmed.ncbi.nlm.nih.gov/31233127/>.
- 19 [27] Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's
20 disease clinical severity and is associated with tau- and amyloid-positron emission
21 tomography. *Alzheimer's Dement* [Internet]. 2018 [cited 2020 Nov 22];14:989–997.
22 Available from: <https://pubmed.ncbi.nlm.nih.gov/29626426/>.
- 23 [28] Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease:
24 relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal
25 progression to Alzheimer's dementia. *Nat Med* [Internet]. 2020 [cited 2020 Nov 22];26:379–
26 386. Available from: <https://pubmed.ncbi.nlm.nih.gov/32123385/>.
- 27 [29] Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in
28 Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med* [Internet]. 2020 [cited
29 2020 Nov 22];26:387–397. Available from: <https://pubmed.ncbi.nlm.nih.gov/32123386/>.
- 30 [30] Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-
31 tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA - J Am Med*
32 *Assoc.* 2020;
33
34
35
36
37
38
39 * **A recent paper exploring the potential role of plasma p-tau217 as a biomarker for AD**
- 40 [31] Mattsson-Carlsson N, Janelidze S, Bateman R, et al. Soluble P-tau217 reflects both amyloid
41 and tau pathology in the human brain and mediates the association of amyloid with
42 neocortical tau. *Brain* [Internet]. 2020 [cited 2020 Nov 22];143:3234–3241. Available from:
43 <https://doi.org/10.21203/rs.3.rs-101153/v1>.
44
45 * **A recent paper exploring the potential role of p-tau217 as a biomarker for AD**
- 46 [32] Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical
47 biochemistry. *Clin Biochem Rev* [Internet]. 2009 [cited 2020 Nov 22];30:19–34. Available
48 from: <http://www.ncbi.nlm.nih.gov/pubmed/19224008>.
- 49 [33] Barthélemy NR, Horie K, Sato C, et al. Blood plasma phosphorylated-tau isoforms track
50 CNS change in Alzheimer's disease. *J Exp Med* [Internet]. 2020 [cited 2020 Nov 22];217.
51 Available from: <https://pubmed.ncbi.nlm.nih.gov/32725127/>.
- 52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [34] Chieh JJ, Yang SY, Horng HE, et al. Immunomagnetic reduction assay using high-Tc
12 superconducting-quantum-interference-device-based magnetosusceptometry. *J Appl Phys*
13 [Internet]. 2010 [cited 2020 Nov 22];107:074903. Available from:
14 <http://aip.scitation.org/doi/10.1063/1.3340861>.
- 15 [35] Yang SY, Chiu MJ, Chen TF, et al. Detection of Plasma Biomarkers Using Immunomagnetic
16 Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease. *Neurol*
17 *Ther.* 2017;6:37–56.
- 18 [36] Lue LF, Sabbagh MN, Chiu MJ, et al. Plasma levels of A β 42 and Tau identified probable
19 Alzheimer's dementia: Findings in two cohorts. *Front Aging Neurosci* [Internet]. 2017 [cited
20 2020 Nov 22];9. Available from: <https://pubmed.ncbi.nlm.nih.gov/28790911/>.
- 21 [37] Lin CH, Yang SY, Horng HE, et al. Plasma biomarkers differentiate Parkinson's disease
22 from atypical parkinsonism syndromes. *Front Aging Neurosci* [Internet]. 2018 [cited 2020
23 Oct 16];10. Available from: <https://pubmed.ncbi.nlm.nih.gov/29755341/>.
- 24 [38] Fan LY, Tzen KY, Chen YF, et al. The relation between brain amyloid deposition, cortical
25 atrophy, and plasma biomarkers in amnesic mild cognitive impairment and Alzheimer's
26 Disease. *Front Aging Neurosci* [Internet]. 2018 [cited 2020 Nov 22];10. Available from:
27 <https://pubmed.ncbi.nlm.nih.gov/29967578/>.
- 28 [39] Yang CC, Chiu MJ, Chen TF, et al. Assay of plasma phosphorylated tau protein (threonine
29 181) and total tau protein in early-stage Alzheimer's disease. *J Alzheimer's Dis* [Internet].
30 2018 [cited 2020 Nov 22];61:1323–1332. Available from:
31 <https://pubmed.ncbi.nlm.nih.gov/29376870/>.
- 32 [40] Manca M, Kraus A. Defining the protein seeds of neurodegeneration using real-time
33 quaking-induced conversion assays. *Biomolecules.* 2020.
- 34 [41] Saijo E, Metrick MA, Shunsuke II, et al. 4 - Repeat tau seeds and templating subtypes as
35 brain and CSF biomarkers of frontotemporal lobar degeneration. *Acta Neuropathol*
36 [Internet]. 2020;139:63–77. Available from: <https://doi.org/10.1007/s00401-019-02080-2>.
- 37 * A paper presenting the potential applications of RT-QuIC for the differentiation of
38 **3R and 4R tauopathies**
- 39 [42] Baldacci F, Lista S, Vergallo A, et al. A frontline defense against neurodegenerative
40 diseases:the development of early disease detection methods. *Expert Rev Mol Diagn.*
41 2019;19:559–563.
- 42 [43] D'abramo C, D'adamio L, Giliberto L. Significance of blood and cerebrospinal fluid
43 biomarkers for alzheimer's disease: Sensitivity, specificity and potential for clinical use. *J*
44 *Pers Med* [Internet]. 2020 [cited 2020 Nov 22];10:1–39. Available from:

- 1
2
3
4
5
6
7
8
9
10
11 <https://pubmed.ncbi.nlm.nih.gov/32911755/>.
- 12 [44] Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of
13 Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol* [Internet]. 2016
14 [cited 2020 Nov 22];15:673–684. Available from:
15 <https://pubmed.ncbi.nlm.nih.gov/27068280/>.
- 16 [45] Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease
17 [Internet]. *Alzheimer's Res. Ther. Alzheimers Res Ther*; 2013 [cited 2020 Nov 22].
18 Available from: <https://pubmed.ncbi.nlm.nih.gov/23551972/>.
- 19 [46] Dage JL, Wennberg AMV, Airey DC, et al. Levels of tau protein in plasma are associated
20 with neurodegeneration and cognitive function in a population-based elderly cohort.
21 *Alzheimer's Dement* [Internet]. 2016 [cited 2020 Nov 22];12:1226–1234. Available from:
22 <https://pubmed.ncbi.nlm.nih.gov/27436677/>.
- 23 [47] Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. *Neurology*
24 [Internet]. 2016 [cited 2020 Nov 22];87:1827–1835. Available from:
25 <https://pubmed.ncbi.nlm.nih.gov/27694257/>.
- 26 [48] Müller S, Preische O, Göpfert JC, et al. Tau plasma levels in subjective cognitive decline:
27 Results from the DELCODE study. *Sci Rep* [Internet]. 2017 [cited 2020 Nov 22];7.
28 Available from: <https://pubmed.ncbi.nlm.nih.gov/28842559/>.
- 29 [49] Pase MP, Beiser AS, Himali JJ, et al. Assessment of Plasma Total Tau Level as a Predictive
30 Biomarker for Dementia and Related Endophenotypes. *JAMA Neurol* [Internet]. 2019 [cited
31 2020 Nov 22];76:598–606. Available from: <https://pubmed.ncbi.nlm.nih.gov/30830207/>.
- 32 [50] Mielke MM, Hagen CE, Wennberg AMV, et al. Association of plasma total tau level with
33 cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic
34 study on aging. *JAMA Neurol* [Internet]. 2017 [cited 2020 Nov 22];74:1073–1080. Available
35 from: <https://pubmed.ncbi.nlm.nih.gov/28692710/>.
- 36 [51] Cavedo E, Lista S, Houot M, et al. Plasma tau correlates with basal forebrain atrophy rates in
37 people at risk for alzheimer disease. *Neurology* [Internet]. 2020 [cited 2020 Nov 22];94:e30–
38 e41. Available from: <https://pubmed.ncbi.nlm.nih.gov/31801830/>.
- 39 [52] Chen J, Wojta K, Yokoyama JS, et al. Genome-wide association study identifies MAPT
40 locus influencing human plasma tau levels. 2017;
- 41 [53] Quinn JP, Corbett NJ, Kellett KAB, et al. Tau Proteolysis in the Pathogenesis of
42 Tauopathies: Neurotoxic Fragments and Novel Biomarkers [Internet]. *J. Alzheimers. Dis.*
43 *NLM (Medline)*; 2018 [cited 2020 Nov 22]. p. 13–33. Available from:
44 <https://pubmed.ncbi.nlm.nih.gov/29630551/>.
- 45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [54] Mattsson-Carlgen N, Palmqvist S, Blennow K, et al. Increasing the reproducibility of fluid
12 biomarker studies in neurodegenerative studies. *Nat Commun* [Internet]. 2020;11:1–11.
13 Available from: <http://dx.doi.org/10.1038/s41467-020-19957-6>.
- 14 [55] Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links
15 tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat*
16 *Med* [Internet]. 2020 [cited 2021 Jan 23];26:398–407. Available from:
17 <https://pubmed.ncbi.nlm.nih.gov/32161412/>.
- 18 [56] Suárez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at
19 T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when
20 only subtle changes in A β pathology are detected. *EMBO Mol Med* [Internet]. 2020 [cited
21 2021 Jan 23];12. Available from: <https://pubmed.ncbi.nlm.nih.gov/33169916/>.
- 22 [57] Forrest SL, Kril JJ, Halliday GM. Cellular and regional vulnerability in frontotemporal
23 tauopathies. *Acta Neuropathol* [Internet]. 2019;138:705–727. Available from:
24 <https://doi.org/10.1007/s00401-019-02035-7>.
- 25 [58] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal
26 degeneration. *Neurology*. 2013;80:496–503.
- 27 [59] Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal Fluid Tau Levels in Neurodegenerative
28 Diseases with Distinct Tau-Related Pathology. 1997;264:262–264.
- 29 [60] Schoonenboom NSM, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for
30 differential dementia diagnosis in a large memory clinic cohort. *Neurology*. 2012;78:47–54.
- 31 [61] Bech S, Hjermind LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage
32 proteins in parkinsonian syndromes. *Park Relat Disord* [Internet]. 2012;18:69–72. Available
33 from: <http://dx.doi.org/10.1016/j.parkreldis.2011.08.012>.
- 34 [62] Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid
35 biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian
36 disorders. *Arch Neurol*. 2012;69:1445–1452.
- 37 [63] Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid
38 biomarkers may identify patients with atypical parkinsonian syndromes. *J Neurol Neurosurg*
39 *Psychiatry*. 2015;86:1240–1247.
- 40 [64] Schirinzi T, Maria G, Di G, et al. Clinical value of CSF amyloid-beta-42 and tau proteins in
41 Progressive Supranuclear Palsy. *J Neural Transm* [Internet]. 2018;125:1373–1379. Available
42 from: <http://dx.doi.org/10.1007/s00702-018-1893-1>.
- 43 [65] Jeppsson A, Wikkelso C, Blennow K, et al. CSF biomarkers distinguish idiopathic normal
44 pressure hydrocephalus from its mimics. 2019;1117–1123.

- 1
2
3
4
5
6
7
8
9
10
11 [66] Urakami K, Mori M, Wada K, et al. A comparison of tau protein in cerebrospinal fluid
12 between corticobasal degeneration and progressive supranuclear palsy. 1999;259:127–129.
13 [67] Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal
14 fluid from patients with corticobasal degeneration or progressive supranuclear palsy.
15 2001;183:95–98.
16 [68] Borroni B, Gardoni F, Parnetti L, et al. Pattern of Tau forms in CSF is altered in progressive
17 supranuclear palsy. 2009;30:34–40.
18 [69] Aerts MB, Esselink RAJ, Bloem BR, et al. Cerebrospinal fluid tau and phosphorylated tau
19 protein are elevated in corticobasal syndrome. *Mov Disord*. 2011;
20 [70] Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive
21 supranuclear palsy and frontotemporal dementia. *Ann Neurol*. 2003.
22 [71] Barthélemy NR, Gabelle A, Hirtz C, et al. Differential mass spectrometry profiles of tau
23 protein in the cerebrospinal fluid of patients with Alzheimer's disease, progressive
24 supranuclear palsy, and dementia with lewy bodies. *J Alzheimer's Dis*. 2016;51:1033–1043.
25 [72] Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E, Bonuccelli U, Grassi
26 M, Perani D, Calabresi P, Di Luca M PA. Tau forms in CSF as a reliable biomarker for
27 progressive supranuclear palsy. *Neurology*. 2008;71:1796–1803.
28 * **First report on tau fragments and truncated tau as a biomarker for PSP**
29 [73] Kuiperij HB, Verbeek MM. Tau forms in CSF as a reliable biomarker for progressive
30 supranuclear palsy. *Neurology*. 2011;76:1443.
31 [74] Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF τ alterations in two common
32 tauopathies: Alzheimer's disease and progressive supranuclear palsy. *J Neurol Neurosurg*
33 *Psychiatry*. 2015;86:244–250.
34 [75] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for
35 Alzheimer's disease: a diagnostic performance and prediction modelling study using data
36 from four prospective cohorts. *Lancet Neurol* [Internet]. 2020 [cited 2020 Oct 16];19:422–
37 433. Available from: <https://pubmed.ncbi.nlm.nih.gov/32333900/>.
38 [76] Constantinescu R, Axelsson M. Cerebrospinal fluid neurofilament light and tau protein as
39 mortality biomarkers in parkinsonism. 2019;147–156.
40 [77] Rojas JC, Bang J, Lobach I V, et al. CSF neuro filament light chain and phosphorylated tau
41 181 predict disease progression in PSP. 2018;
42 [78] Bang J, Spina S, Miller BL. Frontotemporal dementia. *Lancet*. 2015.
43 [79] Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of
44 survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurol*

- [Internet]. 2017 [cited 2020 Oct 10];16:55. Available from: [/pmc/articles/PMC5181646/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/28054827/).
- [80] Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134:2456–2477.
- [81] Murley AG, Coyle-Gilchrist I, Rouse MA, et al. Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. *Brain*. 2020;143:1555–1571.
- [82] Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76:1006–1014.
- [83] Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. *Nat Rev Dis Prim*. 2017;3.
- [84] van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. *Lancet* [Internet]. 2017;390:2084–2098. Available from: [http://dx.doi.org/10.1016/S0140-6736\(17\)31287-4](http://dx.doi.org/10.1016/S0140-6736(17)31287-4).
- [85] Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal Degener* [Internet]. 2017/01/05. 2017;18:153–174. Available from: https://pubmed.ncbi.nlm.nih.gov/28054827.
- [86] Chiò A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. *Neurology*. 2019;
- [87] De Silva D, Hsieh S, Caga J, et al. Motor function and behaviour across the ALS-FTD spectrum. *Acta Neurol Scand*. 2016;
- [88] Burrell JR, Kiernan MC, Vucic S, et al. Motor Neuron dysfunction in frontotemporal dementia. *Brain*. 2011;
- [89] Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. *Dement Geriatr Cogn Disord*. 2017;
- [90] Foiani MS, Cicognola C, Ermann N, et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: An elusive quest. *J Neurol Neurosurg Psychiatry*. 2019;
- ** Comprehensive overview on current state of the art and limitations of CSF tau biomarkers in FTD**
- [91] Ye LQ, Li XY, Zhang Y Bin, et al. The discriminative capacity of CSF β -amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. *J Neurol Sci*. 2020;
- [92] Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. *Amyotroph Lateral Scler Front Degener*. 2015;

- 1
2
3
4
5
6
7
8
9
10
11 [93] Kämäläinen A, Herukka SK, Hartikainen P, et al. Cerebrospinal fluid biomarkers for
12 Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic
13 lateral sclerosis with the C9ORF72 repeat expansion. *Dement Geriatr Cogn Disord*. 2015;
14 [94] Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, et al. Cerebrospinal fluid biomarkers in
15 patients with frontotemporal dementia spectrum: A single-center study. *J Alzheimer's Dis*.
16 2018;
17 [95] Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of
18 Alzheimer's disease: Clinical utility of an extended panel of biomarkers in a specialist
19 cognitive clinic. *Alzheimer's Res Ther*. 2018;
20 [96] Wilke C, Deuschle C, Rattay TW, et al. Total tau is increased, but phosphorylated tau not
21 decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. *Neurobiol Aging*. 2015;
22 [97] Scarafino A, D'Errico E, Introna A, et al. Diagnostic and prognostic power of CSF Tau in
23 amyotrophic lateral sclerosis. *J Neurol*. 2018;
24 [98] Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and
25 electrophysiological correlates of CSF biomarkers of neurodegeneration and
26 neuroinflammation in amyotrophic lateral sclerosis. *J Neurol*. 2020;
27 [99] Schreiber S, Spotorno N, Schreiber F, et al. Significance of CSF NfL and tau in ALS. *J*
28 *Neurol*. 2018;
29 [100] Lanznaster D, Hergesheimer RC, Bakkouche SE, et al. A β 1-42 and tau as potential
30 biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis. *Int J Mol Sci*. 2020;
31 [101] Vergallo A, Carlesi C, Pagni C, et al. A single center study: A β 42/p-Tau181 CSF ratio to
32 discriminate AD from FTD in clinical setting. *Neurol Sci*. 2017;
33 [102] Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and
34 phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology*. 2018;
35 [103] Kuiperij HB, Versleijen AAM, Beenes M, et al. Tau Rather than TDP-43 Proteins are
36 Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes:
37 A Pilot Study. *J Alzheimer's Dis*. 2017;
38 [104] Spillantini MG, Crowther RA, Jakes R, et al. α -Synuclein in filamentous inclusions of Lewy
39 bodies from Parkinson's disease and dementia with Lewy bodies. *Proc Natl Acad Sci U S A*
40 [Internet]. 1998 [cited 2020 Oct 8];95:6469–6473. Available from:
41 <https://pubmed.ncbi.nlm.nih.gov/9600990/>.
42 [105] Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and
43 NACP/ α -synuclein- epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia
44 with Lewy bodies. *Brain Res*. 1999;843:53–61.

- 1
2
3
4
5
6
7
8
9
10
11 [106] Wood SJ, Wypych J, Steavenson S, et al. α -Synuclein fibrillogenesis is nucleation-
12 dependent: Implications for the pathogenesis of Parkinson's disease. *J Biol Chem* [Internet].
13 1999 [cited 2020 Oct 19];274:19509–19512. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/10391881/>.
15
16 [107] Friedhoff P, Von Bergen M, Mandelkow EM, et al. Structure of tau protein and assembly
17 into paired helical filaments. *Biochim. Biophys. Acta - Mol. Basis Dis.* Elsevier; 2000. p.
18 122–132.
19
20 [108] Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and
21 alpha-synuclein. *Science* (80-) [Internet]. 2003 [cited 2020 Oct 16];300:636–640. Available
22 from: <https://pubmed.ncbi.nlm.nih.gov/12714745/>.
23
24 [109] Souza JM, Giasson BI, Lee VMY, et al. Chaperone-like activity of synucleins. *FEBS Lett*
25 [Internet]. 2000 [cited 2020 Oct 19];474:116–119. Available from:
26 <https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2800%2901563-5>.
27
28 [110] Daniele S, Frosini D, Pietrobono D, et al. α -synuclein heterocomplexes with β -amyloid are
29 increased in red blood cells of Parkinson's disease patients and correlate with disease
30 severity. *Front Mol Neurosci* [Internet]. 2018 [cited 2020 Oct 10];11. Available from:
31 <https://pubmed.ncbi.nlm.nih.gov/29520218/>.
32
33 [111] Wong YC, Krainc D. α -synuclein toxicity in neurodegeneration: Mechanism and therapeutic
34 strategies. *Nat Med* [Internet]. 2017;23:1–13. Available from:
35 <http://dx.doi.org/10.1038/nm.4269>.
36
37 [112] Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid β -amyloid 1-
38 42, t-tau, p-tau 181, and α -synuclein levels with clinical features of drug-naive patients with
39 early parkinson disease. *JAMA Neurol* [Internet]. 2013 [cited 2020 Oct 8];70:1277–1287.
40 Available from: <https://pubmed.ncbi.nlm.nih.gov/23979011/>.
41
42 [113] Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longitudinal CSF biomarkers in
43 patients with early Parkinson disease and healthy controls. *Neurology* [Internet]. 2017 [cited
44 2020 Oct 8];89:1959–1969. Available from: <https://pubmed.ncbi.nlm.nih.gov/29030452/>.
45
46 * **A paper reviewing longitudinal changes in CSF biomarkers in Parkinson's Disease**
47
48 [114] Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy:
49 A review of the MSA Biomarker Initiative [Internet]. *Neurobiol. Dis.* Academic Press Inc.;
50 2015 [cited 2020 Oct 8]. p. 29–41. Available from:
51 <https://pubmed.ncbi.nlm.nih.gov/25982836/>.
52
53 [115] Delgado-Alvarado M, Gago B, Gorostidi A, et al. Tau/ α -synuclein ratio and inflammatory
54 proteins in Parkinson's disease: An exploratory study. *Mov Disord* [Internet]. 2017 [cited
55
56
57
58
59
60

- 2020 Oct 8];32:1066–1073. Available from: <https://pubmed.ncbi.nlm.nih.gov/28548309/>.
- [116] Aarsland D, Kurz MW. The epidemiology of dementia associated with parkinson's disease. *Brain Pathol* [Internet]. *Brain Pathol*; 2010 [cited 2020 Oct 16]. p. 633–639. Available from: <https://pubmed.ncbi.nlm.nih.gov/20522088/>.
- [117] Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. *Biol Psychiatry* [Internet]. 2008 [cited 2020 Oct 16];64:850–855. Available from: <https://pubmed.ncbi.nlm.nih.gov/18395699/>.
- [118] Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. *Neurology* [Internet]. 2010 [cited 2020 Oct 16];75:1055–1061. Available from: <https://pubmed.ncbi.nlm.nih.gov/20720189/>.
- [119] Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurol*. 2017;16:55.
- [120] Mukaetova-Ladinska EB, Monteith R, Perry EK. Cerebrospinal fluid biomarkers for Dementia with Lewy Bodies [Internet]. *Int. J. Alzheimers. Dis. Int J Alzheimers Dis*; 2010 [cited 2020 Oct 16]. Available from: <https://pubmed.ncbi.nlm.nih.gov/21048932/>.
- [121] Irwin DJ, Xie SX, Coughlin D, et al. CSF tau and β -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. *Neurology* [Internet]. 2018 [cited 2020 Oct 10];90:e1038–e1046. Available from: <https://n.neurology.org/content/90/12/e1038>.
- [122] Clark CM, Xie S, Chittams J, et al. Cerebrospinal Fluid Tau and β -Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses? *Arch Neurol* [Internet]. 2003 [cited 2020 Oct 10];60:1696–1702. Available from: <https://pubmed.ncbi.nlm.nih.gov/14676043/>.
- [123] Parnetti L, Lanari A, Amici S, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. *Neurol Sci* [Internet]. 2001 [cited 2020 Oct 10];22:77–78. Available from: <https://pubmed.ncbi.nlm.nih.gov/11487210/>.
- [124] Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies [Internet]. *Alzheimer's Res. Ther. BioMed Central Ltd.*; 2014 [cited 2020 Oct 10]. Available from: <https://pubmed.ncbi.nlm.nih.gov/25478030/>.
- [125] Coughlin DG, Xie SX, Liang M, et al. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders Abstract HHS Public Access. *Ann Neurol*. 2019;85:259–271.

- 1
2
3
4
5
6
7
8
9
10
11 [126] van der Zande JJ, Steenwijk MD, ten Kate M, et al. Gray matter atrophy in dementia with
12 Lewy bodies with and without concomitant Alzheimer's disease pathology. *Neurobiol Aging*
13 [Internet]. 2018 [cited 2020 Oct 16];71:171–178. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/30149288/>.
15
16 [127] Abdelnour C, Ferreira D, Oppedal K, et al. The combined effect of amyloid- β and tau
17 biomarkers on brain atrophy in dementia with Lewy bodies. *NeuroImage Clin* [Internet].
18 2020 [cited 2020 Oct 16];27. Available from: [/pmc/articles/PMC7363702/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/30149288/).
19
20 [128] Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy
21 [Internet]. *Auton. Neurosci. Basic Clin. Elsevier B.V.*; 2018 [cited 2020 Oct 9]. p. 15–25.
22 Available from: <https://pubmed.ncbi.nlm.nih.gov/29111419/>.
23
24 [129] Fanciulli A, Wenning GK. Multiple-System Atrophy. *N Engl J Med*. 2015;372:1375–1376.
25
26 [130] Seino Y, Nakamura T, Kawarabayashi T, et al. Cerebrospinal Fluid and Plasma Biomarkers
27 in Neurodegenerative Diseases. *J Alzheimer's Dis* [Internet]. 2019 [cited 2020 Oct
28 10];68:395–404. Available from: <https://pubmed.ncbi.nlm.nih.gov/30814356/>.
29
30 [131] Herbert MK, Eeftens JM, Aerts MB, et al. CSF levels of DJ-1 and tau distinguish MSA
31 patients from PD patients and controls. *Park Relat Disord* [Internet]. 2014 [cited 2020 Oct
32 9];20:112–115. Available from: <https://pubmed.ncbi.nlm.nih.gov/24075122/>.
33
34 [132] Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease
35 diagnosis and progression. *Ann Neurol* [Internet]. 2011 [cited 2020 Oct 9];69:570–580.
36 Available from: [/pmc/articles/PMC3117674/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/21117674/).
37
38 [133] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α -Synuclein and tau concentrations
39 in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. *Lancet*
40 *Neurol*. 2011;10:230–240.
41
42 [134] Constantinides VC, Paraskevas GP, Emmanouilidou E, et al. CSF biomarkers β -amyloid, tau
43 proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. *J Neurol*
44 *Sci*. 2017;382:91–95.
45
46 [135] Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-
47 synuclein in blood. *Neurodegener Dis*. 2008;5:55–59.
48
49 [136] Wang X, Yu S, Li F, et al. Detection of α -synuclein oligomers in red blood cells as a
50 potential biomarker of Parkinson's disease. *Neurosci Lett* [Internet]. 2015 [cited 2020 Oct
51 10];599:115–119. Available from: <https://pubmed.ncbi.nlm.nih.gov/25998655/>.
52
53 [137] Ashton NJ, Hye A, Rajkumar AP, et al. An update on blood-based biomarkers for non-
54 Alzheimer neurodegenerative disorders [Internet]. *Nat. Rev. Neurol. Nature Research*; 2020
55 [cited 2020 Oct 16]. p. 265–284. Available from:

- 1
2
3
4
5
6
7
8
9
10
11 <https://pubmed.ncbi.nlm.nih.gov/32322100/>.
- 12 [138] Universities S, Cu M, Dubois B, et al. Advancing research diagnostic criteria for Alzheimer's
13 disease : The IWG-2 criteria Position Paper Advancing research diagnostic criteria for
14 Alzheimer's disease : the IWG-2 criteria. *Lancet Neurol.* 2014;13 (6):614–649.
- 15 [139] Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-
16 dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging
17 probes for beta-amyloid plaques in Alzheimer's disease. *J Neurosci.* 2001;
- 18 [140] Thompson PW, Ye L, Morgenstern JL, et al. Interaction of the amyloid imaging tracer
19 FDDNP with hallmark Alzheimer's disease pathologies. *J Neurochem.* 2009;
- 20 [141] Villemagne VL, Okamura N. In vivo tau imaging: Obstacles and progress. *Alzheimer's*
21 *Dement.* 2014;
- 22 [142] Villemagne VL, Furumoto S, Fodero-Tavoletti M, et al. The challenges of tau imaging.
23 *Future Neurol.* 2012.
- 24 [143] Lemoine L, Saint-Aubert L, Nennesmo I, et al. Cortical laminar tau deposits and activated
25 astrocytes in Alzheimer's disease visualised by 3 H-THK5117 and 3 H-deprenyl
26 autoradiography. *Sci Rep.* 2017;
- 27 [144] Vermeiren C, Motte P, Viot D, et al. The tau positron-emission tomography tracer AV-1451
28 binds with similar affinities to tau fibrils and monoamine oxidases. *Mov Disord.* 2018;
- 29 [145] Brosch JR, Farlow MR, Risacher SL, et al. Tau Imaging in Alzheimer's Disease Diagnosis
30 and Clinical Trials. *Neurotherapeutics.* 2017.
- 31 [146] Perez-Soriano A, Arena JE, Dinelle K, et al. PBB3 imaging in Parkinsonian disorders:
32 Evidence for binding to tau and other proteins. *Mov Disord.* 2017;
- 33 [147] Lois C, Gonzalez I, Johnson KA, et al. PET imaging of tau protein targets: a methodology
34 perspective. *Brain Imaging Behav.* 2019;
- 35
36
37
38
39
40
41 *** A comprehensive overview on tau imaging in AD**
- 42 [148] Barthel H. First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of
43 Alzheimer Disease. *J. Nucl. Med.* 2020.
- 44 [149] Braak H, Thal DR, Ghebremedhin E, et al. Stages of the Pathologic Process in Alzheimer
45 Disease: Age Categories From 1 to 100 Years. *J Neuropathol Exp Neurol.* 2011;70:960–969.
- 46 [150] Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. *J*
47 *Neurol Sci.* 1970;
- 48 [151] Xia CF, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography
49 imaging agent for Alzheimer's disease. *Alzheimer's Dement.* 2013;
- 50 [152] Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel
51
52
53
54

- 1
2
3
4
5
6
7
8
9
10 PHF-tau radioligand [F18]-T808. *J Alzheimer's Dis.* 2014;
- 11 [153] Fleisher AS, Pontecorvo MJ, Devous MD, et al. Positron Emission Tomography Imaging
12 with [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic
13 Changes. *JAMA Neurol.* 2020;
- 14 [154] Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir
15 positron emission tomography for Alzheimer disease vs other neurodegenerative disorders.
16 *JAMA - J Am Med Assoc.* 2018;
- 17 [155] Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: A novel PET radiotracer for
18 imaging neurofibrillary pathology in Alzheimer disease. *J Nucl Med.* 2016;
- 19 [156] Schöll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging
20 Human Brain. *Neuron.* 2016;
- 21 [157] Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in
22 aging and early Alzheimer disease. *Ann Neurol.* 2016;
- 23 [158] Chiotis K, Saint-Aubert L, Savitcheva I, et al. Imaging in-vivo tau pathology in Alzheimer's
24 disease with THK5317 PET in a multimodal paradigm. *Eur J Nucl Med Mol Imaging.* 2016;
- 25 [159] Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in
26 the Alzheimer disease spectrum. *Ann Neurol.* 2016;
- 27 [160] Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive
28 impairment. *Neurology.* 2016;
- 29 [161] Pontecorvo MJ, Devous MD, Navitsky M, et al. Relationships between flortaucipir PET tau
30 binding and amyloid burden, clinical diagnosis, age and cognition. *Brain.* 2017;
- 31 [162] Marshall GA, Fairbanks LA, Tekin S, et al. Early-onset Alzheimer's disease is associated
32 with greater pathologic burden. *J Geriatr Psychiatry Neurol.* 2007;
- 33 [163] Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease:
34 Implications for prevention trials. *Neuron.* 2014.
- 35 [164] Ishiki A, Okamura N, Furukawa K, et al. Longitudinal assessment of Tau pathology in
36 patients with Alzheimer's disease using [18F] THK-5117 positron emission tomography.
37 *PLoS One.* 2015;
- 38 [165] Jack CR, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer's
39 disease. *Brain.* 2018;
- 40 [166] Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, et al. Longitudinal changes of tau PET
41 imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. *Mol*
42 *Psychiatry.* 2018;
- 43 [167] Cho H, Choi JY, Lee HS, et al. Progressive tau accumulation in Alzheimer disease: 2-year
44
45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8
9
10 follow-up study. *J Nucl Med.* 2019;
- 11 [168] Hansson O, Mormino EC. Is longitudinal tau PET ready for use in Alzheimer's disease
12 clinical trials? *Brain.* 2018.
- 13 [169] Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and
14 neuroanatomical variability in Alzheimer's disease. *Brain.* 2016;
- 15 [170] Dronse J, Fließbach K, Bischof GN, et al. In vivo Patterns of Tau Pathology, Amyloid- β
16 Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. *J*
17 *Alzheimer's Dis.* 2017;
- 18 [171] Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a
19 patient with posterior cortical atrophy. *Ann Neurol.* 2015;
- 20 [172] Phillips JS, Das SR, McMillan CT, et al. Tau PET imaging predicts cognition in atypical
21 variants of Alzheimer's disease. *Hum Brain Mapp.* 2018;
- 22 [173] Okamura N, Harada R, Ishiki A, et al. The development and validation of tau PET tracers:
23 current status and future directions. *Clin. Transl. Imaging.* 2018.
- 24 [174] Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic performance of RO948 F 18 tau
25 positron emission tomography in the differentiation of alzheimer disease from other
26 neurodegenerative disorders. *JAMA Neurol.* 2020;
- 27 [175] Wong DF, Comley RA, Kuwabara H, et al. Characterization of 3 novel tau
28 radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in
29 Alzheimer subjects. *J Nucl Med.* 2018;
- 30 [176] Smith R, Schöll M, Leuzy A, et al. Head-to-head comparison of tau positron emission
31 tomography tracers [18F]flortaucipir and [18F]RO948. *Eur J Nucl Med Mol Imaging.* 2020;
- 32 [177] Stephens A, Seibyl J, Mueller A, et al. IC-P-220: CLINICAL UPDATE: 18 F-PI-2620, A
33 NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH
34 ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY .
35 *Alzheimer's Dement.* 2018;
- 36 [178] Betthausen TJ, Cody KA, Zammit MD, et al. In vivo characterization and quantification of
37 neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from Alzheimer disease
38 dementia to young controls. *J Nucl Med.* 2019;
- 39 [179] Lohith TG, Bennacef I, Vandenberghe R, et al. Brain imaging of Alzheimer dementia
40 patients and elderly controls with 18 F-MK-6240, a PET tracer targeting neurofibrillary
41 tangles. *J Nucl Med.* 2019;
- 42 [180] Pascoal TA, Shin M, Kang MS, et al. In vivo quantification of neurofibrillary tangles with [
43 18 F]MK-6240. *Alzheimer's Res Ther.* 2018;

- 1
2
3
4
5
6
7
8
9
10
11 [181] Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution
12 distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
13 Brain. 2007;
- 14 [182] Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white
15 matter of corticobasal degeneration. Am J Pathol. 2002;
- 16 [183] Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal
17 degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain. 2011;
- 18 [184] Ling H, Kovacs GG, Vonsattel JPG, et al. Astroglial pathology predominates the earliest stage of
19 corticobasal degeneration pathology. Brain. 2016;
- 20 [185] Saeed U, Lang AE, Masellis M. Neuroimaging Advances in Parkinson's Disease and
21 Atypical Parkinsonian Syndromes. Front. Neurol. 2020.
- 22 [186] Ishiki A, Harada R, Okamura N, et al. Tau imaging with [18F]THK-5351 in progressive
23 supranuclear palsy. Eur J Neurol. 2017;
- 24 [187] Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of 18F-AV-1451 in
25 patients with progressive supranuclear palsy. Mov Disord. 2017;
- 26 [188] Cho H, Choi JY, Hwang MS, et al. Subcortical 18F-AV-1451 binding patterns in progressive
27 supranuclear palsy. Mov Disord. 2017;
- 28 [189] Whitwell JL, Lowe VI, Tosakulwong N, et al. [18F]AV-1451 tau positron emission
29 tomography in progressive supranuclear palsy. Mov Disord. 2017;
- 30 [190] Passamonti L, Rodríguez PV, Hong YT, et al. 18F-AV-1451 positron emission tomography
31 in Alzheimer's disease and progressive supranuclear palsy. Brain. 2017;
- 32 [191] Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient
33 with progressive supranuclear palsy. Mov. Disord. 2017.
- 34 [192] Coakeley S, Cho SS, Koshimori Y, et al. Positron emission tomography imaging of tau
35 pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab. 2017;
- 36 [193] Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies:
37 Progressive supranuclear palsy. J Alzheimer's Dis. 2013;
- 38 [194] Schonhaut DR, McMillan CT, Spina S, et al. 18F-flortaucipir tau positron emission
39 tomography distinguishes established progressive supranuclear palsy from controls and
40 Parkinson disease: A multicenter study. Ann Neurol. 2017;
- 41 [195] Brendel M, Schönecker S, Höglinger G, et al. [18F]-THK5351 PET correlates with topology
42 and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2018;
- 43 [196] Hsu JL, Chen SH, Hsiao IT, et al. 18F-THK5351 PET imaging in patients with progressive
44 supranuclear palsy: associations with core domains and diagnostic certainty. Sci Rep. 2020;
- 45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8
9
10
11 [197] Whitwell JL, Tosakulwong N, Botha H, et al. Brain volume and flortaucipir analysis of
12 progressive supranuclear palsy clinical variants. *NeuroImage Clin.* 2020;
13 [198] Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse
14 model and in alzheimer patients compared to normal controls. *Neuron.* 2013;
15 [199] Kikuchi A, Okamura N, Hasegawa T, et al. In vivo visualization of tau deposits in
16 corticobasal syndrome by 18 F-THK5351 PET. *Neurology.* 2016;
17 [200] McMillan CT, Irwin DJ, Nasrallah I, et al. Multimodal evaluation demonstrates in vivo 18F-
18 AV-1451 uptake in autopsy-confirmed corticobasal degeneration. *Acta Neuropathol.* 2016.
19 [201] Ali F, Whitwell JL, Martin PR, et al. [18F] AV-1451 uptake in corticobasal syndrome: the
20 influence of beta-amyloid and clinical presentation. *J Neurol.* 2018;
21 [202] Tsai RM, Bejanin A, Lesman-Segev O, et al. 18F-flortaucipir (AV-1451) tau PET in
22 frontotemporal dementia syndromes. *Alzheimer's Res Ther.* 2019;
23 [203] Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in
24 dementia. *Acta Neuropathol Commun.* 2016;
25 [204] Brendel M, Barthel H, Van Eimeren T, et al. Assessment of 18F-PI-2620 as a Biomarker in
26 Progressive Supranuclear Palsy. *JAMA Neurol.* 2020;
27 [205] Kroth H, Oden F, Molette J, et al. Discovery and preclinical characterization of [18F]PI-
28 2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's
29 disease and other tauopathies. *Eur J Nucl Med Mol Imaging.* 2019;
30 [206] Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer's fluid biomarkers
31 [Internet]. *Acta Neuropathol.* Springer Berlin Heidelberg; 2018. Available from:
32 <https://doi.org/10.1007/s00401-018-1932-x>.
33 [207] Hampel H, Goetzl EJ, Kapogiannis D, et al. Biomarker-drug and liquid biopsy co-
34 development for disease staging and targeted therapy: Cornerstones for Alzheimer's
35 precision medicine and pharmacology. *Front Pharmacol.* 2019;10:1–10.
36 [208] Thijssen EH, Rabinovici GD. Rapid Progress Toward Reliable Blood Tests for Alzheimer
37 Disease. *JAMA Neurol.* 2020;
38 [209] Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-
39 tau181 as a biomarker of Alzheimer's disease. *Nat Commun* [Internet]. 2020 [cited 2020 Dec
40 5];11. Available from: <https://pubmed.ncbi.nlm.nih.gov/32246036/>.
41 * A recent paper exploring the potential role of p-tau217 as a biomarker for AD
42 [210] Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels with
43 Tau Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurol.* 2020;
44 * A recent paper exploring the potential role of p-tau217 as a biomarker for AD
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [211] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α -Synuclein and tau concentrations
12 in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. *Lancet*
13 *Neurol* [Internet]. 2011 [cited 2020 Oct 10];10:230–240. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/21317042/>.
15
16 [212] Hampel H, Lista S, Neri C, et al. Time for the systems-level integration of aging: Resilience
17 enhancing strategies to prevent Alzheimer’s disease. *Prog Neurobiol* [Internet].
18 2019;181:101662. Available from: <https://doi.org/10.1016/j.pneurobio.2019.101662>.
19
20 [213] Toschi N, Lista S, Baldacci F, et al. Biomarker-guided clustering of Alzheimer’s disease
21 clinical syndromes. *Neurobiol Aging*. 2019;83:42–53.
22
23 [214] Hampel H, Caraci F, Cuello AC, et al. A Path Toward Precision Medicine for
24 Neuroinflammatory Mechanisms in Alzheimer’s Disease. *Front Immunol*. 2020;11.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11 **Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other**
12 **neurodegenerative diseases**
13
14

15
16 **Abstract**
17

18 **Introduction** Tau protein misfolding and accumulation in toxic species is a critical
19 pathophysiological process of Alzheimer's Disease (AD) and other neurodegenerative disorders
20 (NDDs). Tau biomarkers, namely cerebrospinal fluid (CSF) total-tau (t-tau), 181-phosphorylated
21 tau (p-tau) and tau-PET tracers, have been recently embedded in the diagnostic criteria for AD.
22 Nevertheless, the role of tau as a diagnostic and prognostic biomarker for other NDDs remains
23 controversial.
24

25
26 **Areas covered** We performed a systematical PubMed-based review of the most recent advances in
27 tau-related biomarkers for NDDs. We focused on papers published from 2015 to 2020 assessing the
28 diagnostic or prognostic value of each biomarker.
29

30 **Expert opinion** The assessment of tau biomarkers in alternative easily accessible matrices, through
31 the development of ultrasensitive techniques, represents the most significant perspective for AD-
32 biomarker research. In NDDs, novel tau isoforms (e.g., p-tau217) or proteolytic fragments (e.g., N-
33 terminal fragments) may represent candidate diagnostic and prognostic biomarkers and may help
34 monitoring disease progression. Protein misfolding amplification assays, allowing the identification
35 of different tau strains (e.g. 3R- vs. 4R-tau) in CSF, may constitute a breakthrough for the in vivo
36 stratification of NDDs. Tau-PET may help tracking the spatial-temporal evolution of tau
37 pathophysiology in AD but its application outside the AD-spectrum deserves further studies.
38
39

40
41
42 **Keywords:** Alzheimer's Disease, Fluid biomarkers, Neurodegenerative diseases, Tau, Tau-PET,
43 Ultrasensitive techniques
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article highlights

- Tau protein misfolding and accumulation in toxic species and tangles is a critical pathophysiological process of Alzheimer's Disease (AD) and other neurodegenerative disorders (NDDs);
- Cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) are included in the current diagnostic criteria for AD; in primary tauopathies and in other NDDs (ALS-FTD spectrum and α -synucleinopathies) the role of tau as a diagnostic and prognostic biomarker is still controversial;
- The quantification of t-tau and p-tau and of emerging tau biomarkers in plasma by using ultrasensitive techniques are gaining momentum in the AD diagnostic workup;
- Novel tau fragments and tau isoforms detectable by means of ultrasensitive methods including Protein Misfolding Cyclic Amplification (PMCA) and Real-time quaking-induced conversion (RT-QuIC) may improve the *in vivo* stratification of NDDs;
- Tau-PET tracers are useful tools for the *in vivo* tracking of the spatial-temporal evolution of tau pathophysiology in AD but further studies are needed to define their proper context-of-use in other tauopathies.

1. Introduction

Tau is a natively unfolded microtubule-associated protein largely expressed in the central nervous system[1]. This protein plays an important role in microtubule polymerization, stabilization and remodeling, and is mainly expressed in the axons, where it also participates in regulating cellular transport processes[2,3]. Tau exists in 6 isoforms generated through the alternative splicing of the exons 2, 3 and 10 of the microtubule-associated protein tau (MAPT) gene[4]. The microtubule-binding domain (MBD) is encoded by the exon 10, whose alternative splicing produces 3 isoforms, each with 3 or 4 repeats, respectively called 3-repeat (3R) and 4-repeat (4R) tau[2]. Under pathological conditions, mutations in the MAPT gene along with a hyper-phosphorylation of tau may reduce the affinity of the MBD to the microtubules[5]. Accordingly, tau free-protein concentrations increase to a tipping point after which misfolded protein intermediates self-assembly into unwanted oligomers, fibrils, and neurofibrillary tangles (NFT)[5].

The neuronal and/or glial accumulation of aberrant tau aggregates represents the pathological hallmark of a broad spectrum of neurodegenerative disorders (NDDs) called tauopathies [6]. These include the so-called primary tauopathies, a group of NDDs, in which tau aggregates, including NFT, represent the main pathological hallmark. Primary tauopathies can be classified into 3R-tauopathies, 4R-tauopathies and mixed 3R/4R tauopathies. The major clinical phenotypes belong to the spectrum of Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) and Frontotemporal Lobar Degeneration with tau deposits (FTLD-Tau) [2,6]. Secondary tauopathies are conditions resulting from a complex interplay between tau and other misfolded proteins (e.g., amyloid- β - A β) or related to alternative causes (e.g., autoimmune processes). Alzheimer's Disease (AD) represents the best characterized and more intensively studied NDDs and is classified as secondary tauopathy[2,7]. More recently, other forms of secondary tauopathies have been described including chronic traumatic encephalopathy (CTE) and the autoimmune anti-IgLN5 encephalitis [2]. Tau cytoplasmic inclusions have also been reported in Frontotemporal Dementia (FTD); up to 30% of patients with the behavioral variant of frontotemporal dementia (bvFTD) and the majority (approximately 90%) of patients with the non-fluent variant of Primary progressive aphasia (nfvPPA) show tau pathologic depositions [8]. Also in α -synucleinopathies, where aberrant α -synuclein aggregates underpin the neurodegenerative mechanisms, NFT are likely to cause neurodegeneration and contribute to the disease burden [9,10].

Tau biomarkers are included in the diagnostic workup of AD according to the 2011 National Institute on Aging – Alzheimer's Association (NIA-AA), the 2014 International Working Group-2 (IWG-2) criteria and the AT(N) classification system [11,12]. In 2018 the AT(N) scheme embed biomarkers of amyloid- β -related pathology (A), tau-pathology (T) and other markers of

1
2
3
4
5
6
7
8
9
10
11 neurodegeneration (N) [13]. This classification includes cerebrospinal fluid (CSF) total-tau (t-tau),
12 as biomarker of neurodegeneration (N) and 181-phosphorylated-tau (p-tau181 or simply p-tau), as
13 biomarker of tau pathology [13]. These biomarkers are all increased in AD individuals. The AT(N)
14 categorization for the first time added cerebral tau- positron emission tomography (PET) as core
15 biomarker of AD. Indeed, the implementation of tau-PET tracers represents a recent step forward in
16 the AD diagnostic workup [13].

17
18 Currently, the *ante-mortem* diagnosis of non-AD NDDs mainly relies on pure clinically
19 based criteria. In this scenario, the diagnostic and prognostic value of tau protein in the spectrum of
20 primary tauopathies remains unsatisfactory when measured with traditional approaches (e.g.
21 ELISA) [14]. In fact, a biomarkers-based diagnosis is still an unmet need in NDDs and several
22 methodological challenges should be addressed to overcome this limitation. In the last years, the
23 use of ultrasensitive assays, the discovery of alternative tau byproducts in biofluids, and the
24 development of innovative techniques, enabling the differentiation of tau strains, have represented
25 potential breakthroughs for the *in vivo* dissection of tau pathology spectrum.

26
27 The validation of biomarkers tracking neurodegenerative processes and predicting
28 pathophysiological progression at the earliest molecular/cellular changes is an unmet need for the
29 early diagnosis, the prognostic evaluation and for patients selection and follow-up in targeted-
30 therapy clinical trials [15].

31
32 We aim to review the current state of the art on the use of tau protein as a biomarker for NDDs.
33 First, we investigated recent advances of this fluid biomarker in the diagnostic and prognostic
34 workup of AD and other NDDs. Secondly, we evaluated the contribution of cerebral PET-imaging
35 in tracking tau pathology across the NDDs spectrum.
36
37
38

39 40 **2. Literature search methods**

41
42 The aim of the present work is to review the most recent advances on tau as a biomarker for
43 neurodegenerative diseases. A systematic PubMed-based literature search was performed to select
44 relevant papers assessing the diagnostic and/or prognostic value of plasma tau (both t-tau, p-tau,
45 and other tau fragments) in AD and other NDDs, as evaluated through novel ultrasensitive
46 techniques and of CSF tau in other neurodegenerative diseases. We screened the papers using the
47 following combination of keywords:

48
49 - for plasma tau in AD and other NDDs: (("plasma" OR "blood" OR "serum") AND ("tau") AND
50 ("Alzheimer" OR "Corticobasal degeneration" OR "Progressive Supranuclear Palsy" OR
51 "Amyotrophic Lateral Sclerosis" OR "Frontotemporal Dementia" OR "Parkinson" OR "Multiple
52 System Atrophy" OR "Lewy Body"));
53
54

1
2
3
4
5
6
7
8
9
10
11 - for CSF tau in NDDs (AD excluded): (("CSF") AND ("tau") AND ("Corticobasal Degeneration"
12 OR "Progressive Supranuclear Palsy" OR "Amyotrophic Lateral Sclerosis" OR "Frontotemporal
13 Dementia" OR "Parkinson's Disease" OR "Multiple System Atrophy" Or "Dementia With Lewy
14 Bodies"))).

15 Only papers written in English, assessing the prognostic and/or diagnostic value of tau and
16 published between 2015 and 2020, were included in the final analysis. A total number of 1480 and
17 297 articles for plasma tau and CSF tau respectively were initially screened. Fourteen papers on
18 plasma tau and 14 on CSF tau were retained in the final analysis (Fig.2).

19 For each study, we analyzed the study population, the technique used for biomarkers detection, the
20 diagnostic and/or prognostic performance of the investigated biomarker. Given the high
21 heterogeneity of the papers included, we used the AuROC values as a concise measure of
22 diagnostic accuracy to compare different studies. The diagnostic value of each marker to properly
23 allocate patients to different diagnostic groups was identified when available and classified as
24 follows: 'excellent' (area under ROC curve [AuROC] 0.90–1.00), 'good' (AuROC: 0.80–0.89),
25 'fair' (AuROC: 0.70–0.79), 'poor' (AuROC: 0.60–0.69), or 'fail' (i.e., no discriminatory capacity)
26 (AuROC: 0.50–0.59) [16]. We used hazard ratios (HR) to compare the prognostic values. Possible
27 comparisons across studies are only qualitative, and not based on statistical analysis.

32 33 **3. Fluid biomarkers tracking tau-pathology: from conventional to ultrasensitive techniques**

34 Fluid biomarkers represent promising tools for the in vivo tracking of early pathophysiological
35 changes in NDDs. Their detection and quantification in different matrices and related technical
36 issues are regarded as hot topics in biomarkers research [14].

37 Tau quantification in CSF represents the first and most widely validated approach for the in vivo
38 detection of tau protein. Tau, quantified in the CSF both as t-tau and p-tau181 currently belongs to
39 the core AD biomarkers, along with amyloid- β_{42} ($A\beta_{42}$), and its assessment is based on traditional
40 Enzyme-linked immunoabsorbent assay (ELISA) techniques [11–13]. Accordingly, several
41 commercial kits are to date available for both clinical and research purposes [17]. Even if broadly
42 used and largely validated, standard tau quantification techniques present three main limitations: 1)
43 they are unable to effectively quantify tau in "peripheral" matrices (e.g., plasma), where its
44 concentration is significantly low [18], 2) they fail in detecting alternative tau species (e.g., p-tau-
45 217) 3) are ineffective in differentiating tau isoforms (e.g., 3R and 4R tau), seeds (e.g., tau fibrils),
46 based on their tridimensional conformation [19].

47 Traditional methods show unsatisfactory and suboptimal power in differentiating patients with
48 NDDs from healthy controls (HC) when applied to biological matrices other than CSF (e.g., blood),
49
50
51
52
53

1
2
3
4
5
6
7
8
9
10 where these molecules are expressed at femtomolar ranges instead of picomoles [20]. The
11 quantification of tau in non-CSF substrates is challenging because the concentration of the analyte
12 may not reflect primary neurodegenerative changes. Variations in tau concentrations could be due
13 to peripheral proteolytic processes, metabolic clearance, the interaction with other proteins and
14 modifications of the of brain blood barrier permeability[21].

15
16 Novel techniques, developed and validated in the last five years, show better sensitivity in
17 measuring tau levels than traditional methods by detecting up to subpicomolar and even
18 subfemtomolar concentrations. These techniques mostly address the N-terminal rather than mid-
19 region of tau. Single Molecule Array (Simoa), a fully-automated ELISA relying on antibody-coated
20 magnetic beads, has been used to assess t-tau, p-tau [22–24] and N-terminal tau fragments [25] in
21 blood samples of AD patients (Table 1). On the other hand, Electrochemiluminescence
22 immunoassays (ECLIA) provide a quantification of t-tau [26], p-tau181 [27–29] and p-tau217
23 [30,31] in patients with AD, with high accuracy even in low sample volumes (Table 1). An upgrade
24 of standard mass spectrometry (MS), combining immunoprecipitation reactions with MS [32,33],
25 tracks different phosphorylated tau isoforms like p-tau217 and p-tau181 in plasma [33](Table 1).
26 Also immunomagnetic reaction (IMR) – an antibody-mediated reaction generating changes in the
27 magnetic fields that enable the quantification of the analyte [34,35] – detects t-tau [36–39] and p-
28 tau181 [37,39] concentrations with a greater sensitivity compared to traditional techniques, but with
29 suboptimal specificity (Table 1).

30
31 However, these ultrasensitive techniques fail in discriminating different tridimensional
32 conformations of tau (e.g., 3R vs 4R tau). Nevertheless, the selective identification of different tau
33 seeds represents a critical issue to understand the pathophysiology of the primary tauopathies.
34 Based also on the hypothesis of a prion-like transcellular propagation of tau, real-time quaking-
35 induced conversion (RT-QuIC) and protein misfolded cycle amplification (PMCA) have been
36 successfully applied in NDDs [40]. These techniques were initially developed for the detection of
37 prion proteins in Creutzfeldt-Jakob disease. RT-QuIC uses recombinant protein substrates
38 undergoing shaking and incubation cycles to quantify seeding activity of prions (e.g. PrP) and
39 prion-like proteins, such as α -synuclein (α -syn) and tau strains [41]. Similarly, in PMCA seeding
40 activity of substrates derived from brain homogenates or recombinant proteins is amplified by
41 cycles of sonification, enabling a sensitive detection and a selective amplification of specific protein
42 seeds [40].

43
44 More extensive research is necessary for the analytical and clinical validation of these approaches
45 by clarifying advantages and drawbacks. Finally, an accurate qualification process, mostly based on
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 clinical performance, will be required to define context(s)-of-use for pharmacological trials and
11 clinical practice.
12
13

14 **4. Advances in tau as a biomarker for Alzheimer's Disease: assessing novel matrices,** 15 **techniques and targets** 16

17 T-tau and p-tau proteins measured in CSF are core biomarkers of neurodegeneration in AD [11,12].
18 The finding of alternative tau isoforms specific for the different clinical and pathological AD
19 subtypes may represent a significant advancement, in parallel with the recent development of
20 ultrasensitive techniques that allow the measurement of tau proteins in blood.
21

22 To overcome several technical issues including the higher dilution of tau biomarkers in
23 blood vs. CSF [42], several antibody-driven assays have been combined with different detection
24 systems reaching subpicomolar and even subfemtomolar limits of detection (LOD) [43]. A
25 metaanalysis indicated that plasma t-tau is increased in AD [44]. A study performed with IMR
26 techniques showed that plasma t-tau levels discriminated AD from controls with optimal accuracy
27 (Table 2) [36]. By contrast, other studies conducted with Simoa and IMR reported higher plasma t-
28 tau concentrations in AD or Mild Cognitive Impairment (MCI) patients compared to HC, but with
29 consistent overlapping results [27,36,39,45,46]. Furthermore, plasma t-tau is not or only weakly
30 correlated with CSF t-tau, p-tau in different studies [45,47–49]. An inverse association between t-
31 tau and cortical thickness in AD-related areas has been reported [38,46]. Plasma t-tau was
32 associated in AD, MCI and HC with a longitudinal decline of cognitive scores and cerebral 18FDG-
33 uptake at PET imaging, increased ventricular volume, and a decrease of hippocampal volume
34 [47,50]. Combining plasma t-tau into ratios (e.g., with plasma amyloid- β_{1-42}) increases the
35 predictive value of cerebral tau accumulation, as assessed by PET, compared to t-tau alone [22]. On
36 the other hand, plasma t-tau did not predict the amyloid- β -status as assessed by cerebral amyloid-
37 PET [27] or CSF [26] in AD, MCI, and HC. Intriguingly baseline plasma t-tau levels seem to be
38 associated with atrophy of the basal forebrain cholinergic system (BFCS) in subjective memory
39 complainers, regardless of their amyloid- β -status [51], although no differences in plasma t-tau
40 levels emerged between SCD and HC in a further study [48]. Finally, plasma t-tau levels were
41 found to be associated with MAPT H1c haplotype in AD, MCI and HC, according to a genome-
42 wide association study (GWAS) [52].
43
44
45
46
47
48

49 Full-length (FL) tau may account only for a small part of plasma tau proteins. Different
50 proteolytic fragments of tau have been explored in plasma with ultrasensitive techniques so far. The
51 levels of tau N1 fragments, measured with Simoa, are higher in AD and AD-MCI subjects than HC,
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 showing good to optimal accuracy in discriminating HC from AD and MCI subjects, respectively
11 [25] (Table 2). The actual eligibility of these fragments is still a matter of debate [53].

12
13 Conversely, plasma p-tau181 seems to be a more specific AD biomarker. Plasma p-tau181
14 concentrations assessed by Simoa, IMR and ECLIA-based techniques are higher in AD and MCI-
15 AD compared to HCs [23,27–29,39]. Plasma p-tau181 distinguishes AD patients from non-AD
16 dementias taken together [28] and from vascular dementia (VaD) with optimal accuracy [23], from
17 FTD with good to optimal accuracy [23,29] and from PSP, CBD and Parkinson's disease (PD) or
18 Multiple System Atrophy (MSA) with good accuracy [23] (Table 2). Furthermore, plasma p-tau
19 concentration is consistent with CSF p-tau levels in A β -PET positive individuals [28,29]. Plasma p-
20 tau181 predicts the A β -PET status with good accuracy and is associated with both A β and tau PET
21 positivity in MCI, AD, and HC [27] (Table 2). Moreover, in a cohort of AD, MCI and HC, plasma
22 p-tau181 correlated with tau deposition within the brain [22].

23
24
25
26 Tau isoforms other than p-tau181 have been recently studied and showed a potential role in
27 the differential diagnosis of AD from MCI and HC. Plasma p-tau217 was able to differentiate AD
28 (clinically assessed) from non-AD patients and autopsy-confirmed AD from non-AD patients with
29 slightly suboptimal accuracy [30] (Table 2). Plasma p-tau-217 levels predict the amyloid- β -status as
30 assessed by amyloid-PET or CSF A β 42/A β 40 ratio with optimal accuracy across preclinical-AD,
31 AD-MCI, moderate AD, non-AD-MCI and HC [33] (Table 2). Furthermore p-tau217 could
32 discriminate amyloid- β positive and tau-PET negative participants from HC and has a potential role
33 as an early, preclinical biomarker, being able to assess tau increase before detectable tau
34 aggregation. Both plasma p-tau217 and p-tau181 correlated with their CSF counterparts and were
35 shown to be released from CNS rather than from peripheral sources, thus probably representing
36 more reliable AD biomarkers than plasma t-tau and p-tau202 [33]. Moreover, the cerebral A β
37 plaques and tau tangles accumulation is independently associated with *ante-mortem* concentrations
38 of plasma p-tau217 in an autopsy-confirmed cohort [54]

39
40
41
42 Recently, dynamic trajectories of subsequent site-specific phosphorylation of tau have been
43 reported from preclinical to full-blown AD stages in CSF. While p-tau217 and p-tau181 increase as
44 early as two decades before and tend to decline close to the symptomatic stage, the levels of t-tau
45 and p-tau205 increase later (between 17-13 estimated years to symptom onset) and constantly
46 increase along disease progression [55] Also p-tau231 assessed in CSF by using a mid-region target
47 antibody increases in preclinical AD, largely before p-tau181 and p-tau217, when only subtle A β
48 pathology is detectable [56]. [These preliminary data suggest the potential role of alternative site-
49 specific phosphorylated isoforms of CSF p-tau for the identification of preclinical AD and for the
50 subsequent risk of phenoconversion. Dynamic changes of tau phosphorylation profile may also
51 represent a potential useful biomarker to assess the efficacy of disease modifying therapies in
52 clinical trials but a better understanding of these changes and a more extensive validation of these
53 biomarkers and their potential context-of-use is needed. Furthermore, whether these changes are
54 reflected in plasma and their timing is an issue that should be assessed.

Commented [EB1]: idem

5. The diagnostic and prognostic role of tau as a biomarker in 4R-tauopathies

Tauopathies are pathologically characterized by a predominant intracellular accumulation of hyperphosphorylated tau fibrils [1,2] Primary tauopathies can be divided into 3R-tauopathies, including Pick's Disease (PiD), and 4R-tauopathies like PSP, CBD, Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT). Mixed 3R- and 4R-tauopathies include Primary Age-Related Tauopathy (PART) and neurofibrillary tangles dementia[2]. The genetic FTLT due to MAPT mutations may be related either to 3R-, 4R- or 3/4 R-tau pathological patterns [3](Figure 1). The clinical phenotype of these forms is highly heterogeneous and may not reflect the underlying pathology [14,57].

Currently, the diagnosis of 4R-tauopathies relies on the post-mortem detection of disease-specific patterns of abnormal tau aggregates [3]. Nevertheless, the in vivo diagnosis of these disorders is based on purely clinical-based criteria without reliable biomarkers to track the different tau pathologies [3,14,58].

The potential role of CSF tau concentration as a diagnostic and prognostic biomarker in 4R-tauopathies (especially PSP and corticobasal syndrome - CBS) has been investigated by several studies since 1997, with conflicting results. The measurement of CSF t-tau and p-tau concentrations is helpful in the diagnostic workup of AD. Indeed the characteristic increase of tau species (t-tau or p-tau) in the CSF is specific to AD pathology and lacks in non-AD dementias (including PSP and CBS) [59,60]. Further, CSF t-tau and p-tau do not distinguish PD from atypical parkinsonism with enough accuracy (in particular from PSP) [61]. Nevertheless these biomarkers when combined with others in CSF – α -synuclein, A β 42, neurofilament (NFL) [62], soluble amyloid precursor protein α (sAPP α), soluble amyloid precursor protein β (sAPP β), monocyte chemoattractant protein-1 (MCP-1), YKL-40 [63] – may discriminate PSP from PD individuals, as well as CBS from PD and AD/FTD though with conflicting results (Table 3). Similarly, p-tau and t-tau CSF concentrations do not differentiate idiopathic normal pressure hydrocephalus (iNPH), a well-known parkinsonian syndrome-mimic, from PSP [64] (Table 3). Nonetheless, the combination of t-tau, A β 40 and MCP-1 differentiate iNPH from other neurodegenerative movement disorders taken as a whole (e.g. PD, MSA, PSP and CBD irrespective of their underlying pathology) with good accuracy (AuROC: 0.80) [65].

Within the tau-spectrum, a trend towards higher CSF tau (both t-tau and p-tau) levels has been reported in CBS compared to PSP and HCs [66–68]. Accordingly, Aerts and colleagues showed that t-tau and p-tau differentiated CBD from PSP with fair diagnostic accuracy (AuROC: 0.77 and 0.76, respectively) and that increased tau levels were associated with lower Mini Mental State Examination (MMSE) scores [69]. These data suggest a role of tau biomarkers in the

1
2
3
4
5
6
7
8
9
10 differential diagnosis of tauopathies and in the stratification of different phenotypes (e.g. motor-
11 dominant vs. cognitive-dominant). However, these results should be taken with caution since AD-
12 pathology underpins CBS in about 20% of cases, thus representing a potential bias for the correct
13 interpretation of CSF tau levels. Additionally, these data come from small samples, and patients'
14 selection are based on obsolete diagnostic criteria [58,70].

17 Tau isoforms may help in differentiating tauopathies from other neuropathologies and to
18 stratify the tau-spectrum. The quantification of alternative tau fragments compared to the classic
19 ones detected by standard ELISA methods is promising [71]. Borroni and colleagues, showed that
20 33kDa-tau/55kDa-tau ratio discriminate PSP from HCs (AuROC: 0.90) and other NDDs (e.g. AD,
21 CBD, FTD etc.) with good to excellent diagnostic accuracy (AuROC: 0.93 for AD, AuROC: 0.87
22 for CBD, AuROC: 0.86 for FTD) [68,72]. These authors reported a lower 33kDa-tau/55kDa-tau
23 ratio, as assessed by semiquantitative immunoprecipitation, in patients with PSP compared to other
24 tauopathies and α -synucleinopathies. They also showed a correlation of this ratio with brainstem
25 atrophy and motor impairment in PSP [68,72]. Other groups did not replicate these results and
26 further investigations are needed [73].

29 Available commercial kits currently quantify tau concentration targeting its central core region.
30 More recently, alternative tau fragments detected using antibodies recognizing the N-terminal
31 fragment τ 12-BT2 has been assessed, showing an excellent diagnostic accuracy in differentiating
32 PSP from AD [74](Table 3). Furthermore, a mass spectrometry-based study (see table 1), identified
33 18 different CSF tau fragments with divergent patterns of expression in PSP compared to AD and to
34 HCs [71].

37 In last year the application of RT-QuIC and PCMA technologies may isolate and quantify
38 different tau strains (e.g. 4R and 3R tau) in CSF, thus representing an ideal tool to stratify *in vivo*
39 3R, 4R and mixed 3R/4R tauopathies [41].

41 Stepping aside from CSF, a single study explored the potential discriminating value of
42 plasma p-tau181 in tauopathies, using ultrasensitive detection techniques (Simoa). Plasma p-tau was
43 able to differentiate PSP and CBS from AD with good diagnostic accuracy (Table 2), being
44 associated with A β 42 pathology assessed by cerebral amyloid-PET examinations [75]. The
45 validation of tau-biomarkers in plasma in large longitudinal cohorts using ultrasensitive techniques
46 is warranted.

49 Tau biomarkers may have a prognostic context-of-use in 4R-tauopathies. Constantinescu
50 and colleagues showed that t-tau CSF levels may predict mortality in a cohort of PSP patients (see
51 table 3 for the Hazard Ratio) [76]. Increased CSF t-tau levels at baseline are associated with a faster
52 decline as measured by clinical progression scores like the Schwab and England ADL (SEADL);

1
2
3
4
5
6
7
8
9
10 decreased baseline p-tau predicts low SEADL scores and rapid decrease in PSP Rating scale
11 (PSPRS). The prognostic value of tau is increased when combining biomarkers into ratios (e.g.,
12 baseline p-tau, t-tau and NFL concentrations) [77]. Currently, the role of tau as prognostic
13 biomarker in 4R-tauopathies is limited and should be clarified in longitudinal studies.
14
15

16 17 **6. The diagnostic and prognostic role of tau in ALS-FTD spectrum**

18 Frontotemporal dementia (FTD) and Amyotrophic lateral sclerosis (ALS) are NDDs with
19 significantly clinical and pathological overlaps.
20

21 FTD is a heterogeneous cognitive disorder, recognizing multiple clinical and pathological
22 phenotypes [78,79], related to the degeneration of frontal and temporal lobes [78]. Three main
23 clinical variants of FTD have been described: the behavioral variant of FTD (bvFTD) [80], primary
24 progressive aphasia (PPA) and the motor FTD syndromes (CBS and PSP) [81]. PPA can be further
25 divided into a semantic variant (svPPA) and in a non-fluent variant (nfvPPA) [82]; the logopenic
26 variant of PPA (lvPPA) is conversely considered an atypical AD variant rather than a proper FTD-
27 syndrome [78]. On the other hand, three main pathological FTD phenotypes have been described,
28 namely FTD with TDP-43 aggregates (FTD-TDP), FTD with tau depositions (FTD-Tau) and FTD
29 with FUS aggregates (FTD-FUS) [8]. It should be noticed that the correlation between the clinical
30 and the pathological phenotype is not always predictable. While nfvPPA is associated in most cases
31 with FTD-tau (85% of all cases) and svPPA with FTD-TDP43 pathology (90% of cases), bvFTD
32 can be associated with both FTD-tau and FTD-TDP43 histological patterns [8].
33
34
35
36

37 ALS is progressive NDD characterized by motor symptoms related to the progressive
38 degeneration of the upper (UMN) and lower motoneuron (LMN) [83]. ALS is strictly associated to
39 TDP-43 pathology in about 95% of patients, alternative pathological inclusions (e.g. SOD-1
40 inclusions) may be reported in specific variants in a minority of cases [83].
41

42 The clinical and pathological boundaries between FTD and ALS are blurry and the current
43 diagnostic criteria consider ALS and FTD as a complex clinical *continuum* and pathologic *spectrum*
44 as well [84,85]. In fact, ALS patients show cognitive impairment in about 50% of cases, meeting
45 current criteria for diagnosing dementia in 10-15% of cases [86], and behavioral impairment in up
46 to 45-50% of patients baseline [87]. Conversely, FTD patients may present motor symptoms in
47 approximately 30% of cases showing motor neuron dysfunction (12.5% of bvFTD patients) [88].
48 The assessment of Tau as a biomarker in the ALS-FTD spectrum is controversial and recent studies
49 on CSF tau showed conflicting results.
50
51

52 Some authors observed a higher concentration of CSF t-tau in FTD patients compared to
53 HC, distinguishing them with a good diagnostic accuracy [89–91], (see Table 3 for AUROC
54
55

1
2
3
4
5
6
7
8
9
10 values). On the other hand, other investigations failed in detecting any significant difference [92–
11 95]. These conflicting results may be due to the fact that FTD is a highly heterogeneous diagnostic
12 frame, including different clinical and pathological phenotypes. Inconsistent results have been
13 reported in ALS studies [91,93,96–100].

14
15 Regarding the differential diagnosis between FTD and AD, p/t-Tau, t-tau and its ratios with A β 42
16 may be of clinical interest; FTD patients show lower levels of t-tau [91,94,95,101] and higher of
17 p/t-Tau [94] when compared to AD patients. Moreover, the ratios between t-tau and A β 42 are able
18 to distinguish between FTD and AD patients [91,95,101].

19
20 The CSF p-Tau and t-Tau ratio (p/t-Tau) is more interesting for the clinical workup. p/t-Tau was
21 observed to be significantly lower in ALS patients [89,96–99] and in FTD patients [89,90,92,102],
22 when compared to HC. Not surprisingly, ALS showed lower levels of CSF p/t-Tau than FTD
23 phenotypes with a likely related tauopathy. This ratio was significantly lower in FTD variants with
24 suspected TDP-related pathology (both patients with autopsy-proven TDP-related pathology and
25 TDP-related mutation carriers) compared to FTD phenotypes with a likely underlying tauopathy
26 [89,90,92,94,102,103] (Table 3). Low p/t-Tau may therefore represent a marker of an underpinning
27 TDP-43 pathology. From a pathophysiological point of view this could be due to a lower tau burden
28 in TDP-related compared to tau-related FTL variants. On the other hand, the different proportion
29 of patients with concomitant MND and amyloid- β co-pathology in the two groups may contribute to
30 these observed differences [102]. Furthermore p/t-Tau ratio seems to correlate with motor cortex
31 thickness and seems to be associated with UMN involvement in ALS [99]. Accordingly p-tau, t-tau
32 or their ratio may find a context-of-use in the differentiation of clinical endophenotypes within the
33 ALS spectrum (e.g. preponderant UMN vs. LMN involvement) but further investigations are
34 needed.

35
36 Different concentrations of CSF tau fragments other than classic tau analytes have been reported by
37 some authors in TDP-related vs. tau-related FTL variants [90]. This suggests that differential proteolytic
38 processes may occur in different FTL variants but this hypothesis and its implications for novel
39 biomarkers research deserves further studies and a more extensive assessment [90].

40
41 As regards the role of CSF tau as a prognostic biomarker, one study showed a potential
42 prognostic value of baseline CSF t-tau in ALS, being a reduction of overall survival observed in
43 individuals with higher CSF t-tau values (Table 3) [97]. Moreover p/t-tau ratio has been associated
44 with survival in FTD [102] and disease progression in ALS [100].

45
46 Moving to surrogated progression biomarkers, a negative correlation between baseline CSF
47 t-tau and the longitudinal increase of ALS Functional Rating Scale Revised (ALSFRS-R) score was
48 described [100].

7. The diagnostic and prognostic role of tau in α -synucleinopathies

Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple system atrophy (MSA) belong to a group of NDDs collectively called α -synucleinopathies. They are pathologically characterized by abnormal deposition of α -synuclein such as the (α -syn)-rich neuron intracytoplasmic inclusions (Lewy bodies, Lewy neuritis and glial cytoplasmic inclusions) or the oligodendrocytes cytoplasmic inclusions [104]. Nevertheless, other misfolded proteins have been recognized in degenerated neurons, including tau proteins [105] highlighting the necessity of a more complex pathophysiological model.

In contrast to tau, which seems to require cofactors, *in vitro* and *in vivo* studies demonstrated how α -syn is able to self-polymerize [106] [107]. Several pathophysiological mechanisms have been proposed to explain the interaction between α -syn and tau. According to different models α -syn can act as the "amyloidogenic seed" promoting tau aggregation with subsequent interaction between the two proteins enhancing each other's fibrillization [108] or as the pathological chaperone for tau fibrillization [109]. Whatever the mechanism, oligomeric forms of α -syn and tau co-exist in α -synucleinopathies and influence each other and perpetuate mutual aggregation, leading to hybrid oligomers' formation [9,110,111].

Interestingly, levels of CSF α -syn and p-tau are directly correlated in α -synucleinopathies. This could be because the accumulation of α -syn in PD brain could inhibit the release of p-tau in CSF through unknown mechanisms, supporting the relationship between α -syn and tau in α -synucleinopathies [112]. With regard to CSF, reduced levels of α -syn, t-tau, p-tau and amyloid- β at disease onset have been found in PD compared to HC [112][113]. Furthermore, p-tau levels and p-/t-tau ratio increased over time after PD onset despite stable levels of t-tau/ α -syn ratio. Patients exhibiting postural instability and gait impairment predominant phenotype had lower CSF p-tau and A β 42 concentrations than those with tremor-dominant phenotype [112]. Male sex and SNCA polymorphism rs316181 were linked to increased levels of p-tau, while an increased t-tau/A β 42 ratio was associated with REM behavior disorder [113].

The diagnostic value of CSF tau biomarkers is higher when they are combined into ratios [112][114][115][113][115]. The p-tau/ α -syn ratio (which is increased in PD compared to HC), showed the highest accuracy for PD diagnosis [115] (Table 3). Roughly 75% of PD patients with a disease course longer than 10 years evolve to PD with dementia (PDD) [116]. CSF t-tau has been reported to be increased in PDD compared to HC, while p-tau did not show differences in the two groups [117]. Longitudinal studies in PD patients found neither a predictive value for the subsequent development of dementia for CSF t-tau and p-tau levels measured at PD onset [118],

1
2
3
4
5
6
7
8
9
10
11 nor an association with dementia severity in PDD [117]. In contrast, plasma t-tau and p-tau181
12 levels measured through immunomagnetic reduction (IMR) were increased in DLB compared to
13 HC, and reduced compared to PDD [37] (Table 2).

14
15 DLB is the second most common cause of dementia after Alzheimer's disease (AD). DLB
16 belongs to the spectrum of α -synucleinopathies, nevertheless, a mixed neuropathology with
17 amyloid- β plaques and tau pathology is present in nearly 40% of patients (α -syn+AD) and are
18 associated with an increased rate of dementia and a decreased survival time [119]. Although
19 previous studies reported increased levels of t-tau in DLB compared to HC [120], these findings
20 were not replicated in more recent studies [121]. The use of different diagnostic criteria and
21 populations may in part explain these inconsistent results. In general, CSF t-tau and p-tau levels are
22 lower in DLB than AD [120], suggesting that levels of p-tau in CSF could represent a valuable
23 marker for the differential diagnosis between these two NDDs [123]. On the other hand, t-tau levels
24 are higher in DLB in comparison to PD and PDD, supporting the hypothesis that limbic and cortical
25 Lewy body pathology is the main and specific pathologic correlate of dementia in PD [124]. In a
26 neuropathological study, the regional distribution of tau and amyloid- β is different in α -syn+AD
27 patients and AD, with a greater proportion of tau in the temporal neocortex for DLB patients and in
28 frontal neocortex in AD. Moreover, the severity of tau burden was correlated with worse *ante-*
29 *mortem* cognitive performances in DLB individuals [125]. Tau pathology has also been correlated
30 to the pattern of brain atrophy in MRI. Indeed, increased CSF t-tau levels were associated with high
31 global atrophy scores [126] and elevated CSF p-tau with a more selective posterior atrophy [127].
32 CSF ratios t-tau/A β 42 and p-tau/A β 42 recently proved to predict the presence of AD co-pathology
33 in DLB, with higher levels of both ratios in α -syn+AD brains when compared to α -syn-AD brains,
34 while no correlation was found analyzing single biomarkers. Besides, higher CSF t-tau/A β 42 and
35 lower CSF A β 42 levels were associated with a higher burden of neocortical α -syn [121].

36
37 MSA is a NDD characterized by autonomic failure associated with a poorly levodopa-
38 responsive parkinsonian syndrome or cerebellar ataxia, thus defining two main phenotypes
39 respectively identified as MSA-P and MSA-C [128,129]. Differential diagnosis between PD and
40 MSA could be challenging because of the clinical overlap in the early stages and a reliable
41 biomarker for the differential diagnosis of MSA from PD yet represents an unmet need. Data on
42 CSF biomarkers in MSA are conflicting. In some studies, CSF t-tau concentration was higher in
43 MSA than PD patients or HC [130][131], whereas others reported a reduction of its level [132]. By
44 contrast, p-tau concentration was similar in MSA and HC [130][132]. Conflicting data have been
45 published on the p-tau/t-tau ratio, reported either higher [130][132] or lower [133][134] in MSA
46 compared to PD. The combination of p-tau181, t-tau and DJ1 (a protein related to PD pathogenesis
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10
11 whose function is still unknown in MSA) proved high sensitivity and specificity (respectively 82%
12 and 81%) to discriminate MSA from PD [131], as well as the p-tau/A β 42 ratio (specificity 71%,
13 sensibility 93%), which is significantly increased in MSA [134] (Table 3). Similarly, the AD index
14 (CSF A β 40/42 ratio \times t-tau) and the ratio t-tau/ α -syn were higher in MSA than HC, while no
15 significant differences were found comparing PD and HC [130]. Finally, no CSF biomarkers proved
16 to be reliable for the differential diagnosis between MSA-C and MSA-P [114].

17
18 Fluid biomarkers for α -synucleinopathies were recently investigated also in blood. Red
19 blood cells (RBC) seem to be a preferential niche for misfolded proteins [135] and oligomeric α -syn
20 was described in RBC of patients with PD [136]. Analysis of RBC in PD patients showed increased
21 levels of phospho-tau (p-tau) in PD compared to HC [110]. Interestingly, RBC t-tau concentration
22 was inversely correlated to MMSE scores both in the general PD cohort and in PD drug naïve
23 patients, suggesting a central role of tau pathology in promoting cognitive decline in PD [110].
24 Plasma t-tau and p-tau were higher in MSA compared to HC when measured through IMR
25 [137][37], while levels of p-tau measured through Simoa did not differ between MSA and HC [24].
26
27
28

29 30 **8. Tau PET in Tauopathies**

31
32 In the field of neurodegenerative dementias, in vivo imaging with radioligands designed to detect
33 each underlying proteinopathy aims to find a gold standard biological marker. Amyloid- β
34 imaging has been incorporated into AD diagnostic criteria since 2007 [138]. However, cerebral
35 amyloid-PET uptake did not correlate with cognitive performance nor neurodegeneration in AD.
36 Biomarkers of tau pathology may be closely related to neuronal injury and changes in cognition.
37 Tau-PET will support the investigation of the spatial-temporal evolution of tau pathophysiology in
38 AD and other NDD as well as the clinical validation of fluid biomarkers. Therefore, research effort
39 is focusing on the development of tau-PET radiotracers in order to reveal underlying tau deposits
40 in a broad range of tauopathies, such as AD, FTD, PSP.
41

42
43 A significant number of tau PET tracers have been synthesized so far, but many of those lack
44 sufficient specificity and selectivity [139,140]. The main difficulties to develop these tracers are
45 related to [141]: 1) lipophilicity, which is necessary to cross the blood-brain barrier and the cell
46 membrane (tau is located both intra and extracellularly); by contrast, excessive lipophilicity could
47 lead to unspecific binding; 2) affinity for tau, relevant to obtain high selectivity for tau molecule
48 and overcoming the high A β concentrations interfering with tau-ligand binding, but requiring
49 prolonged scanning time to reach the steady-state; 3) different conformations of tau aggregates
50 and different tau isoforms [142], making it challenging to develop a unique tau radiotracer for all
51 types of tauopathies. Based on both in vitro and in vivo results, three families of radiotracers were
52
53
54

1
2
3
4
5
6
7
8
9
10 initially synthesized: 1) the THK family (THK117, its (S)-enantiomer THK5317, and THK5351;
11 2) 18F-AV1451, also known as T807 or Flortaucipir; 3) PBB3. The so-called first-generation tau
12 tracers finally showed a lack of specificity, with relevant off-target binding to monoamine
13 oxidase B (MAO-B) for the HK family and Flortaucipir [143], neuromelanin for Flortaucipir
14 [144], and A β -plaques and α -syn for PBB3 [145,146]. Hence, the second generation of tau PET
15 tracers has been developed: RO948, PI2620, JNJ311, MK6240, PM-PBB3 and AM-PBB3 [147].
16 However, the most widely studied agent is [18F]AV-1451 (Flortaucipir). It was the first approved
17 tau PET tracer for estimation of the density and distribution of aggregated tau neurofibrillary
18 tangles in adults with cognitive impairment and suspected AD [148].
19
20
21
22
23

24 **8.1 Aging**

25 First-generation tracers demonstrated retention of uptake confined to the medial temporal lobe in
26 normal cognitively elderly, in accordance with pathological data [149], likely reflecting an age-
27 related process of tau-deposition [150]. Accumulation of tau in the temporal cortex, without an
28 associated significant A β burden, may suggest a promoting effect of tau in mild amnesic deficits;
29 hippocampal atrophy or a PART related pathology in such subjects.
30
31
32

33 **8.2 Alzheimer's Disease**

34 There is now convincing evidence that cortical tau binding at PET imaging reflects tau
35 accumulation reported from histopathological studies in AD brains [149]. 18F-AV1451
36 demonstrated high affinity in vitro for paired helical filaments (PHF) of 3R/4R tau isoforms
37 reported in AD brains [151,152]. A recent study in 82 individuals with or without dementia
38 showed a high concordance between the visual reading of 18F-AV1451 PET scans and staging of
39 cortical neurofibrillary tangles, reinforcing the concept that Flortaucipir effectively reflects
40 pathological changes of AD [153]. Similar results were replicated in vivo, with 18F-AV1451
41 demonstrating to accurately differentiate clinically diagnosed AD from HC and other NDDs
42 [154]. Higher levels of tau tracer retention in the inferior lateral temporal region, but also in the
43 posterior cingulate and lateral parietal regions, provided the best discrimination areas between
44 AD patients and HC [155–158]. Other studies comparing cognitively normal subjects with MCI
45 patients showed differences in binding restricted to medial temporal regions (parahippocampal
46 and entorhinal cortex) [159,160], as well as lateral temporal and parietal areas when examining
47 only amyloid- β -positive MCI individuals [158]. Furthermore, some studies reported greater
48 retention of 18F-AV1451 in the cortex of younger compared to older AD patients, with a cut off
49 of 75 years-old [161], and in early-onset compared to late-onset AD patients with a cut off of 65
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10 years-old [160], as similarly reported in previous post-mortem studies [162]. Moreover,
11 neocortical Flortaucipir retention was found in preclinical AD cases and rarely in amyloid- β
12 negative cases [161,163].

13
14 The extent of tau accumulation intimately correlates with the severity of MCI due to AD and AD
15 dementia, providing an objective index for disease severity. The few available longitudinal tau
16 PET studies in AD demonstrated a tracer retention related to disease duration [164–167].
17 However, results from the largest studies, which compared cognitively unimpaired A β -negative
18 and A β -positive individuals, MCI and AD dementia patients, are conflicting. Cho and colleagues
19 studied 107 participants (45 A β -negative cognitively unimpaired, 7 A β -positive cognitively
20 unimpaired, 31 MCI, and 24 AD dementia) who completed both 18F-flortaucipir and 18F-
21 florbetaben at baseline and who were followed up for 2 years. The authors found a predominant
22 tau accumulation in the medial and basal temporal cortices in MCI and in the lateral temporal
23 cortices in AD dementia [167], thus supporting a progressive tau accumulation pattern in line
24 with the Braak model [149]. Conversely, Jack and colleagues evaluated the longitudinal change in
25 tau PET signal during a one-year follow-up in a group of 126 individuals (59 cognitively
26 unimpaired A β -negative, 37 cognitively unimpaired A β -positive, and 30 cognitively impaired A β -
27 positive). They demonstrated a tau accumulation in the A β -positive clinically unimpaired group
28 in the medial temporal lobe and in the medial parietal areas, including posterior cingulate cortex.
29 This suggests that initial accumulation of tau aggregates in AD may not be restricted to the
30 medial temporal lobes as implied by Braak staging [165]. Overall these evidence proved that
31 longitudinal tau PET may be an useful biomarker in clinical trials to monitor the effect of disease-
32 modifying therapies tailored to reduce tau as well as cerebral amyloid- β plaque burden [168]. In
33 AD increased 18F-AV1451 uptake is strongly co-localized with hypometabolic regions and has
34 been associated with worse performance on various cognitive domains in regionally specific
35 patterns [169]. Accordingly, 18F-AV1451 distribution may predict the clinical variants of AD
36 suggesting on-site neurotoxicity provoked by tau aggregates in posterior cortical atrophy,
37 logopenic variant of primary progressive aphasia, or behavioral/dysexecutive variant of AD [169–
38 172]. The main challenge for tau tracers remains the capability to detect preclinical / prodromal /
39 early AD stages. Importantly, the sensitivity for an early diagnosis is limited by the fact that in
40 the early AD stages (e.g. MCI) neurofibrillary tangles are only present in deep brain regions. In
41 more advanced AD stages 18F-AV1451 discriminate mild-to-moderate AD patients from HC
42 [154].

43
44
45
46
47
48
49
50
51 Currently, there are not conclusive studies on second-generation tau tracers in AD patients and we
52 do not have any head-to-head comparison between them. Available studies suggest that they may
53
54

1
2
3
4
5
6
7
8
9
10
11 be more useful in identifying earlier Braak stages. They also show substantially less non-specific
12 binding or higher affinities to primary tauopathies [173]. These agents include [18F]MK-6240
13 (Merck & Co), PM-PBB3 (APRINOIA Therapeutics), F18-PI-2620 (Life Sciences) (50) and
14 RO-948 (Roche). RO-948 tracer showed similar patterns of cerebral uptake then 18F-AV1451
15 [174]. Moreover, RO-948 showed a greater stability, a higher retention in the medial temporal
16 lobe and lower intracerebral “off-target” binding than Flortaucipir [175,176]. In AD subjects,
17 PET images of F18-PI-2620 showed a significantly higher uptake than control subjects in
18 temporal lobe, parietal and cingulate cortex. Importantly, in non-demented control subjects it
19 showed robust initial brain uptake and fast washout from the brain, as well as no age dependency.
20 This last finding suggests that F18-PI-2620 could improve the discrimination between non-
21 demented control and AD subjects in elderly. Moreover, excellent test-retest variability has been
22 demonstrated confirming the utility of F18-PI-2620 to evaluate longitudinal change of tau
23 deposition during disease course [177]. Finally, three recently published studies have evaluated
24 [18F]MK-6240 in vivo [178–180]. All these studies exhibited favorable kinetic and high binding
25 levels of [18F]MK-6240 to brain regions typically affected from NFT deposition in AD subjects.
26 [18F]MK-6240 PET images in another cohort of patients positive for cerebral amyloid- β
27 deposition (cognitive unimpaired/impaired elderly controls, MCI and AD patients) showed a
28 pattern corresponding to the anatomic distribution of tau as expected in the Braak model [178].
29
30
31
32
33
34
35

36 **8.3 Non-AD tauopathies**

37
38
39 Tau imaging may also be relevant for other tauopathies, such as CBD and PSP. These
40 atypical parkinsonian syndromes are characterized by abundant filamentous tau inclusions that
41 are made of isoforms with four microtubule-binding repeats in tubular or straight filaments. In
42 PSP and CBD abnormal aggregation of pathologically misfolded and hyperphosphorylated tau
43 proteins mainly occur in the basal ganglia in the early stages, spreading later to multiple brain
44 areas: brainstem, posterior frontal lobe, cerebellum and association cortices for PSP; primary
45 motor cortex, frontal lobe, brainstem or cerebellum for CBD [181–184]. Nevertheless, a variety
46 of overlapping syndromes are frequent in tauopathies.
47
48

49 To date few studies using low specific first-generation PET tracers have examined tau binding in
50 parkinsonian disorders. They revealed distinct patterns of tracer retention in PSP and CBD,
51 compared to controls, showing elevated PET signal in the basal ganglia and affected cortical
52 regions, in agreement with postmortem data [185].
53
54

1
2
3
4
5
6
7
8
9
10 Elevated tau deposition in PSP cases was observed in the basal ganglia, thalamus, dentate nucleus
11 of the cerebellum, and midbrain [186–192]. However, an extensive overlap and age-dependent
12 increase in both the PSP and control groups has been reported [187]. Significant differences in
13 18F-AV-1451 distribution between patients with PD and PSP, with increased uptake in the globus
14 pallidus, midbrain, and subthalamus in PSP cases, have been also described [193,194].
15 Interestingly, in some studies the radioligand accumulation correlated with the clinical disease
16 severity [189,195,196], but the lack of correlations between tau binding and symptom severity
17 was observed in the other cohorts [188,194]. A recent study by Whitwell and colleagues using
18 flortaucipir reported that the clinical heterogeneity present in PSP is mirrored by anatomical and
19 tau burden heterogeneity within the brain [197].

20
21
22
23 Studies analyzing the feasibility of tau PET in patients with CBS showed elevated asymmetrical
24 tracer deposition in dentate nucleus of the cerebellum, midbrain, subthalamic nucleus, globus
25 pallidus and putamen, precentral and postcentral cortex, superior frontal and parietal lobe, fitting
26 with the regional distribution of tau pathology [198,199]. Furthermore, longitudinal investigations
27 documented a correlation between tau accumulation over time and disease progression [166,200].
28 However, the degree of uptake in CBS using currently available tau ligands is variable, and some
29 patients resulted negative [201,202].

30
31
32 Overall, studies using in vivo tau PET in PSP and CBD individuals that received a postmortem
33 confirmation have shown conflicting results questioning the usefulness of tau imaging in early
34 diagnosis of such conditions. Indeed, the available tracers are not specific for 4R tau pathology
35 and show substantial off-target binding in the midbrain and basal ganglia to monoamine oxidase
36 B and to neuromelanin-containing cells [192,203].

37
38
39 Second generation of tracers with improved off-target binding are under evaluation also in non-
40 AD tauopathies. Brendel and colleagues found a great potential to diagnose patients with
41 suspected PSP using 18F-PI-2620 which proved high affinity to recombinant 4R tau fibrils and
42 PSP brain homogenate [204,205].
43
44

45 **9. Discussion and perspectives**

46
47 Epidemiological projections indicate that AD evolving epidemic represents a global threat for
48 healthcare systems [54]. Minimally invasive and globally accessible tests are needed to cope with
49 this expected burdensome demand and to manage individuals in suspected preclinical/prodromal
50 stages of NDDs [206,207]. Blood-based biomarkers represent cost-, resource- and time effective
51 tools [208]. They hold the potential to enable large-scale biological screening of individuals who
52 are very unlikely to have AD-related pathophysiology and would support the request of second-
53
54

1
2
3
4
5
6
7
8
9
10 level investigations (e.g. PET imaging or CSF assessment). Blood-based biomarkers not only
11 open up the opportunity of a multi-step diagnostic workup but can also facilitate the re-
12 engineering of drug Research & Development (R&D) pipelines, from subjects' enrollment, target
13 engagement, to treatment efficacy monitoring. In Oncology, serial liquid biopsies offer clues
14 about the evolution of cancer in individual patients across disease stages, enabling individualized
15 genetically and biologically guided therapies [207].

16
17
18 The development of novel ultrasensitive measurement techniques has enabled the detection of
19 tau-related biomarkers, facilitating a liquid biopsy-driven paradigm shift in the field of NDDs,
20 including AD [207]. Plasma t-tau seems to have a limited utility as diagnostic marker in NDDs
21 when assessed alone [47]. On the other hand, plasma p-tau may find a context-of-use in the
22 differential diagnosis between AD and non-AD dementias, including primary tauopathies and
23 vascular dementia [25–29,75]. The combination of tau with other putative biomarkers (e.g. NFL)
24 into panels or ratios seems to increase the diagnostic accuracy of tau biomarkers alone [22]. Sets of
25 multiple biomarkers may accordingly find a context-of-use in the clinical diagnostic workup of
26 neurodegenerative dementias, in patients' selection and their follow-up for disease modifying
27 clinical trials.

28
29
30
31 Studies investigating p-tau isoforms other than p-tau181 (e.g. p-tau217) [30,33,209], and alternative
32 proteolytic fragments like the N1-tau [25] fragment have shown encouraging results in
33 differentiating AD and MCI from HC and in predicting the amyloid β - in preclinical AD. Several
34 studies, performed in AD and NDDs, indicate that plasma p-tau217 is a reliable predictor of tau
35 pathology (as assessed through tau-PET)[210], amyloid- β -mediated tau pathophysiology,
36 longitudinal cortical/subcortical atrophy and AD-like cognitive decline. These findings coupled
37 with the evidence that p-tau217 discriminates AD from non-AD conditions [30,31] explain why
38 plasma p-tau217 will be used as exploratory marker in different COU, including patients' selection
39 and follow-up in clinical trials. The evidence about plasma p-tau217 also support its integration in
40 the ATN matrix for disease diagnosis, prognosis and progression monitoring in clinical practice
41 [31].

42
43
44
45 A better understanding of time-trajectories of these alternative phosphorylation sites of p-tau is
46 mandatory to help understand the more adequate context-of-use of each isoform from preclinical
47 to full-blown AD.

48
49 In primary tauopathies CSF p-tau and t-tau, as assessed by traditional techniques, are not
50 reliable biomarkers for the diagnostic workup of 4R-tauopathies [64]. These biomarkers are useful
51 in both clinical and research settings for differentiating NDDs with an underlying AD pathology,
52 which can mimic primary tauopathies [59,60]. The detection of different tau isoforms and
53

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

fragments (e.g. 33 KDa vs 55 KDa isoforms) [72] and of specific tau strains (e.g. 3R and 4R tau) by means of PMCA and RT-QuIC [41] are promising tools to stratify the pathologic tau-spectrum and to identify different phenotypes. The prognostic value of tau biomarkers in 4R-tauopathies remains to be clarified.

In the ALS-FTD spectrum, CSF t-tau and p-tau may contribute in discriminating AD from FTD and in identifying patients with FTD phenotypes with an underlying AD-pathology [91]. The diagnostic value of p-tau and t-tau alone in differentiating the FTD-ALS continuum from HCs is controversial [89,91,98]. Nevertheless p-tau/t-tau ratio seems to be useful in FTD for the identification of patients with a TDP-43 underlying pathology [89] and may be useful in ALS to discriminate clinical endophenotypes (UMN-predominant vs. LMN-predominant variants) [99]. Baseline CSF t-tau and p-tau/t-tau ratio could represent a prognostic marker for both FTD and ALS [97] but further studies are needed to identify the proper context-of-use of these biomarkers.

In α -synucleinopathies the co-occurrence of underlying tauopathy is commonly reported. T-tau and p-tau concentration may vary according to PD phenotypes, thus suggesting a potential role of tau in differentiating clinical phenotypes [112,113]. An association between tau burden and cognitive impairment in PDD and DLB has been postulated but data are conflicting and inconclusive [117,118]. Similarly the diagnostic value of CSF p-tau and t-tau in atypical parkinsonism (e.g. MSA and DLB) is controversial [117,121,122,124,132,211][130,131].

As regards tau-PET tracers, tau accumulation in the medial and basal temporal cortices was observed in MCI patients, thus suggesting a potential role of tau-PET tracers in the prodromal AD and a potential value of tau-PET uptake in monitoring the efficacy of disease-modifying therapies in clinical trials [165,167]. A possible role of tau-PET imaging in the differential diagnosis between 4R tauopathies is suggested by some studies highlighting a different deposition pattern of tau in PSP compared to CBS. Off-target binding in the midbrain and basal ganglia is currently limiting the use of first generation tracers but was partly solved with the development of second-generation tau tracers [145]. Further evidence on the physiological and pathologic variables influencing tau-PET tracers uptake, on the off-label binding and on the comparison of different tracers is warranted to understand the appropriate context-of-use of these biomarkers.

In conclusions, biomarkers development and related research have significantly contributed to the reengineering of AD as a clinical-biological framework, as reflected by the ATN system, where preclinical stages of the disease are identified and potentially treated for preventive strategies, including tau-targeting approaches. It is conceivable that the same paradigm shift may take place also for NDD others than AD. Individuals with different clinical

1
2
3
4
5
6
7
8
9
10 presentations but similar biomarkers may be grouped into biological clusters facilitating a
11 treatment essentially based on pathophysiological mechanisms and not phenotypes [212,213], in
12 line with the precision medicine paradigm [214].
13
14

15 **11. Expert opinion**

16
17
18 Tau, as assessed in CSF in the form of t-tau and p-tau181, is an established diagnostic
19 biomarker for AD. The detection of tau in alternative easily accessible matrices like plasma
20 currently represents one of the most exciting future directions for AD biomarker research.
21

22 Alternative tau isoforms (e.g. p-tau217) or proteolytic fragments (e.g. N-terminal fragments)
23 quantified in CSF and in blood may represent candidate fluid diagnostic and prognostic markers
24 overcoming the limitations of current CSF t-tau and p-tau measurement in NDDs. In particular
25 plasma p-tau217 could be used as exploratory marker in different drug development pipelines with
26 distinct molecular target and for different COU, including patient selection, and theragnostic. The
27 evidence about plasma p-tau217 also support its integration in the ATN matrix for disease
28 diagnosis, prognosis and progression monitoring in clinical practice.
29

30
31 Nevertheless, the implementation of techniques enabling the identification of different tau
32 strains (e.g. 3R- vs. 4R-tau), enabled by RT-QuIC and PMCA, represents the most important
33 frontier for fluid biomarker discovery in tauopathies.
34

35 The validation of biomarkers tracking tau pathology in the ALS-FTD spectrum is
36 challenging, due to the high clinical and phenotypical heterogeneity of this spectrum. However, tau
37 biomarkers may identify AD-related pathology, and, to a lesser extent, differentiate tau-related from
38 TDP-43 related pathology.
39

40 Intriguingly, tau biomarkers may reveal co-pathologies in NDDs. Biomarkers tracking tau
41 pathology in PD and atypical parkinsonism may in fact be potentially helpful for the segregation of
42 clinical subtypes and to combine tailor disease-modifying treatments.
43

44 The development of tau-PET tracers and the overcome of first-generation tracers' limitations
45 (especially the off-target binding and the necessity of a cyclotron) was a great step forward in the *in*
46 *vivo* understanding of early pathophysiological changes in AD. Further studies are needed to define
47 the context-of-use of tau-PET tracers in AD (especially in preclinical and prodromal AD) and their
48 potential applications outside the AD-spectrum.
49
50
51

52 **Funding**

53 The study was not funded. Academic study without external financial support.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12 **Financial disclosures**

13 The authors have no relevant affiliations or financial involvement with any organization or entity
14 with a financial interest in or financial conflict with the subject matter or materials discussed in the
15 manuscript.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Bibliography

- [1] Spillantini MG, Goedert M. Tau pathology and neurodegeneration. *Lancet Neurol* [Internet]. 2013;12:609–622. Available from: [http://dx.doi.org/10.1016/S1474-4422\(13\)70090-5](http://dx.doi.org/10.1016/S1474-4422(13)70090-5).
- [2] Rösler TW, Tayaranian Marvian A, Brendel M, et al. Four-repeat tauopathies [Internet]. *Prog. Neurobiol.* Elsevier Ltd; 2019 [cited 2020 Nov 22]. Available from: <https://pubmed.ncbi.nlm.nih.gov/31238088/>.
- [3] Höglinger GU, Respondek G, Kovacs GG. New classification of tauopathies. *Rev Neurol (Paris)*. 2018;174:664–668.
- [4] Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau Aggregates and Neurodegeneration. *Annu Rev Neurosci* [Internet]. 2017 [cited 2020 Nov 22];40:189–210. Available from: <https://pubmed.ncbi.nlm.nih.gov/28772101/>.
- [5] La-rocque S De, Moretto E, Schiavo G. Knockin ' on heaven ' s door : Molecular mechanisms of neuronal tau uptake. 2020;1–26.
- [6] Irwin DJ. Tauopathies as clinicopathological entities. *Park Relat Disord* [Internet]. 2016;22:S29–S33. Available from: <http://dx.doi.org/10.1016/j.parkreldis.2015.09.020>.
- [7] Braak H, Zetterberg H, Del Tredici K, et al. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of tau in cerebrospinal fluid. *Acta Neuropathol*. 2013;126:631–641.
- [8] Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol*. 2017;13:457–476.
- [9] Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, et al. Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. *Biol Psychiatry* [Internet]. 2015 [cited 2020 Oct 8];78:672–683. Available from: <https://pubmed.ncbi.nlm.nih.gov/25676491/>.
- [10] Henderson MX, Sengupta M, Trojanowski JQ, et al. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. *Acta Neuropathol Commun*. 2019;7:1–16.
- [11] Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement* [Internet]. 2011;7:257–262. Available from: <http://dx.doi.org/10.1016/j.jalz.2011.03.004>.
- [12] Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. *Lancet Neurol*. 2014.
- [13] Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* [Internet]. 2018;14:535–

562. Available from: <https://doi.org/10.1016/j.jalz.2018.02.018>.

**** Recommendations for a biomarker-based diagnosis of AD**

- [14] Baldacci F, Mazzucchi S, Della Vecchia A, et al. The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases [Internet]. *Expert Rev. Mol. Diagn.* Taylor and Francis Ltd; 2020 [cited 2020 Oct 8]. p. 421–441. Available from: <https://pubmed.ncbi.nlm.nih.gov/32066283/>.
- [15] Baldacci F, Lista S, Vergallo A, et al. A frontline defense against neurodegenerative diseases: the development of early disease detection methods. *Expert Rev Mol Diagn* [Internet]. 2019;19:559–563. Available from: <https://doi.org/10.1080/14737159.2019.1627202>.
- [16] Xia J, Broadhurst DI, Wilson M, et al. Translational biomarker discovery in clinical metabolomics: An introductory tutorial. *Metabolomics*. 2013;9:280–299.
- [17] Kawarabayashi T, Nakamura T, Miyashita K, et al. Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. *Neurosci Lett* [Internet]. 2020;722:134826. Available from: <https://doi.org/10.1016/j.neulet.2020.134826>.
- [18] Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. *J. Intern. Med.* 2018.
- [19] Saijo E, Metrick MA, Koga S, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. *Acta Neuropathol* [Internet]. 2020;139:63–77. Available from: <https://doi.org/10.1007/s00401-019-02080-2>.
- [20] Hampel H, O’Byrne SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat. Rev. Neurol.* 2018.
- [21] Del Prete E, Beatino MF, Campese N, et al. Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach. *J Pers Med* [Internet]. 2020;10:221. Available from: <https://www.mdpi.com/2075-4426/10/4/221>.
- [22] Park JC, Han SH, Yi D, et al. Plasma tau/amyloid- β 1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease. *Brain* [Internet]. 2019 [cited 2020 Nov 22];142:771–786. Available from: <https://pubmed.ncbi.nlm.nih.gov/30668647/>.
- [23] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. 2020;19.
- [24] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol.* 2020;19:422–433.

- 1
2
3
4
5
6
7
8
9
10
11 [25] Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau
12 aid development of a blood-based screen for Alzheimer's disease. *Alzheimer's Dement*
13 [Internet]. 2019 [cited 2020 Nov 22];15:487–496. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/30419228/>.
- 15 [26] Palmqvist S, Janelidze S, Stomrud E, et al. Performance of Fully Automated Plasma Assays
16 as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. *JAMA Neurol*
17 [Internet]. 2019 [cited 2020 Nov 22];76:1060–1069. Available from:
18 <https://pubmed.ncbi.nlm.nih.gov/31233127/>.
- 19 [27] Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's
20 disease clinical severity and is associated with tau- and amyloid-positron emission
21 tomography. *Alzheimer's Dement* [Internet]. 2018 [cited 2020 Nov 22];14:989–997.
22 Available from: <https://pubmed.ncbi.nlm.nih.gov/29626426/>.
- 23 [28] Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease:
24 relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal
25 progression to Alzheimer's dementia. *Nat Med* [Internet]. 2020 [cited 2020 Nov 22];26:379–
26 386. Available from: <https://pubmed.ncbi.nlm.nih.gov/32123385/>.
- 27 [29] Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in
28 Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med* [Internet]. 2020 [cited
29 2020 Nov 22];26:387–397. Available from: <https://pubmed.ncbi.nlm.nih.gov/32123386/>.
- 30 [30] Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-
31 tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA - J Am Med*
32 *Assoc.* 2020;
33
34
35
36
37
38
39 *** A recent paper exploring the potential role of plasma p-tau217 as a biomarker for AD**
- 40 [31] Mattsson-Carlsson N, Janelidze S, Bateman R, et al. Soluble P-tau217 reflects both amyloid
41 and tau pathology in the human brain and mediates the association of amyloid with
42 neocortical tau. *Brain* [Internet]. 2020 [cited 2020 Nov 22];143:3234–3241. Available from:
43 <https://doi.org/10.21203/rs.3.rs-101153/v1>.
44
45 *** A recent paper exploring the potential role of p-tau217 as a biomarker for AD**
- 46 [32] Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical
47 biochemistry. *Clin Biochem Rev* [Internet]. 2009 [cited 2020 Nov 22];30:19–34. Available
48 from: <http://www.ncbi.nlm.nih.gov/pubmed/19224008>.
- 49 [33] Barthélemy NR, Horie K, Sato C, et al. Blood plasma phosphorylated-tau isoforms track
50 CNS change in Alzheimer's disease. *J Exp Med* [Internet]. 2020 [cited 2020 Nov 22];217.
51 Available from: <https://pubmed.ncbi.nlm.nih.gov/32725127/>.
- 52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [34] Chieh JJ, Yang SY, Horng HE, et al. Immunomagnetic reduction assay using high-Tc
12 superconducting-quantum-interference-device-based magnetosusceptometry. *J Appl Phys*
13 [Internet]. 2010 [cited 2020 Nov 22];107:074903. Available from:
14 <http://aip.scitation.org/doi/10.1063/1.3340861>.
- 15 [35] Yang SY, Chiu MJ, Chen TF, et al. Detection of Plasma Biomarkers Using Immunomagnetic
16 Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease. *Neurol*
17 *Ther.* 2017;6:37–56.
- 18 [36] Lue LF, Sabbagh MN, Chiu MJ, et al. Plasma levels of A β 42 and Tau identified probable
19 Alzheimer's dementia: Findings in two cohorts. *Front Aging Neurosci* [Internet]. 2017 [cited
20 2020 Nov 22];9. Available from: <https://pubmed.ncbi.nlm.nih.gov/28790911/>.
- 21 [37] Lin CH, Yang SY, Horng HE, et al. Plasma biomarkers differentiate Parkinson's disease
22 from atypical parkinsonism syndromes. *Front Aging Neurosci* [Internet]. 2018 [cited 2020
23 Oct 16];10. Available from: <https://pubmed.ncbi.nlm.nih.gov/29755341/>.
- 24 [38] Fan LY, Tzen KY, Chen YF, et al. The relation between brain amyloid deposition, cortical
25 atrophy, and plasma biomarkers in amnesic mild cognitive impairment and Alzheimer's
26 Disease. *Front Aging Neurosci* [Internet]. 2018 [cited 2020 Nov 22];10. Available from:
27 <https://pubmed.ncbi.nlm.nih.gov/29967578/>.
- 28 [39] Yang CC, Chiu MJ, Chen TF, et al. Assay of plasma phosphorylated tau protein (threonine
29 181) and total tau protein in early-stage Alzheimer's disease. *J Alzheimer's Dis* [Internet].
30 2018 [cited 2020 Nov 22];61:1323–1332. Available from:
31 <https://pubmed.ncbi.nlm.nih.gov/29376870/>.
- 32 [40] Manca M, Kraus A. Defining the protein seeds of neurodegeneration using real-time
33 quaking-induced conversion assays. *Biomolecules.* 2020.
- 34 [41] Saijo E, Metrick MA, Shunsuke II, et al. 4 - Repeat tau seeds and templating subtypes as
35 brain and CSF biomarkers of frontotemporal lobar degeneration. *Acta Neuropathol*
36 [Internet]. 2020;139:63–77. Available from: <https://doi.org/10.1007/s00401-019-02080-2>.
- 37 * A paper presenting the potential applications of RT-QuIC for the differentiation of
38 **3R and 4R tauopathies**
- 39 [42] Baldacci F, Lista S, Vergallo A, et al. A frontline defense against neurodegenerative
40 diseases:the development of early disease detection methods. *Expert Rev Mol Diagn.*
41 2019;19:559–563.
- 42 [43] D'abramo C, D'adamio L, Giliberto L. Significance of blood and cerebrospinal fluid
43 biomarkers for alzheimer's disease: Sensitivity, specificity and potential for clinical use. *J*
44 *Pers Med* [Internet]. 2020 [cited 2020 Nov 22];10:1–39. Available from:

- 1
2
3
4
5
6
7
8
9
10
11 <https://pubmed.ncbi.nlm.nih.gov/32911755/>.
- 12 [44] Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of
13 Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol* [Internet]. 2016
14 [cited 2020 Nov 22];15:673–684. Available from:
15 <https://pubmed.ncbi.nlm.nih.gov/27068280/>.
- 16 [45] Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease
17 [Internet]. *Alzheimer's Res. Ther. Alzheimers Res Ther*; 2013 [cited 2020 Nov 22].
18 Available from: <https://pubmed.ncbi.nlm.nih.gov/23551972/>.
- 19 [46] Dage JL, Wennberg AMV, Airey DC, et al. Levels of tau protein in plasma are associated
20 with neurodegeneration and cognitive function in a population-based elderly cohort.
21 *Alzheimer's Dement* [Internet]. 2016 [cited 2020 Nov 22];12:1226–1234. Available from:
22 <https://pubmed.ncbi.nlm.nih.gov/27436677/>.
- 23 [47] Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. *Neurology*
24 [Internet]. 2016 [cited 2020 Nov 22];87:1827–1835. Available from:
25 <https://pubmed.ncbi.nlm.nih.gov/27694257/>.
- 26 [48] Müller S, Preische O, Göpfert JC, et al. Tau plasma levels in subjective cognitive decline:
27 Results from the DELCODE study. *Sci Rep* [Internet]. 2017 [cited 2020 Nov 22];7.
28 Available from: <https://pubmed.ncbi.nlm.nih.gov/28842559/>.
- 29 [49] Pase MP, Beiser AS, Himali JJ, et al. Assessment of Plasma Total Tau Level as a Predictive
30 Biomarker for Dementia and Related Endophenotypes. *JAMA Neurol* [Internet]. 2019 [cited
31 2020 Nov 22];76:598–606. Available from: <https://pubmed.ncbi.nlm.nih.gov/30830207/>.
- 32 [50] Mielke MM, Hagen CE, Wennberg AMV, et al. Association of plasma total tau level with
33 cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic
34 study on aging. *JAMA Neurol* [Internet]. 2017 [cited 2020 Nov 22];74:1073–1080. Available
35 from: <https://pubmed.ncbi.nlm.nih.gov/28692710/>.
- 36 [51] Cavedo E, Lista S, Houot M, et al. Plasma tau correlates with basal forebrain atrophy rates in
37 people at risk for alzheimer disease. *Neurology* [Internet]. 2020 [cited 2020 Nov 22];94:e30–
38 e41. Available from: <https://pubmed.ncbi.nlm.nih.gov/31801830/>.
- 39 [52] Chen J, Wojta K, Yokoyama JS, et al. Genome-wide association study identifies MAPT
40 locus influencing human plasma tau levels. 2017;
- 41 [53] Quinn JP, Corbett NJ, Kellett KAB, et al. Tau Proteolysis in the Pathogenesis of
42 Tauopathies: Neurotoxic Fragments and Novel Biomarkers [Internet]. *J. Alzheimers. Dis.*
43 *NLM (Medline)*; 2018 [cited 2020 Nov 22]. p. 13–33. Available from:
44 <https://pubmed.ncbi.nlm.nih.gov/29630551/>.
- 45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [54] Mattsson-Carlsson N, Palmqvist S, Blennow K, et al. Increasing the reproducibility of fluid
12 biomarker studies in neurodegenerative studies. *Nat Commun* [Internet]. 2020;11:1–11.
13 Available from: <http://dx.doi.org/10.1038/s41467-020-19957-6>.
- 14 [55] Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links
15 tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat*
16 *Med* [Internet]. 2020 [cited 2021 Jan 23];26:398–407. Available from:
17 <https://pubmed.ncbi.nlm.nih.gov/32161412/>.
- 18 [56] Suárez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at
19 T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when
20 only subtle changes in A β pathology are detected. *EMBO Mol Med* [Internet]. 2020 [cited
21 2021 Jan 23];12. Available from: <https://pubmed.ncbi.nlm.nih.gov/33169916/>.
- 22 [57] Forrest SL, Kril JJ, Halliday GM. Cellular and regional vulnerability in frontotemporal
23 tauopathies. *Acta Neuropathol* [Internet]. 2019;138:705–727. Available from:
24 <https://doi.org/10.1007/s00401-019-02035-7>.
- 25 [58] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal
26 degeneration. *Neurology*. 2013;80:496–503.
- 27 [59] Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal Fluid Tau Levels in Neurodegenerative
28 Diseases with Distinct Tau-Related Pathology. 1997;264:262–264.
- 29 [60] Schoonenboom NSM, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for
30 differential dementia diagnosis in a large memory clinic cohort. *Neurology*. 2012;78:47–54.
- 31 [61] Bech S, Hjermind LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage
32 proteins in parkinsonian syndromes. *Park Relat Disord* [Internet]. 2012;18:69–72. Available
33 from: <http://dx.doi.org/10.1016/j.parkreldis.2011.08.012>.
- 34 [62] Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid
35 biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian
36 disorders. *Arch Neurol*. 2012;69:1445–1452.
- 37 [63] Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid
38 biomarkers may identify patients with atypical parkinsonian syndromes. *J Neurol Neurosurg*
39 *Psychiatry*. 2015;86:1240–1247.
- 40 [64] Schirinzi T, Maria G, Di G, et al. Clinical value of CSF amyloid-beta-42 and tau proteins in
41 Progressive Supranuclear Palsy. *J Neural Transm* [Internet]. 2018;125:1373–1379. Available
42 from: <http://dx.doi.org/10.1007/s00702-018-1893-1>.
- 43 [65] Jeppsson A, Wikkelso C, Blennow K, et al. CSF biomarkers distinguish idiopathic normal
44 pressure hydrocephalus from its mimics. 2019;1117–1123.

- 1
2
3
4
5
6
7
8
9
10 [66] Urakami K, Mori M, Wada K, et al. A comparison of tau protein in cerebrospinal fluid
11 between corticobasal degeneration and progressive supranuclear palsy. 1999;259:127–129.
12
13 [67] Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal
14 fluid from patients with corticobasal degeneration or progressive supranuclear palsy.
15 2001;183:95–98.
16
17 [68] Borroni B, Gardoni F, Parnetti L, et al. Pattern of Tau forms in CSF is altered in progressive
18 supranuclear palsy. 2009;30:34–40.
19
20 [69] Aerts MB, Esselink RAJ, Bloem BR, et al. Cerebrospinal fluid tau and phosphorylated tau
21 protein are elevated in corticobasal syndrome. *Mov Disord*. 2011;
22 [70] Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive
23 supranuclear palsy and frontotemporal dementia. *Ann Neurol*. 2003.
24
25 [71] Barthélemy NR, Gabelle A, Hirtz C, et al. Differential mass spectrometry profiles of tau
26 protein in the cerebrospinal fluid of patients with Alzheimer's disease, progressive
27 supranuclear palsy, and dementia with lewy bodies. *J Alzheimer's Dis*. 2016;51:1033–1043.
28
29 [72] Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E, Bonuccelli U, Grassi
30 M, Perani D, Calabresi P, Di Luca M PA. Tau forms in CSF as a reliable biomarker for
31 progressive supranuclear palsy. *Neurology*. 2008;71:1796–1803.
32
33 * **First report on tau fragments and truncated tau as a biomarker for PSP**
34 [73] Kuiperij HB, Verbeek MM. Tau forms in CSF as a reliable biomarker for progressive
35 supranuclear palsy. *Neurology*. 2011;76:1443.
36
37 [74] Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF τ alterations in two common
38 tauopathies: Alzheimer's disease and progressive supranuclear palsy. *J Neurol Neurosurg*
39 *Psychiatry*. 2015;86:244–250.
40
41 [75] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for
42 Alzheimer's disease: a diagnostic performance and prediction modelling study using data
43 from four prospective cohorts. *Lancet Neurol* [Internet]. 2020 [cited 2020 Oct 16];19:422–
44 433. Available from: <https://pubmed.ncbi.nlm.nih.gov/32333900/>.
45
46 [76] Constantinescu R, Axelsson M. Cerebrospinal fluid neurofilament light and tau protein as
47 mortality biomarkers in parkinsonism. 2019;147–156.
48
49 [77] Rojas JC, Bang J, Lobach I V, et al. CSF neuro filament light chain and phosphorylated tau
50 181 predict disease progression in PSP. 2018;
51
52 [78] Bang J, Spina S, Miller BL. Frontotemporal dementia. *Lancet*. 2015.
53
54 [79] Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of
55 survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurol*

- [Internet]. 2017 [cited 2020 Oct 10];16:55. Available from: [/pmc/articles/PMC5181646/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/28054827/).
- [80] Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134:2456–2477.
- [81] Murley AG, Coyle-Gilchrist I, Rouse MA, et al. Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. *Brain*. 2020;143:1555–1571.
- [82] Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76:1006–1014.
- [83] Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. *Nat Rev Dis Prim*. 2017;3.
- [84] van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. *Lancet* [Internet]. 2017;390:2084–2098. Available from: [http://dx.doi.org/10.1016/S0140-6736\(17\)31287-4](http://dx.doi.org/10.1016/S0140-6736(17)31287-4).
- [85] Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal Degener* [Internet]. 2017/01/05. 2017;18:153–174. Available from: https://pubmed.ncbi.nlm.nih.gov/28054827.
- [86] Chiò A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. *Neurology*. 2019;
- [87] De Silva D, Hsieh S, Caga J, et al. Motor function and behaviour across the ALS-FTD spectrum. *Acta Neurol Scand*. 2016;
- [88] Burrell JR, Kiernan MC, Vucic S, et al. Motor Neuron dysfunction in frontotemporal dementia. *Brain*. 2011;
- [89] Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. *Dement Geriatr Cogn Disord*. 2017;
- [90] Foiani MS, Cicognola C, Ermann N, et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: An elusive quest. *J Neurol Neurosurg Psychiatry*. 2019;
- ** Comprehensive overview on current state of the art and limitations of CSF tau biomarkers in FTD**
- [91] Ye LQ, Li XY, Zhang Y Bin, et al. The discriminative capacity of CSF β -amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. *J Neurol Sci*. 2020;
- [92] Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. *Amyotroph Lateral Scler Front Degener*. 2015;

- 1
2
3
4
5
6
7
8
9
10
11 [93] Kämäläinen A, Herukka SK, Hartikainen P, et al. Cerebrospinal fluid biomarkers for
12 Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic
13 lateral sclerosis with the C9ORF72 repeat expansion. *Dement Geriatr Cogn Disord*. 2015;
14 [94] Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, et al. Cerebrospinal fluid biomarkers in
15 patients with frontotemporal dementia spectrum: A single-center study. *J Alzheimer's Dis*.
16 2018;
17 [95] Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of
18 Alzheimer's disease: Clinical utility of an extended panel of biomarkers in a specialist
19 cognitive clinic. *Alzheimer's Res Ther*. 2018;
20 [96] Wilke C, Deuschle C, Rattay TW, et al. Total tau is increased, but phosphorylated tau not
21 decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. *Neurobiol Aging*. 2015;
22 [97] Scarafino A, D'Errico E, Introna A, et al. Diagnostic and prognostic power of CSF Tau in
23 amyotrophic lateral sclerosis. *J Neurol*. 2018;
24 [98] Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and
25 electrophysiological correlates of CSF biomarkers of neurodegeneration and
26 neuroinflammation in amyotrophic lateral sclerosis. *J Neurol*. 2020;
27 [99] Schreiber S, Spotorno N, Schreiber F, et al. Significance of CSF NfL and tau in ALS. *J*
28 *Neurol*. 2018;
29 [100] Lanznaster D, Hergesheimer RC, Bakkouche SE, et al. A β 1-42 and tau as potential
30 biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis. *Int J Mol Sci*. 2020;
31 [101] Vergallo A, Carlesi C, Pagni C, et al. A single center study: A β 42/p-Tau181 CSF ratio to
32 discriminate AD from FTD in clinical setting. *Neurol Sci*. 2017;
33 [102] Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and
34 phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology*. 2018;
35 [103] Kuiperij HB, Versleijen AAM, Beenes M, et al. Tau Rather than TDP-43 Proteins are
36 Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes:
37 A Pilot Study. *J Alzheimer's Dis*. 2017;
38 [104] Spillantini MG, Crowther RA, Jakes R, et al. α -Synuclein in filamentous inclusions of Lewy
39 bodies from Parkinson's disease and dementia with Lewy bodies. *Proc Natl Acad Sci U S A*
40 [Internet]. 1998 [cited 2020 Oct 8];95:6469–6473. Available from:
41 <https://pubmed.ncbi.nlm.nih.gov/9600990/>.
42 [105] Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and
43 NACP/ α -synuclein- epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia
44 with Lewy bodies. *Brain Res*. 1999;843:53–61.

- 1
2
3
4
5
6
7
8
9
10
11 [106] Wood SJ, Wypych J, Steavenson S, et al. α -Synuclein fibrillogenesis is nucleation-
12 dependent: Implications for the pathogenesis of Parkinson's disease. *J Biol Chem* [Internet].
13 1999 [cited 2020 Oct 19];274:19509–19512. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/10391881/>.
15
16 [107] Friedhoff P, Von Bergen M, Mandelkow EM, et al. Structure of tau protein and assembly
17 into paired helical filaments. *Biochim. Biophys. Acta - Mol. Basis Dis.* Elsevier; 2000. p.
18 122–132.
19
20 [108] Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and
21 alpha-synuclein. *Science* (80-) [Internet]. 2003 [cited 2020 Oct 16];300:636–640. Available
22 from: <https://pubmed.ncbi.nlm.nih.gov/12714745/>.
23
24 [109] Souza JM, Giasson BI, Lee VMY, et al. Chaperone-like activity of synucleins. *FEBS Lett*
25 [Internet]. 2000 [cited 2020 Oct 19];474:116–119. Available from:
26 <https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2800%2901563-5>.
27
28 [110] Daniele S, Frosini D, Pietrobono D, et al. α -synuclein heterocomplexes with β -amyloid are
29 increased in red blood cells of Parkinson's disease patients and correlate with disease
30 severity. *Front Mol Neurosci* [Internet]. 2018 [cited 2020 Oct 10];11. Available from:
31 <https://pubmed.ncbi.nlm.nih.gov/29520218/>.
32
33 [111] Wong YC, Krainc D. α -synuclein toxicity in neurodegeneration: Mechanism and therapeutic
34 strategies. *Nat Med* [Internet]. 2017;23:1–13. Available from:
35 <http://dx.doi.org/10.1038/nm.4269>.
36
37 [112] Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid β -amyloid 1-
38 42, t-tau, p-tau 181, and α -synuclein levels with clinical features of drug-naive patients with
39 early parkinson disease. *JAMA Neurol* [Internet]. 2013 [cited 2020 Oct 8];70:1277–1287.
40 Available from: <https://pubmed.ncbi.nlm.nih.gov/23979011/>.
41
42 [113] Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longitudinal CSF biomarkers in
43 patients with early Parkinson disease and healthy controls. *Neurology* [Internet]. 2017 [cited
44 2020 Oct 8];89:1959–1969. Available from: <https://pubmed.ncbi.nlm.nih.gov/29030452/>.
45
46 * **A paper reviewing longitudinal changes in CSF biomarkers in Parkinson's Disease**
47 [114] Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy:
48 A review of the MSA Biomarker Initiative [Internet]. *Neurobiol. Dis.* Academic Press Inc.;
49 2015 [cited 2020 Oct 8]. p. 29–41. Available from:
50 <https://pubmed.ncbi.nlm.nih.gov/25982836/>.
51
52 [115] Delgado-Alvarado M, Gago B, Gorostidi A, et al. Tau/ α -synuclein ratio and inflammatory
53 proteins in Parkinson's disease: An exploratory study. *Mov Disord* [Internet]. 2017 [cited
54
55
56
57
58
59
60

- 2020 Oct 8];32:1066–1073. Available from: <https://pubmed.ncbi.nlm.nih.gov/28548309/>.
- [116] Aarsland D, Kurz MW. The epidemiology of dementia associated with parkinson's disease. *Brain Pathol* [Internet]. *Brain Pathol*; 2010 [cited 2020 Oct 16]. p. 633–639. Available from: <https://pubmed.ncbi.nlm.nih.gov/20522088/>.
- [117] Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. *Biol Psychiatry* [Internet]. 2008 [cited 2020 Oct 16];64:850–855. Available from: <https://pubmed.ncbi.nlm.nih.gov/18395699/>.
- [118] Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. *Neurology* [Internet]. 2010 [cited 2020 Oct 16];75:1055–1061. Available from: <https://pubmed.ncbi.nlm.nih.gov/20720189/>.
- [119] Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurol*. 2017;16:55.
- [120] Mukaetova-Ladinska EB, Monteith R, Perry EK. Cerebrospinal fluid biomarkers for Dementia with Lewy Bodies [Internet]. *Int. J. Alzheimers. Dis. Int J Alzheimers Dis*; 2010 [cited 2020 Oct 16]. Available from: <https://pubmed.ncbi.nlm.nih.gov/21048932/>.
- [121] Irwin DJ, Xie SX, Coughlin D, et al. CSF tau and β -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. *Neurology* [Internet]. 2018 [cited 2020 Oct 10];90:e1038–e1046. Available from: <https://n.neurology.org/content/90/12/e1038>.
- [122] Clark CM, Xie S, Chittams J, et al. Cerebrospinal Fluid Tau and β -Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses? *Arch Neurol* [Internet]. 2003 [cited 2020 Oct 10];60:1696–1702. Available from: <https://pubmed.ncbi.nlm.nih.gov/14676043/>.
- [123] Parnetti L, Lanari A, Amici S, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. *Neurol Sci* [Internet]. 2001 [cited 2020 Oct 10];22:77–78. Available from: <https://pubmed.ncbi.nlm.nih.gov/11487210/>.
- [124] Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies [Internet]. *Alzheimer's Res. Ther. BioMed Central Ltd.*; 2014 [cited 2020 Oct 10]. Available from: <https://pubmed.ncbi.nlm.nih.gov/25478030/>.
- [125] Coughlin DG, Xie SX, Liang M, et al. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders Abstract HHS Public Access. *Ann Neurol*. 2019;85:259–271.

- 1
2
3
4
5
6
7
8
9
10
11 [126] van der Zande JJ, Steenwijk MD, ten Kate M, et al. Gray matter atrophy in dementia with
12 Lewy bodies with and without concomitant Alzheimer's disease pathology. *Neurobiol Aging*
13 [Internet]. 2018 [cited 2020 Oct 16];71:171–178. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/30149288/>.
15
16 [127] Abdelnour C, Ferreira D, Oppedal K, et al. The combined effect of amyloid- β and tau
17 biomarkers on brain atrophy in dementia with Lewy bodies. *NeuroImage Clin* [Internet].
18 2020 [cited 2020 Oct 16];27. Available from: [/pmc/articles/PMC7363702/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/30149288/).
19
20 [128] Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy
21 [Internet]. *Auton. Neurosci. Basic Clin. Elsevier B.V.*; 2018 [cited 2020 Oct 9]. p. 15–25.
22 Available from: <https://pubmed.ncbi.nlm.nih.gov/29111419/>.
23
24 [129] Fanciulli A, Wenning GK. Multiple-System Atrophy. *N Engl J Med*. 2015;372:1375–1376.
25
26 [130] Seino Y, Nakamura T, Kawarabayashi T, et al. Cerebrospinal Fluid and Plasma Biomarkers
27 in Neurodegenerative Diseases. *J Alzheimer's Dis* [Internet]. 2019 [cited 2020 Oct
28 10];68:395–404. Available from: <https://pubmed.ncbi.nlm.nih.gov/30814356/>.
29
30 [131] Herbert MK, Eeftens JM, Aerts MB, et al. CSF levels of DJ-1 and tau distinguish MSA
31 patients from PD patients and controls. *Park Relat Disord* [Internet]. 2014 [cited 2020 Oct
32 9];20:112–115. Available from: <https://pubmed.ncbi.nlm.nih.gov/24075122/>.
33
34 [132] Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease
35 diagnosis and progression. *Ann Neurol* [Internet]. 2011 [cited 2020 Oct 9];69:570–580.
36 Available from: [/pmc/articles/PMC3117674/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/24075122/).
37
38 [133] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α -Synuclein and tau concentrations
39 in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. *Lancet*
40 *Neurol*. 2011;10:230–240.
41
42 [134] Constantinides VC, Paraskevas GP, Emmanouilidou E, et al. CSF biomarkers β -amyloid, tau
43 proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. *J Neurol*
44 *Sci*. 2017;382:91–95.
45
46 [135] Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-
47 synuclein in blood. *Neurodegener Dis*. 2008;5:55–59.
48
49 [136] Wang X, Yu S, Li F, et al. Detection of α -synuclein oligomers in red blood cells as a
50 potential biomarker of Parkinson's disease. *Neurosci Lett* [Internet]. 2015 [cited 2020 Oct
51 10];599:115–119. Available from: <https://pubmed.ncbi.nlm.nih.gov/25998655/>.
52
53 [137] Ashton NJ, Hye A, Rajkumar AP, et al. An update on blood-based biomarkers for non-
54 Alzheimer neurodegenerative disorders [Internet]. *Nat. Rev. Neurol. Nature Research*; 2020
55 [cited 2020 Oct 16]. p. 265–284. Available from:

- 1
2
3
4
5
6
7
8
9
10
11 <https://pubmed.ncbi.nlm.nih.gov/32322100/>.
- 12 [138] Universities S, Cu M, Dubois B, et al. Advancing research diagnostic criteria for Alzheimer ' s disease : The IWG-2 criteria Position Paper Advancing research diagnostic criteria for
13 s disease : The IWG-2 criteria. *Lancet Neurol.* 2014;13 (6):614–649.
- 14 [139] Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-
15 dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging
16 probes for beta-amyloid plaques in Alzheimer's disease. *J Neurosci.* 2001;
- 17 [140] Thompson PW, Ye L, Morgenstern JL, et al. Interaction of the amyloid imaging tracer
18 FDDNP with hallmark Alzheimer's disease pathologies. *J Neurochem.* 2009;
- 19 [141] Villemagne VL, Okamura N. In vivo tau imaging: Obstacles and progress. *Alzheimer's*
20 *Dement.* 2014;
- 21 [142] Villemagne VL, Furumoto S, Fodero-Tavoletti M, et al. The challenges of tau imaging.
22 *Future Neurol.* 2012.
- 23 [143] Lemoine L, Saint-Aubert L, Nennesmo I, et al. Cortical laminar tau deposits and activated
24 astrocytes in Alzheimer's disease visualised by 3 H-THK5117 and 3 H-deprenyl
25 autoradiography. *Sci Rep.* 2017;
- 26 [144] Vermeiren C, Motte P, Viot D, et al. The tau positron-emission tomography tracer AV-1451
27 binds with similar affinities to tau fibrils and monoamine oxidases. *Mov Disord.* 2018;
- 28 [145] Brosch JR, Farlow MR, Risacher SL, et al. Tau Imaging in Alzheimer's Disease Diagnosis
29 and Clinical Trials. *Neurotherapeutics.* 2017.
- 30 [146] Perez-Soriano A, Arena JE, Dinelle K, et al. PBB3 imaging in Parkinsonian disorders:
31 Evidence for binding to tau and other proteins. *Mov Disord.* 2017;
- 32 [147] Lois C, Gonzalez I, Johnson KA, et al. PET imaging of tau protein targets: a methodology
33 perspective. *Brain Imaging Behav.* 2019;
- 34 * **A comprehensive overview on tau imaging in AD**
- 35 [148] Barthel H. First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of
36 Alzheimer Disease. *J. Nucl. Med.* 2020.
- 37 [149] Braak H, Thal DR, Ghebremedhin E, et al. Stages of the Pathologic Process in Alzheimer
38 Disease: Age Categories From 1 to 100 Years. *J Neuropathol Exp Neurol.* 2011;70:960–969.
- 39 [150] Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. *J*
40 *Neurol Sci.* 1970;
- 41 [151] Xia CF, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography
42 imaging agent for Alzheimer's disease. *Alzheimer's Dement.* 2013;
- 43 [152] Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel
44

- 1
2
3
4
5
6
7
8
9
10 PHF-tau radioligand [F18]-T808. *J Alzheimer's Dis.* 2014;
- 11 [153] Fleisher AS, Pontecorvo MJ, Devous MD, et al. Positron Emission Tomography Imaging
12 with [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic
13 Changes. *JAMA Neurol.* 2020;
- 14 [154] Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir
15 positron emission tomography for Alzheimer disease vs other neurodegenerative disorders.
16 *JAMA - J Am Med Assoc.* 2018;
- 17 [155] Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: A novel PET radiotracer for
18 imaging neurofibrillary pathology in Alzheimer disease. *J Nucl Med.* 2016;
- 19 [156] Schöll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging
20 Human Brain. *Neuron.* 2016;
- 21 [157] Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in
22 aging and early Alzheimer disease. *Ann Neurol.* 2016;
- 23 [158] Chiotis K, Saint-Aubert L, Savitcheva I, et al. Imaging in-vivo tau pathology in Alzheimer's
24 disease with THK5317 PET in a multimodal paradigm. *Eur J Nucl Med Mol Imaging.* 2016;
- 25 [159] Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in
26 the Alzheimer disease spectrum. *Ann Neurol.* 2016;
- 27 [160] Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive
28 impairment. *Neurology.* 2016;
- 29 [161] Pontecorvo MJ, Devous MD, Navitsky M, et al. Relationships between flortaucipir PET tau
30 binding and amyloid burden, clinical diagnosis, age and cognition. *Brain.* 2017;
- 31 [162] Marshall GA, Fairbanks LA, Tekin S, et al. Early-onset Alzheimer's disease is associated
32 with greater pathologic burden. *J Geriatr Psychiatry Neurol.* 2007;
- 33 [163] Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease:
34 Implications for prevention trials. *Neuron.* 2014.
- 35 [164] Ishiki A, Okamura N, Furukawa K, et al. Longitudinal assessment of Tau pathology in
36 patients with Alzheimer's disease using [18F] THK-5117 positron emission tomography.
37 *PLoS One.* 2015;
- 38 [165] Jack CR, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer's
39 disease. *Brain.* 2018;
- 40 [166] Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, et al. Longitudinal changes of tau PET
41 imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. *Mol*
42 *Psychiatry.* 2018;
- 43 [167] Cho H, Choi JY, Lee HS, et al. Progressive tau accumulation in Alzheimer disease: 2-year
44
45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8
9
10 follow-up study. *J Nucl Med.* 2019;
- 11 [168] Hansson O, Mormino EC. Is longitudinal tau PET ready for use in Alzheimer's disease
12 clinical trials? *Brain.* 2018.
- 13 [169] Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and
14 neuroanatomical variability in Alzheimer's disease. *Brain.* 2016;
- 15 [170] Dronse J, Fliessbach K, Bischof GN, et al. In vivo Patterns of Tau Pathology, Amyloid- β
16 Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. *J*
17 *Alzheimer's Dis.* 2017;
- 18 [171] Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a
19 patient with posterior cortical atrophy. *Ann Neurol.* 2015;
- 20 [172] Phillips JS, Das SR, McMillan CT, et al. Tau PET imaging predicts cognition in atypical
21 variants of Alzheimer's disease. *Hum Brain Mapp.* 2018;
- 22 [173] Okamura N, Harada R, Ishiki A, et al. The development and validation of tau PET tracers:
23 current status and future directions. *Clin. Transl. Imaging.* 2018.
- 24 [174] Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic performance of RO948 F 18 tau
25 positron emission tomography in the differentiation of alzheimer disease from other
26 neurodegenerative disorders. *JAMA Neurol.* 2020;
- 27 [175] Wong DF, Comley RA, Kuwabara H, et al. Characterization of 3 novel tau
28 radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in
29 Alzheimer subjects. *J Nucl Med.* 2018;
- 30 [176] Smith R, Schöll M, Leuzy A, et al. Head-to-head comparison of tau positron emission
31 tomography tracers [18F]flortaucipir and [18F]RO948. *Eur J Nucl Med Mol Imaging.* 2020;
- 32 [177] Stephens A, Seibyl J, Mueller A, et al. IC-P-220: CLINICAL UPDATE: 18 F-PI-2620, A
33 NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH
34 ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY .
35 *Alzheimer's Dement.* 2018;
- 36 [178] Betthausen TJ, Cody KA, Zammit MD, et al. In vivo characterization and quantification of
37 neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from Alzheimer disease
38 dementia to young controls. *J Nucl Med.* 2019;
- 39 [179] Lohith TG, Bennacef I, Vandenberghe R, et al. Brain imaging of Alzheimer dementia
40 patients and elderly controls with 18 F-MK-6240, a PET tracer targeting neurofibrillary
41 tangles. *J Nucl Med.* 2019;
- 42 [180] Pascoal TA, Shin M, Kang MS, et al. In vivo quantification of neurofibrillary tangles with [
43 18 F]MK-6240. *Alzheimer's Res Ther.* 2018;

- 1
2
3
4
5
6
7
8
9
10
11 [181] Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution
12 distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
13 *Brain*. 2007;
- 14 [182] Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white
15 matter of corticobasal degeneration. *Am J Pathol*. 2002;
- 16 [183] Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal
17 degeneration presenting as corticobasal syndrome or Richardson syndrome. *Brain*. 2011;
- 18 [184] Ling H, Kovacs GG, Vonsattel JPG, et al. Astroglial pathology predominates the earliest stage of
19 corticobasal degeneration pathology. *Brain*. 2016;
- 20 [185] Saeed U, Lang AE, Masellis M. Neuroimaging Advances in Parkinson's Disease and
21 Atypical Parkinsonian Syndromes. *Front. Neurol*. 2020.
- 22 [186] Ishiki A, Harada R, Okamura N, et al. Tau imaging with [18F]THK-5351 in progressive
23 supranuclear palsy. *Eur J Neurol*. 2017;
- 24 [187] Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of 18F-AV-1451 in
25 patients with progressive supranuclear palsy. *Mov Disord*. 2017;
- 26 [188] Cho H, Choi JY, Hwang MS, et al. Subcortical 18F-AV-1451 binding patterns in progressive
27 supranuclear palsy. *Mov Disord*. 2017;
- 28 [189] Whitwell JL, Lowe VI, Tosakulwong N, et al. [18F]AV-1451 tau positron emission
29 tomography in progressive supranuclear palsy. *Mov Disord*. 2017;
- 30 [190] Passamonti L, Rodríguez PV, Hong YT, et al. 18F-AV-1451 positron emission tomography
31 in Alzheimer's disease and progressive supranuclear palsy. *Brain*. 2017;
- 32 [191] Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient
33 with progressive supranuclear palsy. *Mov. Disord*. 2017.
- 34 [192] Coakeley S, Cho SS, Koshimori Y, et al. Positron emission tomography imaging of tau
35 pathology in progressive supranuclear palsy. *J Cereb Blood Flow Metab*. 2017;
- 36 [193] Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies:
37 Progressive supranuclear palsy. *J Alzheimer's Dis*. 2013;
- 38 [194] Schonhaut DR, McMillan CT, Spina S, et al. 18F-flortaucipir tau positron emission
39 tomography distinguishes established progressive supranuclear palsy from controls and
40 Parkinson disease: A multicenter study. *Ann Neurol*. 2017;
- 41 [195] Brendel M, Schönecker S, Höglinger G, et al. [18F]-THK5351 PET correlates with topology
42 and symptom severity in progressive supranuclear palsy. *Front Aging Neurosci*. 2018;
- 43 [196] Hsu JL, Chen SH, Hsiao IT, et al. 18F-THK5351 PET imaging in patients with progressive
44 supranuclear palsy: associations with core domains and diagnostic certainty. *Sci Rep*. 2020;
- 45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8
9
10
11 [197] Whitwell JL, Tosakulwong N, Botha H, et al. Brain volume and flortaucipir analysis of
12 progressive supranuclear palsy clinical variants. *NeuroImage Clin.* 2020;
13 [198] Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse
14 model and in alzheimer patients compared to normal controls. *Neuron.* 2013;
15 [199] Kikuchi A, Okamura N, Hasegawa T, et al. In vivo visualization of tau deposits in
16 corticobasal syndrome by 18 F-THK5351 PET. *Neurology.* 2016;
17 [200] McMillan CT, Irwin DJ, Nasrallah I, et al. Multimodal evaluation demonstrates in vivo 18F-
18 AV-1451 uptake in autopsy-confirmed corticobasal degeneration. *Acta Neuropathol.* 2016.
19 [201] Ali F, Whitwell JL, Martin PR, et al. [18F] AV-1451 uptake in corticobasal syndrome: the
20 influence of beta-amyloid and clinical presentation. *J Neurol.* 2018;
21 [202] Tsai RM, Bejanin A, Lesman-Segev O, et al. 18F-flortaucipir (AV-1451) tau PET in
22 frontotemporal dementia syndromes. *Alzheimer's Res Ther.* 2019;
23 [203] Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in
24 dementia. *Acta Neuropathol Commun.* 2016;
25 [204] Brendel M, Barthel H, Van Eimeren T, et al. Assessment of 18F-PI-2620 as a Biomarker in
26 Progressive Supranuclear Palsy. *JAMA Neurol.* 2020;
27 [205] Kroth H, Oden F, Molette J, et al. Discovery and preclinical characterization of [18F]PI-
28 2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's
29 disease and other tauopathies. *Eur J Nucl Med Mol Imaging.* 2019;
30 [206] Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer's fluid biomarkers
31 [Internet]. *Acta Neuropathol.* Springer Berlin Heidelberg; 2018. Available from:
32 <https://doi.org/10.1007/s00401-018-1932-x>.
33 [207] Hampel H, Goetzl EJ, Kapogiannis D, et al. Biomarker-drug and liquid biopsy co-
34 development for disease staging and targeted therapy: Cornerstones for Alzheimer's
35 precision medicine and pharmacology. *Front Pharmacol.* 2019;10:1–10.
36 [208] Thijssen EH, Rabinovici GD. Rapid Progress Toward Reliable Blood Tests for Alzheimer
37 Disease. *JAMA Neurol.* 2020;
38 [209] Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-
39 tau181 as a biomarker of Alzheimer's disease. *Nat Commun* [Internet]. 2020 [cited 2020 Dec
40 5];11. Available from: <https://pubmed.ncbi.nlm.nih.gov/32246036/>.
41 * A recent paper exploring the potential role of p-tau217 as a biomarker for AD
42 [210] Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels with
43 Tau Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurol.* 2020;
44 * A recent paper exploring the potential role of p-tau217 as a biomarker for AD
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11 [211] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α -Synuclein and tau concentrations
12 in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. *Lancet*
13 *Neurol* [Internet]. 2011 [cited 2020 Oct 10];10:230–240. Available from:
14 <https://pubmed.ncbi.nlm.nih.gov/21317042/>.
15
16 [212] Hampel H, Lista S, Neri C, et al. Time for the systems-level integration of aging: Resilience
17 enhancing strategies to prevent Alzheimer’s disease. *Prog Neurobiol* [Internet].
18 2019;181:101662. Available from: <https://doi.org/10.1016/j.pneurobio.2019.101662>.
19
20 [213] Toschi N, Lista S, Baldacci F, et al. Biomarker-guided clustering of Alzheimer’s disease
21 clinical syndromes. *Neurobiol Aging*. 2019;83:42–53.
22
23 [214] Hampel H, Caraci F, Cuello AC, et al. A Path Toward Precision Medicine for
24 Neuroinflammatory Mechanisms in Alzheimer’s Disease. *Front Immunol*. 2020;11.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Tau isoforms and the pathological classification of tauopathies. Six tau isoforms are generated through the alternative splicing of exons 2,3 and 10 of the Microtubule-associated protein tau (MAPT) gene. The microtubule-binding domain (MBD) is encoded by exon 10, whose alternative splicing generates three tau isoforms with 3 or 4 repeats called 3R and 4R tau respectively (panel A). Tauopathies are classified accordingly into primary tauopathies, which are further divided into 3R, 4R and mixed 3R/4R tauopathies, and secondary tauopathies (panel B).

1057x1730mm (72 x 72 DPI)




Figure 2. Paper selection flow-chartThe paper selection algorithm for plasma tau in NDDs and CSF tau in NDDs other than AD is summarized in the figure. Abbreviations: AD: Alzheimer's Disease, CSF: cerebrospinal fluid, NDDs: neurodegenerative diseases.

1057x634mm (72 x 72 DPI)

Technology	Key characteristics	Tau species detected	Comments
Simoa	<p>Fully-automated digitalized standard-ELISA.</p> <p><i>How it works</i></p> <ol style="list-style-type: none"> Specific antibody-coated paramagnetic microbeads and fluorescence-emitting detection antibodies are embedded with the analytes. The sample containing immunocomplexes (bead, bound protein and detection antibody) is loaded into arrays of subfemtomolar-sized reaction chambers, large enough to hold one bead. The emitted signal reflects the presence of single enzyme-associated immunocomplexes on single beads. <p>(https://www.quanterix.com/simoa-bead-technology)</p>	<p>t-tau</p> <p>p-tau181</p> <p>N-terminal tau fragment</p>	<p><i>Advantages</i></p> <ul style="list-style-type: none"> - greatest sensitivities; - multiplexing (short turn-around times and high throughput); - flexibility and cost-saving; - most established ultrasensitive technology for blood-biomarkers in AD. <p><i>Limitations</i></p> <ul style="list-style-type: none"> - standardization of the protocol and further cross-assay evaluations are needed.
ECLIA	<p>Electrochemiluminescent labels generate light when activated by the interaction with ligands. The magnitude of the signal reflects the concentration of the analyte.</p> <p><i>How it works</i></p> <ol style="list-style-type: none"> Labels interact with ligands; The interaction generates a luminescent signal, whose magnitude is proportional to the analytes concentration. <p>The reaction relies on a complex of ruthenium and TPA and can be incorporated into different immunoassays. (https://www.creative-biolabs.com/drug-discovery/diagnostics/eclia-based-kits-development.htm)</p>	<p>t-tau</p> <p>p-tau181</p> <p>p-tau217</p>	<p><i>Advantages</i></p> <ul style="list-style-type: none"> - rapid measurement, wide measuring range, high sensitivity (up to femtomolar range); - low sample volume; - MSD platform is a multiplex technology enabling parallel measurements of different biomarkers and matrices (e.g., plasma, CSF); - optimal accuracy for different tau-species. <p><i>Limitations</i></p> <ul style="list-style-type: none"> - further head-to-head comparisons are required to assess sensitivity and specificity.

IP-LC/MS	Combines immunoprecipitation and liquid chromatography (LC) /mass spectrometry (MS) <i>How it works</i> 1. peptides are isolated with specific antibodies [30]; 2. Peptides are physically separated based on their mass and biochemical properties by means of LC/MS.	p-tau181	<i>Limitations</i> - a multiple-step extraction phase to purify and concentrate the analytes is required to increase sensitivity and reduce the interference of contaminants; - labor-intensive, low-throughput and time-consuming method.
		p-tau217	
IMR	An antibody-mediated reduction in the magnetic field generates a signal for analyte concentration quantification. <i>How it works</i> 1. Magnetic antibody-coated nanoparticles oscillate under multiple AC magnetic fields; 2. Binding of target molecules enlarges or clusters magnetic nanoparticles, leading to a reduction in their magnetic susceptibility, which is proportional to the concentration of the analytes.	t-tau	<i>Advantages</i> - does not require beads to purify the antigens, relying on a single-antibody detection strategy - great sensitivity (up to the femtomolar range)
		p-tau181	<i>Limitations</i> - suboptimal specificity.

Table 1. Overview of ultrasensitive measurement techniques for the detection of tau species in plasma

Abbreviations: AC: alternating current; AD: Alzheimer's disease; ECL: electrochemiluminescence; ECLIA: electrochemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; IMR: immunomagnetic reduction; IP/LC-MS: immunoprecipitation coupled with liquid chromatography-mass spectrometry; LoD: limit of detection; MSD: mesoscale discovery; p-tau181: phosphorylated-tau at threonine 181; p-tau217: phosphorylated-tau at threonine 217; Simoa: single molecule array; TPA: tripropylamine; t-tau: total tau.

Reference	Population	Study design	Technique	Tau species	Diagnostic value	Prognostic value
Lue LF. et al., 2017	n=129 - U.S. cohort: n=32 CU (n=16); AD dementia (n=16) - Taiwan cohort: n=97 CU (n=66); AD dementia (n=31)	Cross-sectional	IMR	t-tau	CU vs. probable AD: - AuROC=0.81 (U.S. cohort) - AuROC=0.96 (Taiwan cohort) - AuROC=0.92(combined cohort) (clinical diagnosis as reference)	NA
Mielke MM. et al., 2017	n=458 CU (n=335); MCI (n=123)	Longitudinal	Simoa HD-1 Analyzer	t-tau	NA	Risk of evolving to MCI in CU: - middle tertile (HR=2.43) - highest tertile (HR=2.02)
Mielke MM et al., 2018	n=269 CU (n=172); MCI (n=57); AD (n=40)	Cross-sectional	Simoa HD-1 Analyzer	t-tau	Amyloid-negative vs. amyloid-positive: AuROC=0.60 (amyloid-PET as reference)	NA
			MSD	p-tau181	Amyloid-negative vs. amyloid-positive: AuROC=0.80 (amyloid-PET as reference)	NA
Yang C. et al., 2018	n=73 CU (n=23); AD-MCI (n=29); AD (n=21)	Cross-sectional	IMR	p-tau181	CU vs. AD-MCI: AuROC=0.85; AD-MCI vs. AD: AuROC=0.78 (clinical diagnosis as reference)	NA
Lin CH. et al., 2018	n=205 CU (n=35); PD (n=102); DLB (n=6); MSA (n=22); PSP (n=6); CBD (n=3); FTD-P (n=6); FTD without P (n=25)	Cross-sectional	IMR	p-tau181	FTD vs. parkinsonian syndromes (PD, DLB, PSP and CBD) A β ₁₋₄₂ x p-tau181 at a cut-off value of 92.66 (pg/ml) ² AuROC=0.93 (clinical diagnosis as reference)	NA
Chen Z. et al., 2019	n=151 - Discovery cohort: n=65 CU (n=19); AD-MCI (n=21); AD (n=25) - Validation cohort n=86	Cross-sectional	Simoa HD-1 Analyzer	N-terminal detected tau (including tau fragments)	CU vs.AD-MCI: AuROC=0.88 CU vs AD: AuROC=0.96 (clinical diagnosis as reference standard) (discovery cohort)	NA

	CU (n=41); AD-MCI (n=22); AD (n=23)					
Park JC. et al., 2019	n=76 CU (n=52); MCI (n=9); AD dementia (n=15)	Cross-sectional and longitudinal	Simoa HD-1 Analyzer -(t-tau) xMAP ($A\beta_{1-42}$)	t-tau	tau-positive vs. tau-negative: -t-tau: AuROC=0.80 -t-tau/ $A\beta_{1-42}$: AuROC=0.89 (amyloid-PET as reference)	NA
Pase MP. et al., 2019	n=1820 - Cohort 1: n=1453* (CU > 65 years) - Cohort 2: n=367° (MCI, SMC) *at FU: - dementia onset n=134 AD dementia (n=105); non-AD dementia (n=29) ° at FU: - AD dementia onset (n=19)	Prospective	Simoa HD-1 Analyzer	t-tau	NA	Cohort 1: - each SD unit increase in the log levels is associated with a 35% increased risk of AD (HR=1.35) - after adjustment for APOE $\epsilon 4$ allele and vascular risk factors: <ul style="list-style-type: none">all dementia risk: HR=1.31AD risk: HR=1.38 Cohort 2: each SD unit increase in the log levels is associated with a 54% increased risk of AD (HR=2.33) after adjusting for age and sex
Janelidze S. et al., 2020	n=589 - Cohort 1: n=182 CU (n=64); MCI (n=28); AD (n=38); non-AD dementia (n=52) - Cohort 2: n=344 CU (n=219); MCI (n=125) - Cohort 3 (neuropathology cohort): n=63 AD (n=16); non-AD	Both cross-sectional and longitudinal designs	MSD	p-tau181	Cohort 1: - tau-positive vs. negative participants AuROC=0.87 with tau-PET as reference; - AD vs. non-AD dementia: AuROC=0.94 (clinical diagnosis as reference) Cohort 1 and cohort 2 combined: - $A\beta_{+}$ vs. $A\beta_{-}$ participants AuROC=0.80 ($A\beta$ PET as reference)	Cohort 2: higher p-tau levels are associated with progression to AD for both CU (HR=2.48) and MCI (HR=3.07)

	dementia (n=47)				Cohort 3: AD vs. non-AD dementia: AuROC=0.85 (neuropathology as reference)	
Thijssen E. et al., 2020	n=404 Cohort 1: n=362 CU (n=69); MCI (n=47); AD (n=56); CBS (n=39); PSP (n=48); bvFTD (n=50); nfvPPA (n=27); svPPA (n=26) Cohort 2: n=42 (MCI, AD)	Cross-sectional (retrospective) and longitudinal	MSD/Lilly immunoassays	p-tau181	Cohort 1: - AD vs. FTLD (n=190): AuROC=0.89 (clinical diagnosis as reference); - A β -PET positive participants vs. negative: AuROC = 0.86 with amyloid-PET as reference; - autopsy-confirmed AD (n =15) vs. FTLD-tau (n=52) AuROC=0.86 (neuropathology as reference)	NA
Karikari T. et al., 2020	n=1331 - Discovery cohort: n=37 CU (n=18); AD (n=19) - Validation cohort 1: n=763 CU (n=140); MCI (n=45); AD (n=33); FTD (n=8) - Validation cohort 2: n=763 CU (n=337); MCI (n=191); AD (n=126); bvFTD/PPA (n=18); PD/MSA (n=36); VD (n=12); PSP/CBS (n=21) - Primary care cohort: N=105 CU (n=83); MCI (n=12); AD (n=10)	Longitudinal	Simoa	p-tau181	Across cohorts - AD vs. CU: AuROC=0.90-0.98 Validation cohort 1 - AD vs. FTD: AuROC=0.76-0.82 (clinical diagnosis as reference) - tau-PET + vs. tau-PET -: AuROC=0.83-0.93 across cohorts (tau-PET as reference) - AD vs. amyloid- β -: AuROC=0.99 (amyloid-PET as reference) Validation cohort 2 - AD vs VaD: AuROC=0.92 - AD vs PSP/CBS: AuROC=0.89 - AD vs PD/MSA: AuROC=0.82 (clinical diagnosis as reference) Primary care cohort - AD vs CU young adults: AuROC = 1.0 - AD vs CU older adults: AuROC=0.84 (clinical diagnosis as reference)	NA
Palmqvist S. et al., 2020	n=1402 - Cohort 1 (neuropathology cohort): n=81	Cross-sectional	MSD/Lilly immunoassays	p-tau 217	Cohort 1: AD vs. non-AD: AuROC=0.89 (neuropathology as reference) Cohort 2:	NA

	AD (n=34); non-AD (n=47) - Cohort 2: n=699 CU (n=301); MCI (n=178); AD dementia (n=121); non-AD dementia: PD/PDD/MSA, PSP/CBS, bvFTD/PPA, VD (n=99) - Cohort 3: n= 622 PSEN1 mutation carriers n=365; age- and sex-matched noncarriers: n=257				- AD vs. non-AD dementia: AuROC=0.96 (clinical diagnosis as reference) - tau + vs. tau -: AuROC=0.93 (tau-PET as reference) - amyloid + vs. amyloid -: AuROC=0.87 (amyloid-PET as reference)	
Barthélemy NR. et al., 2020	n=128 - Discovery cohort: n=36 CU (n=17); non-AD MCI (n=2); preclinical AD (n=5); AD-MCI (n=8); moderate AD (n=2) - Validation cohort: n=92 CU (n=31); non-AD MCI (n=11); preclinical AD (n=20); AD-MCI (n=24); moderate AD (n=6)	Cross-sectional	IP-LC/MS	p-tau181	Amyloid + vs. -: - discovery cohort: AuROC=0.98 - validation cohort: AuROC=0.75 (amyloid-PET or CSF A β_{1-42} /A β_{1-40} as reference)	NA
				p-tau217	Amyloid positive vs. amyloid-negative subjects: - discovery cohort: AuROC=0.99 - validation cohort: AuROC=0.92 (amyloid-PET or CSF A β_{1-42} /A β_{1-40} as reference)	NA
Janelidze S. et al., 2020	n=490 CU (n=225); SCI (n=89); MCI (n=176)	Cross-sectional and longitudinal	MSD/ Lilly immunoassays	p-tau217	A β -PET ⁺ /tau-PET ⁻ CU vs. A β -PET ⁻ /tau-PET ⁻ : AuROC=0.832 (amyloid-PET as reference)	NA

1
2 ***Table 2. Diagnostic and prognostic value of plasma tau species in NDDs assessed with ultrasensitive measurement techniques***
3

4 *Abbreviations:* AD: Alzheimer's Disease; AuROC: area under the receiver operating curve; A β : amyloid β ; A β 1–40: amyloid β -peptide 1–40; A β 1–42: amyloid
5 β -peptide 1–42; bvFTD: behavioral variant Frontotemporal Dementia; CBS: Corticobasal Syndrome; CU: Cognitively Unimpaired; FTD: Frontotemporal
6 Dementia; FTLD: Frontotemporal Lobar Degeneration; FTD-P: Frontotemporal Dementia with parkinsonism; FU: follow-up; HR: hazard ratio; IMR:
7 immunomagnetic reduction; IP LC/MS: immunoprecipitation coupled to liquid chromatography/mass spectrometry; MCI: mild cognitive impairment; MSD:
8 meso scale discovery; MSA: Multiple System Atrophy; NA: not assessed; nfvPPA: non-fluent variant primary progressive aphasia; PD: Parkinson's disease;
9 PDD: Parkinson's disease dementia; PPA: Primary Progressive Aphasia; PSP: Progressive Supranuclear Palsy; p-tau181: phospho-tau181; p-tau217: phospho-
10 tau217; SD: standard deviation; Simoa: single molecule array; SCI: subjective cognitive impairment; -SMC: subjective memory complainer; svPPA: semantic
11 variant primary progressive aphasia; t-tau: total-tau; VaD: vascular dementia; xMAP: multi-analyte profiling.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Reference	Population	Study design	Technique	Tau species	Diagnostic value	Prognostic value
Magdalinou NK. et al., 2015	n=190 CU (n=30); PD (n=31); PSP (n=33); CBS (n=14); MSA (n=31); AD (n=26); FTD (n=16); "unclassified" parkinsonism (n=9)	Prospective	ELISA INNOTEST (t-tau; p-tau; A β ₁₋₄₂)	t-tau, p-tau	t-tau, p-tau combined with A β ₁₋₄₂ , NFL, α -syn, sAPP α , sAPP β , MCP-1, YKL-40): - PD vs. APSs (PSP, CBS, MSA): AuROC=0.95 - PD vs. PSP: AuROC=0.95 - PD vs. CBS: AuROC=0.98 - CBS vs. AD/FTD: AuROC=0.93 (clinical diagnosis as reference)	NA
Wagshal D. et al., 2015	n=87 CU (n=26); AD (n=37); PSP (n=24)	Cross-sectional	INNO-BIA AlzBio3 with xMAP platform (t-tau; p-tau181)/ ELISA _s (alternative N-terminal and mid-tau fragments)	t-tau, p-tau181, tau fragments	t-tau, p-tau181 and tau fragments: - AD vs. PSP: AuROC=0.79-0.95; - AD vs. CU: AuROC=0.65-0.73 N-terminal fragment tau12-BT2 shows the best accuracy: - AD vs PSP: AuROC=0.95 - AD vs CU: AuROC=0.73	NA
Wilke C. et al., 2015	n=180 CU (n=20); ALS (n=60)	Cross-sectional	ELISA INNOTEST	t-tau, p-tau181	CU vs. ALS: - t-tau: AuROC=0.68 - p-tau/t-tau: AuROC=0.75 (clinical diagnosis as reference)	NA
Llorens F. et al., 2016	n=140 CU (n=55); ET (n=8); PD (n=40); PDD (n=10); DLB (n=18); MSA (n=11)	Cross-sectional	ELISA (t-tau)/MSD (α -syn)	t-tau	CU vs. DLB: - t-tau/ α -syn: AuROC=0.88 - t-tau: AuROC=0.77 (clinical diagnosis as reference)	NA
Bourbouli M. et al., 2017	n=100 CU (n=17); ALS (n=32); FTD (n=51)	Cross-sectional	Sandwich ELISA	t-tau, p-tau181	t-tau: - CU vs. ALS: AuROC=0.80 - CU vs. FTD: AuROC=0.77; TDP-43 x t-tau/p-tau181 in: - CU vs. ALS: AuROC=0.97 - CU vs. FTD: AuROC=0.90 (clinical diagnosis as reference)	NA
Constantinides VC. et al., 2017	n=86 CU (n=18); PSP (n=19); MSA (n=15); CBD (n=17); PD (n=17)	Cross-sectional	ELISA INNOTEST	t-tau	t-tau/A β ₁₋₄₂ in: - MSA vs. PD: AuROC=0.80 - cut-off point 0.344: 71.4 % sensitivity, 93.3 % specificity - cut-off point 0.305: 78.6 % sensitivity, 80 % sensitivity (clinical diagnosis as reference)	NA

1 2 3 4 5 6 7	Delgado-Alvarado M. et al., 2017	n=80 CU (n=40); PD (n=40)	Cross-sectional	ELISA INNOTEST	t-tau, p-tau181	CU vs. PD: - t-tau/ α -syn: AuROC=0.79 - p-tau181/ α -syn: AuROC=0.86 - p-tau181/ α -syn and TNF- α : AuROC=0.91 (clinical diagnosis as reference)	NA
8 9 10 11 12 13 14	Irwin DJ. et al., 2018	n=83 CU (n=36); autopsy-confirmed AD (n=23); autopsy-confirmed DLB (n=24)	Cross-sectional	xMAP platform	t-tau, p-tau181	Predicting α -syn + AD pathology: - t-tau: AuROC=0.80 - p-tau/ $A\beta_{1-42}$: AuROC=0.80 - t-tau/ $A\beta_{1-42}$: AuROC=0.92; Predicting of neocortical Lewy Bodies pathology t-tau/ $A\beta_{1-42}$: AuROC=0.76 (neuropathology as reference)	NA
15 16 17 18 19	Scarafino A. et al., 2018	n=166 ALS (n=85); AM (n=30); non-NDDs (n=51)	Longitudinal	ELISA	t-tau, p-tau181	t-tau in: - ALS vs. AM: AuROC = 0.70 - ALS vs. non-NDDs: AuROC=0.74 (clinical diagnosis as reference)	Higher baseline t-tau levels are associated with decreased overall survival (HR=2.08)
20 21 22 23 24 25 26 27 28	Schirinzi T. et al., 2018	n=128 CU (n=58); PSP (n=39); PD (n=31)	Cross-sectional	ELISA INNOTEST	t-tau, p-tau181	PSP vs. CU: - p-tau (cut-off 206 pg/ml): AuROC=0.67 - t-tau (cut-off 34.5 pg/ml): AuROC=0.69; PSP vs. PD: - p-tau/t-tau (cut-off 0.185 pg/ml): AuROC=0.70 (clinical diagnosis as reference)	NA
29 30 31 32 33	Constantinescu R. et al., 2019	n=151 PD (n=68); APS (n=83) including MSA (n=34), PSP (n=34), CBS (n=15)	Prospective	ELISA INNOTEST	t-tau, p-tau181	NA	In PSP t-tau is associated with increased mortality (HR=9.59)
34 35 36 37 38 39	Abu-Rumeileh S. et al., 2020	n=169 CU (n=43); ALS (n=80); AM (n=46)	Longitudinal	ELISA INNOTEST	t-tau, p-tau181	ALS vs. CU: - t-tau: AuROC=0.74 - p-tau/t-tau: AuROC=0.81; ALS vs. AM: - p-tau/t-tau: AuROC=0.75 (clinical diagnosis as reference)	NA
40 41 42	Bousiges O. et al., 2020	n=166 CU (n=21); DLB	Cross-sectional	ELISA INNOTEST	t-tau; p-tau181	t-tau: - DLB vs. AD: AuROC=0.92	NA

	(n=67); AD (n = 65);				- DLB vs. AD: AuROC=0.94; p-tau181: - DLB vs. AD: AuROC = 0.93 (clinical diagnosis as reference)	
Ye LQ. et al., 2020	n=240 CU (n=24); AD (n=82); FTD (n=20); HD (n=27); MSA (n=24); SCA3 (n=27); ALS (n=36)	Cross-sectional	ELISA	t-tau; p-tau181	t-tau: - CU vs. FTD: AuROC=0.76 - ALS vs. AD AuROC=0.87 t-tau/A β ₁₋₄₂ : - CU vs. FTD: AuROC=0.80 - AD vs. FTD: AuROC=0.95 (clinical diagnosis as reference)	NA

Table 3. Diagnostic and prognostic value of CSF tau species in non-AD NDDs

Abbreviations: α -syn: α -synuclein; AD: Alzheimer's Disease; ALS: Amyotrophic Lateral Sclerosis; AM: Amyotrophic Lateral Sclerosis mimics; APS: Atypical Parkinsonian Syndrome; AuROC: area under the receiver operating curve; A β ₁₋₄₂: amyloid β -peptide 1–42; CBS: Corticobasal Syndrome; CU: Cognitively Unimpaired; DLB: Dementia with Lewy Bodies; ELISA: enzyme-linked immunosorbent assay; ET: Essential Tremor; FTD: Frontotemporal Dementia; HD: Huntington's Disease; HR: hazard ratio; MCP-1: monocyte chemoattractant protein-1; MSD: mesoscale discovery; MSA: multiple system atrophy; NA: not assessed; NDD: neurodegenerative disease; NFL: neurofilament light chain; PD: Parkinson's Disease; PDD: Parkinson's Disease Dementia; PSP: Progressive Supranuclear Palsy; p-tau: phospho-tau; p-tau181: phospho-tau181; sAPP α : soluble amyloid precursor protein α ; sAPP β : soluble amyloid precursor protein β ; SCA3: spinocerebellar ataxia-type 3; TDP-43: TAR DNA-binding protein 43; t-tau: total-tau; TNF- α : tumor necrosis factor α ; xMAP: multi-analyte profiling; YKL-40: chitinase-3-like protein 1.